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     Adenylyl cyclases (ACs) catalyze the conversion of ATP to cAMP, an 
important second messenger central to many signaling pathways. Nine 
different isoforms of mammalian ACs (mACs) are present, each with distinct 
localization, physiological function and regulatory mechanisms by activators 
and inhibitors. In addition to mACs, bacterial AC toxins such as edema factor 
(EF) from Bacillus anthracis and CyaA from Bordetella pertussis have also 
been identified. Following infection, the AC toxins cause a dramatic increase 
in cAMP levels, thereby disrupting several intracellular signaling pathways. 
     This thesis is broadly divided into two parts and is aimed at validating the 
active-site nucleotide analogs of mACs and EF. The first part of the thesis 
focuses on understanding mAC regulation and the mechanism of interaction 
of mACs with fluorescent 2’, 3’-O-(2, 4, 6-Trinitrophenyl) (TNP)- nucleotides. 
Using purified catalytic subunits of mAC (C1/C2) as model for mACs, we have 
observed the binding of TNP-nucleotides to C1/C2 and the resulting 
conformational changes monitored by fluorescence spectroscopy. The 
enzymatic assays have shown that TNP-nucleotides potently inhibit C1/C2 as 
well as holo-AC isoforms. An isoform-selective inhibition of AC1, AC2 and 
AC5 by TNP-nucleotides has been reported for the first time indicating that 
TNP-nucleotides can serve as models for rational design of potent isoform-
specific AC inhibitors. Furthermore, biophysical and biochemical analysis of 
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the effects of TNP- and 2’ (3’)-O-(N-methylanthraniloyl) (MANT) -nucleotides 
on the individual subunits C1 and C2 show that C1 and C2 can exist as 
homodimers. This homodimerization may play an important physiological role 
in cAMP signaling. 
     The second part of the thesis addresses the structure-activity relationship 
in regulating the catalytic activity of EF and its interaction with calmodulin 
(CaM) using MANT derivatives of ATP and GTP as probes. Our enzymatic 
assays have shown that MANT-nucleotides are highly potent at inhibiting EF. 
MANT-nucleotides are also favorable for FRET studies indicating that our 
robust fluorescence assays can be used for High-Throughput Screening 
(HTS) of EF inhibitors. Additionally, EF-CaM interaction was probed by 
MANT-nucleotides. We have observed that binding and activation of EF by 
CaM are two independent processes in the presence and absence of calcium. 
Furthermore, our fluorescence assays to monitor binding of oxidized CaM to 
EF also indicate that methionine residues in CaM play an important role in 
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Chapter 1: Introduction 
    Adenylyl cyclases (AC) catalyze the conversion of adenosine 5’-
triphosphate (ATP) to 3’, 5’-cyclic adenosine monophosphate (cAMP), an 
important second messenger that mediates several intracellular signaling 
pathways (Sutherland and Rall, 1958; Hurley, 1998; Hanoune and Defer, 
2001). cAMP is central to various functions ranging from activation of protein 
kinase A to cell growth, differentiation and regulation of transcription (Robison 
et al., 1968; Rodbell, 1980).  
    Mammalians ACs are typically transmembrane proteins with the exception 
of one soluble form of AC (sAC) identified in testes (Buck et al., 1999). Nine 
different AC isoforms have been identified in mammals that differ in tissue 
distribution, activation and inhibition by different mediators (Tang and Hurley, 
1998; Hanoune and Defer, 2001; Sunahara and Taussig, 2002).  
    In addition to mACs, several microorganisms such as Bacillus anthracis, 
Bordetella pertussis and Pseudomonas aeroginosa, release AC toxins that 
play an important role in disrupting several host intracellular signaling 
pathways (Seigel et al., 1977; Wolff et al., 1980; Leppla, 1982). These 
exotoxins enter the host cells via different mechanisms and bring about a 
dramatic increase in cAMP levels (Seigel et al., 1977; Wolff et al., 1980; 
Leppla, 1982). One such toxin is Edema Factor, released by Bacillus 
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anthracis that alters water homeostasis and causes edema by increasing 
cAMP levels (O’ Brien et al., 1985; Drum et al., 2002) 
    Though mACs and EF are structurally distinct, both these enzymes are 
important cAMP modulators and they both constitute potential drug targets. 
By regulating cAMP levels, mACs play an important role in several diseases 
such as congestive heart failure, asthma etc (Hanoune and Defer, 2001; 
Sunahara and Taussig, 2002).  By increasing cAMP levels, EF contributes 
significantly to cutaneous and systemic forms of anthrax (Sirisanthana et al., 
1988; Bhatnagar and Batra, 2001). 
 
1.1  Mammalian membranous adenylyl cyclases (mACs) 
    Mammalian adenylyl cyclases play an important role in the G-protein 
signaling cascade (Robison et al., 1968; Sunahara et al., 1996). Following 
activation of G-protein-coupled receptors (GPCRs) by extracellular signals 
such as hormones and neurotransmitters, GPCRs in turn activate the 
heterotrimeric G-proteins. G-proteins then bind to AC mediating activation of 
AC and subsequent conversion of ATP to cAMP (Smigel et al., 1985; Gilman, 
1987).  
    After AC1 gene was first cloned by Krupinski et al (1989), nine different 
isoforms of mAC were cloned and characterized. Each AC isoform is 
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differentially regulated and has unique functional attributes (Taussig and 
Gilman, 1995; Sunahara et al., 1996; Smit and Iyengar, 1998).  All nine AC 
isoforms are stimulated by the Gsα  subunit of G-proteins and metal ions 
(Taussig and Zimmerman, 1998; Sunahara and Taussig, 2002). With the 
exception of AC9, AC1-AC8 are also stimulated by the diterpene activator, 
forskolin (FS), isolated from the root of the Indian herb Coleus forskolhii 
(Seamon and Daly, 1981; Premont et al., 1996; Yan et al., 1998). In addition 
to the nine membranous AC isoforms, a tenth distinct soluble AC isoform 
(sAC) has been identified in the testes (Neer, 1978; Buck et al., 1999). cAMP 
production by sAC is bicarbonate dependent and sAC is not activated by any 
of the mAC effectors (Braun, 1991; Buck et al., 1999).  
    All nine AC isoforms share a common structural topology featuring a short 
variable cytoplasmic N-terminus followed by two transmembrane domains 
(M1 and M2). M1 and M2 have 6 transmembrane spans that alternate with 
two cytoplasmic domains C1 and C2 (Sunahara et al., 1996; Sunahara and 
Taussig, 2002) as indicated in Figure 1. Though initially transmembrane 
domains M1 and M2 were thought to play a role in anchoring and 
coordinating C1/C2 interaction, there is growing evidence of an important role 
for M1 and M2 in AC dimerization and regulation. ACs are now known to 
dimerize via their transmembrane domains (Gu et al., 2002; Cooper and 
Crossthwaite, 2006). M1 and M2 also serve as isoform-specific sites for 
glycosylation (Wu et al., 2001). C1 and C2 domains are further divided into 
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C1a, C1b and C2a, C2b respectively. C1a and C2a share ~50% sequence 
similarity and are highly conserved in all AC isoforms (Sunahara et al., 1997). 
C1a and C2a form the catalytic core of the enzyme and constitute the binding 
sites for ATP, Gsα, divalent metal ions and forskolin (Tang and Gilman, 1995; 
Dessauer and Gilman, 1996; Whisnant et al., 1996; Yan et al., 1996). The 
C1b and C2b regions are poorly conserved in all AC isoforms. The C1b 
domain serves as an important regulatory subunit and an isoform-specific 
binding site for βγ subunits of G-proteins (Yan et al., 2001; Beeler et al., 
2004). Recent evidence suggests that C1 and C2 domains, in association 
with other proteins,  can target specific AC isoforms to lipid raft regions of the 











Figure 1-1 Structure of mammalian membranous adenyl yl cyclases  
Schematic representation of the structure of mammalian adenylyl cyclases. 
Shown are transmembrane domains M1 and M2 (tan color), a short variable 
N-terminus and cytoplasmic domains C1 and C2. C1 and C2 domains are 
divided into C1a, C1b (light grey) and C2a, C2b regions (dark grey). C1a and 
C2a together constitute the catalytic core of the enzyme and possess binding 





1.1.1 AC isoforms - tissue distribution, physiologi cal role and potential 
therapeutic targets 
     To gain a better understanding of the expression patterns of AC isoforms 
in different tissues and their role in signaling, a variety of approaches such as 
RT-PCR, confocal immunofluorescence studies, knock out and transgenic 
animal models for ACs have been used. Growing evidence suggests that, 
depending on the localization of AC isoforms, ACs play an important 
functional role in regulating cAMP levels in these tissues.  
    Overlapping expression patterns of AC isoforms have been observed in 
different tissues, nonetheless some isoforms are more predominant 
compared to other isoforms in different tissues. For example all AC isoforms 
are expressed in the brain; however AC1, AC2 and AC8 are the predominant 
ones in the brain and are the major contributors to long term potentiation 
(LTP), learning and memory. AC1 is expressed in the brain, retina and 
adrenal medulla (Xia et al., 1993). AC1 is neurospecific and plays an 
important role in cAMP dependent synaptic plasticity (Wu et al., 1995; Abdel-
Majid et al., 1998, Lev-Ram et al., 2002). AC1 is also known to regulate 
circadian expression of melatonin biosynthesis (Borjigin et al., 1995; Tzavara 
et al., 1996; Chan et al., 2001). AC1 being neurospecific, may play a role in 
neurodegenerative diseases, stroke and Huntington’s disease (Wang et al., 
2007; Fan and Raymond, 2006). AC8 is not neurospecific and is expressed in 
22 
 
lung, heart, pancreas and parotid glands (Muglia et al., 1999; Watson et al., 
2000, Guenifi et al., 2000). Transgenic animal studies have shown that AC8 
in the heart may play a role in myocardial contractility and AC8 expression in 
parotid glands may be important for regulation of parotid function (Esposito et 
al., 2008; Watson et al., 2000). Studies with double AC1 and AC8 knockout 
mice have shown defects in learning and memory (Wong et al., 1999). The 
AC2 isoform is expressed in the brain and lung (Furuyama et al, 1993; 
Jourdan et al, 2001).  AC2 and AC8 in the lung contribute to cAMP regulation 
and cAMP mediated pathways in pulmonary artery myocytes (Jourdan et al, 
2001).  
    AC3 was first identified in the olfactory epithelium and later in other tissues 
such as heart, pancreas and lung (Bakalyar and Reed, 1990; Xia et al., 1992; 
Ishikawa et al., 2000). Gene disruption studies in mice have demonstrated 
that the AC3 isoform is important for olfaction and implicated in cAMP 
mediated detection of odorants in the olfactory epithelium (Wong et al., 2000). 
Immunofluorescence studies have shown that AC3 and AC8 are expressed in 
pancreas and may play a role in glucose mediated insulin secretion (Guenifi 
et al., 2000) and in type 2 diabetes (Ishikawa et al., 2000). Expression of AC4 
is widespread and along with other AC isoforms, AC4 is expressed in rodent 
outer retina and may play a role in photoreception (Abdel-Majid et al, 2002).  
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    AC5 and AC6 are the predominant isoforms expressed in heart (Ostrom et 
al, 2002). AC6 is widely expressed in many other tissues (Roth et al., 1999). 
Several knockout studies have indicated that AC5 and AC6 are particularly 
important isoforms in the cardiovascular system (D’ Angelo et al., 1997; Gao 
et al., 2002; Okumura et al., 2003). AC5 and AC6 knockouts serve as suitable 
models to study congestive heart failure. Recent studies have suggested that 
AC5 knockout mice are resistant to cardiac stress (Yan et al, 2007). Selective 
AC5 antagonists may have a therapeutic value against depression and 
anxiety (Krishnan et al., 2008). AC5 gene disruption also played a role in 
longevity and stress and AC5 knockouts have been useful models for 
studying pain mechanisms (Yan et al., 2007; Kim et al., 2007). In sharp 
contrast, AC6 knockout can cause abnormal left ventricular function (Tang et 
al, 2008). AC6 plays a cardioprotective role and may be very important for 
congestive heart failure therapy (Phan et al., 2007). 
    The AC7 isoform is expressed in the brain and in several other tissues. 
Using a combination of approaches, Hines et al (2006) have shown that AC7 
may play a sex-specific role in depression. Recent studies also reveal that 
alcohol interacts directly with AC molecules and AC7 has been identified as 
the most ethanol sensitive AC isoform (Yoshimura et al., 2006). This suggests 
a possible role for AC7 in the development and predisposition to alcoholism. 
AC9 is the least characterized and FS- insensitive AC isoform (Premont et al, 
1996). AC9 is expressed in the brain as well as in many other major tissues 
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(Hacker et al., 1998; Paterson et al., 2000). In the brain, AC9 is expressed in 
regions important for learning and memory (Antoni et al., 1998). sAC, the 
soluble isoform found in testes, is important for sperm maturation and sAC 
inhibitors can act as potential male contraceptives (Marquez and Suarez, 
2008).   
   AC isoforms are important potential therapeutic targets because cAMP is 
directly or indirectly implicated to play a major role in several diseases 
ranging from depression, heart failure to diabetes. However, there are very 
few known activators and inhibitors of specific AC isoforms. P-site inhibitors 
and several other small molecule inhibitors such as calmidazolium and 
tyrphostin A25 have been identified that are isoform-selective to a certain 
extent (Ahlijanian and Cooper, 1987; Jaleel et al., 2004). FS and FS analogs 
activate and inhibit various AC isoforms with some specificity (Pinto et al., 
2008). Keeping in view the different roles of different AC isoforms, there is a 
good possibility that isoform-specific and therefore tissue-specific AC 




Table 1-1 A summary of tissue distribution and puta tive function of 
mammalian membranous adenylyl cyclase  
AC isoforms Tissue distribution  Putative function         References 







Xia et al., 1993; Wu 
et al., 1995;  
Lev-Ram et al., 
2002; Wong et al., 
1999 





Furuyama et al, 
1993; Jourdan et al, 
2001 





Bakalyar and Reed, 
1990; Xia et 
al.,1992; Ishikawa et 
al., 2000; Wong et 
al., 2000;  
      AC4 Widespread Photoreception Abdel-Majid et al., 
2002 
      AC5 Brain, heart, kidney Heart rate 
regulation, 
longevity, stress 
Yan et al, 2007; Kim 
et al., 2007 
      AC6 Heart, kidney, widely 
expressed 
Heart function Tang et al, 2008; 
Roth et al., 1999; 
Gao et al, 2002 
      AC7 Brain, ubiquitous 
expression 
Alcohol sensitivity Hines et al., 2006; 
Yoshimura et al., 
2006 








Muglia et al., 1999; 
Watson et al., 2000, 
Wong et al., 1999, 
Jourdan et al, 2001 




Hacker et al., 1998; 





1.1.2 AC isoforms - regulation 
    Adenylyl cyclases can be broadly divided into five groups based on 
regulation by G-proteins and ions. The first group consists of Ca2+-Calmodulin 
(CaM) sensitive AC1, AC3 and AC8. This group is stimulated by Ca2+-CaM 
and AC1 and AC8 are inhibited by Gβγ subunits of G-proteins (Krupinski et 
al., 1989; Cali et al., 1994; Choi et al., 1992; Tang and Gilman, 1991; Taussig 
et al., 1993). In addition to regulation by G-proteins and ions, post-
translational modifications such as phosphorylation, glycosylation and 
nitrosylation of ACs are commonly observed. AC1 and AC3 are stimulated by 
protein kinase C (PKC) and inhibited by CaM kinase IV and CaM kinase II, 
respectively, in a feedback regulation (Yoshimura and Cooper, 1993; 
Zimmermann and Taussig, 1996; Wayman et al., 1996; Wei et al., 1996). 
PAM (protein associated with myc) is known to interact with AC1, thereby 
inhibiting cAMP production (Scholich et al., 2001). AC3 is also known to 
interact with RGS2 (Regulators of G-protein signaling) (Sinnarajah et al., 
2001).  
    The second group of ACs, namely AC2, AC4, and AC7, is directly 
stimulated by Gβγ subunits of G-proteins and are insensitive to calcium (Gao 
and Gilman, 1991; Lustig et al., 1993; Yoshimura et al., 1996; Cooper et al., 
1998). AC2 is activated by PKC, and AC4 is inhibited by PKC (Ebina et al., 
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1997; Zimmermann and Taussig, 1996). However, modulation of AC activity 
by PKC is not clearly known.  
    The third group of ACs, namely AC5 and AC6, are the best studied 
isoforms and are inhibited by micromolar concentrations of calcium and Giα 
proteins (Goα, Giα1, Giα2, Giα3, Gzα) (Guillou et al., 1999; Cooper et al., 
1995; Taussig et al., 1993; Kozasa et al., 1995). PKC activates and inhibits 
AC5 and AC6 respectively (Lai et al., 1997). AC5 and AC6 are also directly 
phosphorylated and inhibited by PKA (Iwami et al., 1995). AC5 and AC6 are 
glycosylated at the extracellular loops of their transmembrane domains.  
However, the physiological role of these glycosylation events is not clearly 
understood. Blocking AC6 glycosylation decreases inhibition by PKC (Wu et 
al., 2001). AC5 and AC6 are also nitrosylated and can be inhibited by nitric 
oxide (NO) (McVey et al., 1999; Ostrom et al., 2004). RGS2 is known to bind 
to the C1a regions of AC5 and AC6 causing inhibition of cAMP production 
(Salim et al., 2003; Roy et al., 2003). PAM is also known to physically interact 
with the C2 region of AC5 and AC6 (Gao and Patel, 2005; Scholich et al., 
2001). Patel’s group has shown that specific hormones such as EGF 
(Epidermal growth factor) can indirectly activate AC5 by phosphorylating 
specific residues on Gsα. This increase in cAMP levels has a positive 
inotropic effect (increase in strength of muscular contractions) on the heart 
(Nair et al., 1989; Nair and Patel, 1993). AC6 also specifically interact with 
Raf1, a protein in the MAPK/ERK signaling pathway (Mitrogen activated 
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protein kinase/extracellular signal regulated kinase) and Snapin, a component 
of the SNAP-25/SNARE complex of proteins. Raf1 binds to C1b region and 
the intracellular loop of M2 and is predicted to play a role in heterologous 
sensitization of AC6 (Ueda et al., 1996). Snapin interacts with the N-terminus 
of AC6 and, therefore, AC6 is speculated to play a role in synaptic signaling 
and vesicle fusion (Chou et al., 2004).  
    AC9, the FS-insensitive AC isoform, is poorly characterized and the only 
member of the fourth group of ACs. AC9 is activated by Gsα and inhibited by 
Giα, PKC and Ca
+2/Calcineurin (Hacker et al., 1998). AC9 also undergoes 
glycosylation which is known to determine AC9’s relative sensitivity to 
Gsα (Cumbay and Watts., 2004).  
    The fifth group of ACs is comprised of sAC, a soluble isoform found in 
testes and other bicarbonate sensitive tissues. sAC is distinct from other 
mammalian AC isoforms and is regulated by Ca2+ and bicarbonate. sAC is 
closely related to cyanobacterial ACs and may provide a link between 
bacterial and mammalian signaling pathways (Buck et al., 1999). sAC plays a 
role in cAMP mediated sperm maturation and motility in the testes and is 





Figure 1-2. Regulation of Mammalian membranous AC i soforms and 
soluble AC 
Figure A – Schematic representation of the regulation of nine AC isoforms. 
Stimulating effectors are represented in red, inhibitors are shown in blue. 
PKA, Protein Kinase A; PKC, protein kinase C; CaM, Calmodulin; EGF, 
epidermal growth factor; RTK, receptor tyrosine kinase. All the AC isoforms 




Figure B – Crystal structure of CyaC, a sAC homolog from Cyanobacterium 
Spirulina platensis in complex with an ATP analog and calcium (Steegborn et 
al., 2005). sACs are stimulated by bicarbonate and calcium. Two sAC 
homodimers (one in red and one in blue) form the catalytic site for ATP 












1.1.3 Catalytic mechanism of AC 
    Several crystallographic, kinetic, mutational and modeling studies have 
been carried out to gain insight into the catalytic mechanism of AC. First the 
crystal structure of C1 and C2 in complex with FS and Gsα.GTPγS was solved 
by Tesmer’s group (Figure 1-3). They showed that the interfacial surface of 
C1 and C2 buried approx. 3300 Å of solvent – accessible surface area and 
two pseudosymmetric regions were observed at the interface. ATP binds to 
one region, and Gsα  and FS bind to the other. Modeling studies have 
demonstrated that ATP binding changes the conformation of AC from an 
inactive and open to an active and closed state (Tesmer et al., 1997).  
     A detailed study of the Gsα  and FS binding sites has shown that seventy 
five percent of Gsα  is accommodated by C2 and the remainder by C1. F379 
of C1 has been identified as an important residue for interaction with Gsα. 
Binding of Gsα  changes the relative orientation of C1/C2 and prepares the 
active site for catalysis. 
    The crystal structure of the C2 homodimer possesses two binding sites for 
FS (Zhang et al., 1997). Since C1 and C2 share at least 30% sequence 
homology, it was predicted that C1/C2 would also have two FS binding sites 
similar to C2 homodimers. However, the consensus is that C1/C2 possesses 
only one FS binding site. FS and Gsα,  both together and separately, increase 
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the affinity of C1 for C2, promoting their dimerization, and also increase the 
Vmax of the enzyme (Sunahara et al., 1997).  
    Several critical amino acid residues have been identified that are important 
for ATP binding and catalysis. For example, R1029 is a very important amino 
acid residue in C2 that helps to stabilize the α-phosphate intermediate in ATP 
conversion. N1025 on C2 coordinates a water molecule that forms a 
hydrogen bond with ATP. Mutational studies have shown that E518 is 
important for ATP binding because the E518A mutation reduces the affinity 
for an ATP analog (Dessauer et al., 1997). ACs catalyze the conversion of 
ATP to cAMP using a two metal ion mechanism. The two - metal ions 
catalyze the phosphoryl transfer and are coordinated by D396 and D440 
residues on C1 (Tesmer et al., 1999).  
    P-site inhibitors have been extensively used as probes to understand the 
catalytic mechanism of AC. These inhibitors possess an intact ring and are 
dead end inhibitors of product (PPi) release. They bind to the active site and 
stabilize the enzyme-PPi complex. P-site inhibitors are non-
competitive/uncompetitive depending on metal-ATP and regulators and are 
known to inhibit only the stimulated forms of AC (Johnson et al., 1989; 
Tesmer et al., 2000).  
    Fluorescent nucleotides have also been used as probes to study the 
conformational changes in C1/C2 upon binding of activators such as Gsα  and 
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FS. Gille et al., (2004) showed that the fluorescent 2’ (3’)-O-(N-
methylanthraniloyl) MANT derivatives of ATP and GTP are highly potent 
inhibitors of C1/C2 as well as AC isoforms with Ki values in the 10 to 100 nM 
range. The crystal structure of C1/C2 with MANT-GTP and MANT-ATP, 
solved by Mou et al., (2005) showed that the MANT substituent of MANT-ATP 
and MANT-GTP make van der Waals contacts with C1 and C2 (Figure 1-4a). 
The MANT group prevents movement of the β1-α1-α2 loop of C1 and the α4’-
β5’ and β7’-β8’ loops of C2, thus preventing the change from the inactive 
(open) to the active (closed) conformation (Gille et al., 2003; Mou et al., 
2005).  
    2’, 3’-O-(2, 4, 6-Trinitrophenyl) (TNP) nucleotides were also studied in our 
laboratory to monitor conformational changes in ACs (the results will be 
described in some detail in later chapters). TNP nucleotides have been widely 
used to study conformational changes in proteins. In collaboration with Mou 
and group, the crystal structure of C1/C2 was solved in complex with TNP-
ATP (Figure 1-4b). We observed that the TNP group acts as a wedge 
preventing the change from the inactive (open) to active (closed) 
conformation, very similar to MANT-ATP and MANT-GTP. The relative 
orientations of MANT-ATP, MANT-GTP and TNP-ATP are slightly different in 
the catalytic pocket of C1/ C2.  Nonetheless, all three nucleotides reside in 
the same pocket formed by C1/C2. This indicates that mAC has a broad 
nucleotide binding specificity because the catalytic pocket is flexible enough 
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to accommodate different bases and fluorophore. Therefore, a general 
tripartite mAC pharmacophore model was generated where the inhibitor 
binding site overlaps the substrate binding site and contains a spacious base-
binding pocket, a hydrophobic pocket for the fluorophore (ribose substituent) 















Figure 1-3. Crystal structure of C1/C2 in complex w ith G sα, FS and ATP 
as shown in Tesmer et al., 1999.  
C1a and C2a are shown in tan and mauve colors respectively. Gsα  is shown 
in red, ATP and FS in stick models bind at the interface between C1 and C2. 










Figure 1-4.  (a)Crystal structure of C1/C2, G sα  and FS in complex with 
MANT-GTP 
C1 in mauve, C2 in tan and Gsα  is shown gray. Switch II of Gsα  is shown in 
red. FS, MANT-GTP and metal ions occupy the cleft formed by C1 and C2.  
 
(b) Crystal structure of C1/C2, G sα  and FS in complex with TNP-ATP 
(Mou et al., 2006) 
C1 in tan, C2 in mauve and Gsα  is shown grey. Switch II of Gsα  is shown in 
red. FS, TNP-ATP and metal ions occupy the cleft formed by C1 and C2. 
α helices and β-loops in respective C1 and C2 domains involved in change 




Figure 1-5. (a) Superimposition of MANT-ATP, MANT-G TP and TNP-ATP 
bound to the C1/C2/ G sα /FS complex. (Mou et al., 2006) 
 
(b) General tripartite AC pharmacophore model for A C inhibitors based 




1.1.4 Challenges, limitations and future directions  of AC research 
    Purifying AC protein in its intact membrane bound form has been one of 
the most difficult challenges faced by AC researchers to date. Fortunately, C1 
and C2 have been expressed as separate polypeptides and, when mixed 
together, they retain many properties of the intact enzyme. Using C1/C2 as a 
model for ACs, the first crystal structure was solved by Tesmer et al in 1997 
and the structure provided considerable information about the catalytic 
mechanism of ACs and the conformational changes that occur when Gsα  and 
FS bind. In the last 20 years, several biochemical, kinetic and structural 
studies using C1/C2 have been carried out that have also provided insight 
into the catalytic mechanism, its regulation and inhibition.  
    Gene knockout studies and studies using transgenic animal models have 
helped to understand the physiological roles of some AC isoforms. However, 
the roles of other specific AC isoforms are not clearly evident due to 
overlapping expression patterns of AC isoforms in tissues which is due in part 
to the lack of isoform- specific antibodies (Sunahara et al., 1996). It has also 
been difficult to identify AC isoform-specific activators and inhibitors.  
    A major and as yet untapped approach to identification of isoform-selective 
inhibitors is through the application of high throughput screening experiments.  
This will require development of suitable assays that can be miniaturized for 
automated screening formats. Once identified, it will be important to study the 
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effects of AC isoform-specific inhibitors and activators in intact cells or in 
animal models.  Future biochemical studies will also be required to gain a 
better understanding of the roles of the different AC isoforms and their 
regulation in different tissues.  
    Since the cytoplasmic units of C1 and C2 form the catalytic core of the 
enzyme, a fundamental question is what is the importance of the 
transmembrane domains when all that are needed for AC catalysis are the 
cytoplasmic domains?  Emerging evidence suggests that the transmembrane 
domains play an important role in AC regulation by helping to localize AC, by 
anchoring the cytoplasmic domains, and by interacting with other regulatory 
proteins (Wu et al., 2001). Additional information is also needed to describe 
the exact roles of the C1b and C2b regions in catalysis and regulation. The 
C1b region is thought to interact with other proteins in some isoforms (Yan et 
al., 2001; Beeler et al., 2004). Therefore, potential interactions between the 
C1b and C2b regions with other proteins during the signaling process must 
also be explored.  
    G-protein coupled receptors (GPCRs), membrane proteins that are 
upstream to ACs are known to dimerize as part of their normal function 
(Prinster et al., 2005). A combination of approaches including co-
immunoprecipitation and FRET (fluorescence resonance energy transfer) has 
suggested that ACs may also dimerize via their transmembrane domains (Gu 
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et al., 2002). It is speculated that a dimer between two similar or different AC 
isoforms may constitute a basic functional unit of AC.  In addition to 
interaction with other proteins, transmembrane domains may also participate 
in AC dimerization.  
    Recent advancement in AC research has also highlighted the importance 
of localization of AC isoforms. Some AC isoforms are thought to be localized 
on lipid rafts and caveolae, a sub set of lipid rafts formed by polymerization of 
caveolin. Due to localization of ACs, changes in cAMP levels may also be 
localized in defined cell compartments rather than being distributed 
throughout the cytoplasm (Gorodinsky et al., 1995; Huang et al., 1997). The 
possibility of localization of ACs leading to compartmentalization of cAMP 










1.2  Bacterial adenylyl cyclase toxin Edema factor (EF) from Bacillus 
anthracis. 
    Anthrax, caused by Bacillus anthracis, is a deadly epizootic disease 
primarily affecting cattle and occasionally humans that come in contact with 
infected animals or animal products (Mock and Fouet, 2001; Mourez et al, 
2002). Human anthrax is more common in developing countries of Asia and 
Africa compared to the developed countries. Anthrax cases have been 
described as early as 16th century BC in Egypt and several publications 
describing anthrax were produced in the 1800s (Scorpio et al, 2006; Oncu et 
al., 2003). More recently, anthrax spores were used during the terrorist 
attacks in the US in 2001 giving a new meaning to the word bioterrorism.  
     Bacillus anthracis is a large gram-positive bacterium that forms spores 
when in contact with oxygen (Figure 1-6). The spores which carry the virulent 
factors are highly resistant to a wide range of climatic conditions such as high 
temperature, UV light and high pH (Watson and Keir, 1994). The spores carry 
three exotoxins namely Edema Factor (EF), Lethal Factor (LF) and Protective 
Antigen (PA) and a poly-γ-D glutamyl capsule, all of which are released when 
the spores come in contact with host cells. Crystallographic, biochemical, 
kinetic and structural studies have greatly improved our understanding of the 
mode of action of these toxins.  
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Figure 1-6. (a) Original photomicrograph of Bacillu s anthracis by Robert 
Koch  (www.bact.wisc.edu/themicrobialworld/anthrax.html)  
 
 





1.2.1 Anthrax – infection, diagnosis, treatment and  prevention   
    Anthrax is primarily divided into three types depending on the mode of 
entry of the spores into the host. They are (a) cutaneous anthrax (b) 
inhalational anthrax and (c) gastrointestinal anthrax. There are also some 
minor and rare forms of anthrax such as anthrax sepsis and renal and 
ophthalmic forms of anthrax (Oncu et al., 2003).  
Cutaneous anthrax 
    Cutaneous anthrax occurs due to entry of spores through a cut, break or 
abrasion on the skin. In most cases, cutaneous anthrax in humans is due to 
handling of infected animals or their products. There have also been reports 
of some rare cases of cutaneous anthrax due to biting of flies that have fed on 
anthrax infected animals. The incubation period of spores is typically between 
1-12 days. The symptoms start with development of papule on the skin which 
slowly turns into a vesicle showing necrosis, edema and a characteristic black 
eschar (lesion) (Figure 1-7). The cutaneous form of anthrax can be effectively 
treated with antibiotics and can be fatal if left untreated (Oncu et al, 2003; 
Brey, 2005).  
Inhalational anthrax 
    Inhalational anthrax, also called pulmonary anthrax, is the most lethal form 
of anthrax. Initial symptoms start with fever and cough. Within a few hours, 
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more serious symptoms such as dyspnea (shortness of breath), cyanosis 
(blue coloration of the skin) and respiratory failure develop leading to 
septicemia, shock and death. Current models for inhalational anthrax assume 
that spores enter the macrophages in the lungs, multiply and lyse cells, then 
spread through lymph nodes causing extensive septicemia (Figure 1-8). 
Inhalational anthrax cases have a high mortality rate and broad-spectrum 
antibiotic therapies have not been very helpful (Brey, 2005; Ascenzi et al., 
2002; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5510a4.htm) . 
Gastrointestinal anthrax (GI anthrax)  
    The gastrointestinal form of anthrax accounts for less than 5% of anthrax 
infections. Gastrointestinal anthrax occurs due to ingestion of spores through 
contaminated food or water. This form of anthrax has a high mortality rate and 
two subforms i.e. the oropharygeal form where spores get deposited in the 
upper GI tract and the intestinal or abdominal form with deposition of spores 
in the lower GI tract have been reported. Extensive edema and necrosis 
occurs in both forms of GI anthrax. If detected early, GI anthrax can be 
treated with antibiotics. Once spores invade the bloodstream, they cause 






Figure 1-7 Cutaneous anthrax 
(a) Characteristic central eschar with plaque and erythema (b) Necrotic ulcer, 
black eschar and edema. (www.nlm.nih.gov/medlineplus/anthrax.html) 
 
Figure 1-8 Inhalational anthrax  
A chest X-ray of an inhalational anthrax infected patient. Clear lungs and 






Diagnosis, treatment and prevention  
    Laboratory diagnosis of anthrax includes Gram and polychrome methylene 
blue staining the specimen from potentially infected patients to identify the 
polypeptide capsules of B.anthracis. B.anthracis from body fluids can also be 
cultured in blood agar and identified as large colonies, white or grey in color. 
The anthrax skin test is performed by injecting an attenuated strain and is 
positive in 85% of cases immediately after infection (Oncu et al., 2003; 
Shlyakov et al., 1996).  
    The first vaccine for anthrax was developed by Louis Pasteur by injection 
of an attenuated B.anthracis strain. Protective antigen (PA) was discovered 
as one of the toxins responsible for virulence by Gladstone (Gladstone, 
1946). By the 1950s, the AVA vaccine was developed with PA and small 
amounts of Edema factor (EF) and lethal factor (LF) from an attenuated strain 
adsorbed to aluminum hydroxide. AVA, the only vaccine for anthrax approved 
for use by humans, was licensed by the FDA in the 1970s. AVA with trade 
name BioThrax® is manufactured by Bioport Corp (Lansing, Michigan), 
parent company of Emergent Biosolutions (Rockville, MD). Due to problems 
related to purity, differences in reactivity and manufacturing, a next generation 
vaccine called rPA is being clinically tested to determine its safety and 
reactivity. rPA is a recombinant protective antigen purified from an 
asporogenic B.anthracis strain. rPA was clinically tested by VaxGen Inc 
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(Brisbane, CA) and later acquired by Emergent Biosolutions (Rockville, MD) 
in 2006 (www.google.com/anthrax news). In addition to vaccines, post 
exposure treatment for anthrax is aggressive and comprises timely antibiotic 
therapy with penicillin, doxicyclin and other broad spectrum antibiotics such 
as fluoroquinolone compounds.  
    Approaches to development of next generation drugs and vaccines for 
anthrax are exploring new avenues such as inhibitor design for receptor 
binding, toxin assembly, endocytosis, enzymatic activity of toxins and 
targeting virulence of the poly-γ-D glutamyl acid capsule. 
    Prevention is effective by surveillance and regular check-up of humans 
working closely associated with animals and military personnel working in 
higher-risk areas where anthrax spores may be used for potential biological 
warfare. Timely immunization of animals and humans is also a key to 
preventing anthrax infections in case of a suspicious exposure to anthrax 
spores.  
1.2.2 Anthrax – Biological warfare and incidence in  developing countries 
     B.anthracis spores have been used as bioweapons and several significant 
incidents occurred during the last few centuries.  Anthrax spores were 
purportedly used to kill millions of people and cattle during the movement of 
Huns across Eurasia in 80 AD 
(http://www.defencejournal.com/dec98/anthrax.htm). In 1941, the British 
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Government tested the effect of anthrax spores as a bioweapon in Gruinard 
Island near Scotland. The island was uninhabited until 1986 after several 
attempts were made to sterilize the soil (Manchee et al., 1981). In 1979, 96 
cases of anthrax including 68 deaths resulted due to accidental release of 
anthrax spores from a military facility in Russia (Meselson et al., 1994). In 
1993, an attenuated strain of anthrax was sprayed from the top of a building 
by the Aum Shinrikyo, a doomsday cult in Tokyo (Keim et al., 2001). In 2001, 
anthrax spore-laced letters caused widespread panic among people in the 
United States and worldwide.  Due to its high potency, hardiness and 
resistance to a wide range of conditions, anthrax is classified as Category A 
bioterrorism agent by the US Centers for Disease Control and Prevention 
(CDC). It is estimated that a 50 kg of anthrax aerosol spray would result in 
millions of deaths and, therefore, the potential devastating effects of anthrax 
cannot be underestimated (Trull et al., 2007). 
    Naturally occurring anthrax is still a major problem in several developing 
countries such as India, Turkey, Greece and countries in the African 
continent. Until 2006, at least 205 cases of anthrax have been reported in 
parts of Southern India especially in the under-developed regions (Rao et al., 
2007; Vijaikumar et al., 2001). Poverty, lack of awareness and lack of 
vaccinations for both humans and livestock are the primary reasons for high 
incidence of anthrax infection.  
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    In view of the potential use of anthrax as a bioweapon and the high 
incidence of naturally occurring infections, there is an urgent need for the 
development of efficient, accessible and cost-effective drugs, vaccines and 
other therapeutics to prevent and cure anthrax.  
    
1.2.3 Anthrax tripartite toxin and mechanism of tox in translocation into 
host cells      
    Virulence factors of B.anthracis are encoded on two plasmids: - pXO1 
which contains genes responsible for synthesizing the exotoxins EF, LF and 
PA, and pXO2 which carries genes that synthesize the poly-γ-D glutamyl 
capsule. B.anthracis toxin is a member of the bacterial binary A-B toxin family 
where the B moiety acts as a transporter helping the A moiety to translocate 
into the cytosol. The A moiety exerts its deleterious effects after it enters the 
cytosol. In the case of B.anthracis, PA acts as a transporter protein and 
translocates EF and LF into the host cell (Mock and Fouet, 2001; Mourez et 
al., 2002). 
    Protective antigen (PA) is an 83 kDa protein that binds to specific receptors 
referred to as ANTXR1 (tumor endothelial marker 8) and ANTXR2 (Capillary 
morphogenesis protein 2), on host cells. Both ANTXR1 and ANTXR2 are 
widely expressed in cells and consist of regions similar to the von Willebrand 
factor type A domain and the Integrin I domain, thus binding to collagen and 
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collagen/laminin respectively. LRP6, a cell surface protein, can also act as a 
coreceptor. By interacting directly or indirectly with ANTXR1 and ANTXR2, 
LRP6 can stimulate PA binding to ANTXR1 and ANTXR2 (Bradley et al., 
2001; Scobie et al., 2003; Liu and Leppla, 2003; Nanda et al., 2004; Wei et 
al., 2006). 
    After PA83 is bound to ANTXR1 or ANTXR2, it is cleaved by a member of 
the furin family of proteases. The N terminal region of PA83 is cleaved, 
releasing PA20 extracellularly, and PA63 is bound to the receptors (Klimpel et 
al., 1992). PA63 then self oligomerizes to form a ring-shaped heptamer 
referred to as prepore conformation. EF and LF bind competitively with high 
affinity to the PA63 heptameric prepore conformation. Several studies have 
shown that a maximum of three molecules of EF and/or LF can be 
accommodated by the PA63 heptamer. The recognition sites of the interaction 
of EF and LF with PA63 heptamer have been mapped and both EF and LF are 
positioned with their N termini at the entrance of the PA63 prepore and 
therefore can translocate in the N- to C terminal direction. The PA63 heptamer 
with bound LF and or EF then undergoes receptor-mediated endocytosis and 
is transferred into an intracellular acidic compartment. The low pH in the 
endosomal compartment results in structural rearrangements, giving rise to 
the PA63 pore conformation that can now insert itself in the endosomal 
membrane. The PA63 pore is typically a 14-strand transmembrane β barrel 
with a water-filled central cavity of about 15 Å in diameter (Gao-Sheridan et 
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al., 2003; Abrami et al., 2003; Lacy et al., 2002 and 2005). EPR (Electron 
Paramagnetic Resonance) studies have shown that seven F427 residues 
from the PA63 heptamer form a “Φ” (phi) clamp exposing their aromatic rings 
in the lumen. The Φ clamp causes partial unfolding and translocation of EF 
and LF through the pore coupled to a positive membrane potential across the 














Figure 1-9 Schematic representation of PA binding, assembly, 
endocytosis and translocation of EF and LF inside t he cytosol. 
PA83 binds to specific receptors on the membrane. Furin endoproteases 
present on the cell membrane cleave PA83, releasing PA20 extracellularly, and 
PA63 bound to the receptor. PA63 self-oligomerizes to form a ring-shaped 
heptamer termed the prepore complex that can bind to EF and or LF. Prepore 
complex with bound EF and or LF is then endocytosed to an intracellular 
acidic compartment. The lower pH in the endosome triggers structural 
rearrangements causing a change in conformation from prepore to pore 




















1.2.4 Anthrax toxin components and their function 
    Protective antigen (PA), an 83 kDa protein, is divided into four domains. 
Domain 1 has a recognition site for Furin-like family endoproteases and part 
of domain 1 is cleaved giving rise to PA20 that is released extracellularly and 
PA63 which can self oligomerize. Domain 2 undergoes pH-dependent 
conformational changes and helps in oligomerization, conversion from 
prepore to pore forms and translocation of EF and LF into the cytosol. 
Domain 2 from seven PA63 monomers forms the transmembrane β barrel and 
consists of the Φ clamp for unfolding and translocation of EF and LF. 
Furthermore, it has been shown that K397 from one PA domain 2 can form a 
salt bridge with D426 of the neighboring PA domain 2 thus giving rise to a 
loop bringing the F427 residues closer to form the Φ clamp. Mutational 
studies have shown that Domain 3 is also important for oligomerization of 
PA63. Domain 4 consists of the receptor-binding domain and is important for 
the interaction of PA with its cellular receptors ANTXR1 and ANTXR2 (Petosa 
et al., 1997; Santelli et al., 2004; Mogridge et al., 2001; Young and Collier, 
2007).  
    Lethal factor (LF) is a 90 kDa  zinc-dependent metalloprotease that can 
cleave the proline rich N-terminal of mitogen–activated protein kinase (MAPK) 
kinases (Meks).  LF can cleave and inactivate all Meks except Mek 2. Since 
Meks serve as important substrates for downstream signaling, proteolytic 
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inactivation of Meks by LF inhibits the MAP kinase signal transduction 
pathways that include p38, JNK and ERK. The crystal structure of LF with 
bound substrate and inhibitor has shown the presence of four domains. The 
N-terminal domain 1, or LF-N, is the protective antigen binding domain and 
has residues similar to EF-N. Domain 2 and Domain 3 serve as sites for 
substrate recognition. The C terminal domain 4 consists of the zinc 
metalloprotease site (Pannifer et al., 2001; Lacy et al., 2002; Tonello et al., 
2003). Though several studies have shown that EF and LF can bind only to 
PA63 heptamers, recent evidence suggests that LF and LF-N (N-terminal 
region of LF) can bind to PA63 monomer, albeit with lower affinity. It has also 
been shown that PA20 interacts with LF-N, though a functional role for this 
interaction has not been determined (Lacy et al., 2005; Chvyrkova et al., 
2007). It has also been demonstrated that low concentrations of LF bind to 
PA63 and higher concentrations inhibit PA63 assembly (Christiansen et al., 
2006).  
    Edema Factor (EF) is a 93 kDa calmodulin (CaM) activated adenylyl 
cyclase that can convert ATP to cAMP (Leppla, 1982). Increased cAMP levels 
can cause several changes by activating downstream targets such as PKA, in 
turn disrupting intracellular signaling pathways. EF is thought to be primarily 
responsible for the cutaneous form of anthrax (Leppla, 1982; Dixon et al., 
1999). A detailed analysis of the structure and intracellular activation of EF is 
dicussed in the following sections.  
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ET (EF with PA) and LT (LF with PA) can together or separately impair host 
defenses by promoting bacterial invasion (Firoved et al., 2007). Both ET and 
LT suppress innate immune responses and impair human neutrophil activity 
(Kammer et al., 1988; Kyriakis et al., 2001). ET and LT inhibit the generation 
of superoxides and reactive oxygen species (ROS) by NADPH oxidase 
activity of human neutrophils needed to cause bacterial killing (Crawford et 
al., 2006). ET increased cAMP levels of lymphocytes can cause changes in 
important gene expression resulting in suppression of the immune response. 
ET can also inhibit chemotaxis in endothelial cells by activating downstream 
effectors such as Epac and RAP1 (Hong et al., 2007). Also, the PA binding 
domain of EF is not essential for potency of ET (Hong et al., 2005). 
Furthermore, ET can inhibit platelet aggregation and cause hemorrhage, an 
important symptom of anthrax (Alam et al., 2006).  It has also been 
demonstrated that EF and LF are capable of inducing hemolysis (lysis of 
blood cells) in the presence of neutrophils (Wu et al., 2003).  
 
1.2.5 Edema Factor – structure and intracellular ac tivation 
    Edema factor can be considered to have two domains, a 30 kDa N-terminal 
protective antigen binding domain and a 63 kDa CaM sensitive adenylyl 
cyclase domain or EF3 (Drum et al., 2000; Bhatnagar et al, 2001). The 
protective antigen binding domain is homologous to the N terminal region of 
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LF (Collier and Young, 2003). EF3 can be further divided into N terminal EF3 
(EF3-N) and a C terminal EF3 (EF3-C). EF3-N is homologous to AC 
exotoxins from Bordetella pertussis and Pseudomonas aeuroginosa.  It is 
resistant to protease digestion. EF3-C is sensitive to protease digestion in the 
absence of CaM (Drum et al., 2000).  
    After PA-mediated entry of EF into the cells, EF binds to calmodulin (CaM). 
CaM is a 16.5 kDa protein, ubiquitously expressed in cells. CaM binds and 
modulates activities in a large number of targets that include enzymes, pumps 
and ion channels in a calcium-dependent manner, thus playing an important 
role in several intracellular processes such as signal transduction and gene 
transcription (Deisseroth et al., 1998; Demaria et al., 2001).  
    X-ray and NMR studies have shown that CaM exists as a flexible dumbbell-
shaped structure with two globular end domains each consisting of two 
calcium binding motifs. CaM adopts a closed conformation in the absence of 
calcium and changes to an open conformation exposing a large hydrophobic 
binding site in the presence of calcium (Babu et al., 1985; Zhang et al., 1995).  
    The crystal structure of EF with and without CaM and inhibitor, solved by 
Drum et al (2001), showed that the C terminus of EF consists of three 
domains, CA, CB and a helical domain. A linker region connects CA to the 
helical domain and CA and CB together form the catalytic core of the enzyme. 
CaM binding causes large conformational changes in the structure of EF. 
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CaM is almost completely wrapped by a clamp formed by CA, linker and the 
helical domain in such a manner that it causes a 30˚ rotation and a 15Å 
movement of the helical domain. In addition, three regions, switch A, B and C 
in EF also undergo large conformational changes due to CaM binding. Switch 
A (residues 502-551) consists of amino acid residues important for CaM- and 
nucleotide binding. Switch B (residues 578-591) contains residues important 
for ATP binding and catalysis. Switch C (residues 630-659) consists of 
residues from the linker region and swings almost 33Å when CaM binds to 
EF. The EF-CaM interaction is stabilized and strengthened by a large number 
of both hydrophobic and hydrophilic contacts. FRET (Fluorescence 
resonance energy transfer) experiments have also shown that CaM binds to 
EF in an extended conformation unlike its binding to a number of other 





















Figure 1-11 Crystal structure of EF (a) EF alone (b ) EF with bound CaM 
and 3’dATP (Drum et al 2002)  
CA and CB domains of EF are shown in green and the helical domain is shown in 
yellow. Switch A, B and C regions are shown in blue, orange and magenta 
respectively. CaM is shown in red and metal ions and 3’dATP are shown in purple. 
CaM is wrapped by the helical domain and the switch A, C and CA regions. The CA 
and CB domains form the catalytic core of EF (Drum et al., 2002). 
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1.2.6 Catalytic mechanism of EF 
    Following activation of EF by CaM, EF catalyzes conversion of ATP to 
cAMP. Several crystal structures of EF with bound CaM and 
nucleotide/inhibitor have been solved that greatly helped to improve our 
understanding of the ATP binding and catalysis processes. The first crystal 
structure of EF with bound CaM and 3’ d ATP published by Drum et al (2002) 
indicates a single metal ion-mediated catalytic mechanism unlike the 
mammalian ACs where two-metal-ion-catalysis is observed. Drum et al 
(2002) observed that the single metal ion is coordinated by a pair of aspartate 
residues (D491 and D493) and interacts with the oxygens of the α and β 
phosphates of the substrate analog 3’dATP. Furthermore, H351 serves as a 
catalytic base and is thought to interact with the 3’-OH of the substrate to 
promote nucleophilic attack (Drum et al., 2002). In support of this hypothesis, 
Gupta et al (2005) have shown in their kinetic studies that when H351 was 
mutated to alanine, aspargine or phenyl alanine, AC activity was reduced 
several fold, indicating the importance of H351 in catalysis by EF (Gupta et 
al., 2005).  
    Shen et al (2005) refined the first model and found that EF contains two 
metal ions similar to mammalian ACs and DNA polymerases. Metal ion A is 
coordinated by the conserved aspartate residues and H577. Metal ion B is 
coordinated by D493 and the non-bridging oxygens of all three phosphates of 
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ATP. Furthermore, it was shown that H351 may not act as a catalytic base 
because it was at least 6Å away from the 3’-OH of the substrate making it 
unlikely to be able to accept a proton from the 3’-OH during the cyclization 
reaction. Site directed mutagenesis studies have shown that when H351 was 
mutated to lysine, there was no change in AC activity or the pH optimum, 
further confirming that H351 is not the catalytic base but may act to stabilize 
the 3’-OH group. Nonetheless, both crystal structures have indicated several 
amino acid residues that are important for interaction of EF with substrate 
ATP. R329, K346, S354 and K372 interact with the phosphates of 3’dATP 
and are important for stabilization of the reaction intermediate and the release 
of the PPi. The side chain of N583 hydrogen bonds with the ribose ring and 
holds the 3’-OH group in place for nucleophilic attack.  
    Shen et al (2004) have also demonstrated an alternate binding mode of 
ATP to the catalytic core of EF. They showed that AMPCPP (adenosine 5’-(α, 
β-methylene)-triphosphate) binds to EF differently compared to 3’dATP and 
2’d3’ ANT-ATP. The ribose ring of AMPCPP is rotated 105˚ and the adenine 






Figure 1-12 Catalytic mechanism of EF 
(a) A ball and stick model of the EF active site. EF shown in green, side 
chains of important residues in blue and ligand in black (Drum et al., 2002);  
(b) Proposed catalytic mechanism of EF. Single metal ion-mediated catalysis 
is shown. H351 is indicated as the catalytic base (Drum et al 2002); (c) 
Simulated model based on the EF-CaM-3’dATP catalytic site. EF is in green, 
ligand in black and Mg ions are shown in orange (Shen et al., 2005); (d) 











1.2.7 Challenges, limitations and future directions  of anthrax research 
with special focus on EF 
     With a better understanding of the detrimental effects of anthrax, it will 
become possible to develop highly specific control measures to prevent and 
treat anthrax infections. The efficacy of the AVA vaccine currently used is a 
cause for major concern since adverse side effects have been reported in 
some cases. Another disadvantage of AVA vaccine is that it is available only 
for military personnel. Antibiotic treatment is effective only against the 
cutaneous forms of anthrax. Therefore, there is a need for better 
vaccinations, drugs and other therapeutics to prevent anthrax infection not 
only in military personnel but also in humans and animals that are at a higher 
risk of contracting the infection.  
     With recent evidence that LF binds to monomeric PA, the question arises 
as to whether monomeric PA could translocate LF and EF into the cytosol? 
To this end, it has been shown that LF binds to monomeric PA with low 
affinity and would probably require PA oligomer/heptmer for its translocation. 
Another important challenge faced by researchers is the lack of crystal 
structure of PA heptamer since it is a transmembrane protein. Solving the 
crystal structure of the PA heptamer would substantially improve our 
understanding of the PA prepore formation, binding of LF and EF, and help 
develop PA-based inhibitors. With the current model of the PA heptamer, it is 
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known that the Φ clamp formed by the PA heptamer facilitates the 
translocation of EF and LF, however, it is not clear how these proteins unfold 
and refold in the cytosol. 
     With the solution of crystal structures of both LF and EF we have gained 
considerable insight into the catalytic mechanisms of these toxins. What 
remains to be determined is how EF and LF carry out a synergistic action to 
impair the immune system and whether or not they must interact with other 
proteins as part of this process.  
     Using various approaches to study the anthrax toxins, several steps in the 
intoxication mechanism can be blocked and studied for future rational drug 
design. For example, the binding sites of EF on PA have been mapped, so it 
would be interesting to study inhibitors that would block EF-PA interaction, 
thus preventing entry of EF into the cytosol. Once inside the cell, inhibitors 
can be developed to block two important processes of EF. One is CaM-
dependent activation of EF, the second is the catalytic activity of EF. The 
crystal structure of EF-CaM shows that EF makes extensive contacts with 
CaM and CaM changes the conformation of EF from a closed to an open 
conformation, thus exposing the substrate binding site. An important 
challenge here is to understand the specificity of this interaction, since CaM is 
a ubiquitously expressed protein that binds to several other protein targets. 
Although several small molecules have been designed to block the catalytic 
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activity of EF both in vitro and in vivo, there is a critical need for more potent 
and cell-permeable inhibitors (Chen et al., 2008; Pini et al., 2006).  
     In summary, early detection, appropriate timely treatment and improved 
vaccines combined with a better understanding of the molecular basis of the 
biological action of anthrax toxins are critical for control and prevention of 
anthrax. 
 
1.3 Research presented in this thesis 
     This thesis is comprised of two independent yet interconnected projects 
aimed at improving our overall understanding of the regulation of mammalian 
adenylyl cyclases and bacterial adenylyl cyclase toxins. The specific aims 
are:  
• Monitor binding and  conformational changes in mACs and EF using 
fluorescent nucleotides as probes; 
• Characterize different AC isoforms using fluorescent nucleotides and 
identify potent isoform-specific mAC inhibitors; 
• Characterize individual catalytic subunits, C1 and C2, of mACs using 
biochemical and biophysical approaches;  
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• Studying EF-Calmodulin interaction and identify potent EF inhibitors for 
rational drug design. 
     Chapter 2 describes the interaction of fluorescent nucleotides with purified 
C1/C2 subunits as well as with the holo AC isoforms. Earlier studies in our lab 
have shown that MANT and TNP-nucleotides are potent inhibitors of C1/C2 
and bind in a similar but non-identical way to the catalytic site formed by C1 
and C2. A detailed analysis of MANT nucleotide binding to C1/C2 has been 
carried out. However it is not known if TNP nucleotides inhibit holo AC 
isoforms, and if so, are they isoform specific? The studies focus on interaction 
of TNP purine and pyrimidine nucleotides with both C1/C2 and holo AC 
isoforms and on the specificity of TNP nucleotides for ACs and G-proteins. 
      Recent evidence suggests that AC dimerization occurs via 
transmembrane domains and that the cytoplasmic domains are essential for 
catalytic activity. The cytoplasmic domains C1 and C2 can heterodimerize to 
form the catalytic core of the enzyme. However it is not clear if C1 and C2 can 
homodimerize and if they did then how does this dimerization affect the 
catalytic activity and regulation of mACs?  The studies described in Chapter 3 
are aimed at studying the individual catalytic subunits C1 and C2 of mACs 
using a variety of techniques and addresses the possibility of 
homodimerization of the C1 and C2 subunits and a potential role of this 
dimerization in regulation of mACs. 
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     The primary goal of studies described in Chapter 4 is to study, in detail, 
the inhibitory effects of several MANT nucleotide analogs on EF/CaM. These 
studies also focus on understanding the mechanism of interaction between 
EF and CaM using MANT nucleotides and the effects of modulating this 
interaction. The importance of calcium binding to CaM and the effect of partial 
oxidation of CaM on EF function has been examined.  
     Future perspectives of Chapters 2-4 are discussed in Chapter 5. 
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Chapter 2: Molecular Analysis of the Interaction of  2’, 
3’-O-(2, 4, 6-trinitrophenyl) (TNP) nucleotides wit h 
Purified Catalytic C1/C2 subunits of mammalian 
Adenylyl cyclase and holo Adenylyl cyclase isoforms  
2.1 Introduction 
      Fluorescent nucleotides are excellent probes for investigating receptor-
mediated processes and enzymatic reactions (Jameson and Eccleston, 
1997).  The 2’, 3’-O-(2, 4, 6-trinitrophenyl) (TNP) nucleotides are 
environmentally sensitive fluorescent probes that  have been extensively 
used to study conformational changes in proteins especially in nucleotide 
binding proteins such as P-glycoprotein multidrug transporters and histidine 
protein kinases ( Liu and Sharom, 1997; Stewart et al., 1998). 
      Our earlier studies have shown that MANT-substituted nucleotides are 
potent inhibitors of the soluble C1/C2 as well as several mAC isoforms (Gille 
and Seifert, 2003; Gille et al., 2004). Crystallographic studies also showed 
that TNP-substituted nucleotides can bind to C1/C2 with high affinity (Mou et 
al., 2006). Both TNP and MANT-nucleotides bind to the same catalytic site of 
mAC but in different conformations. Both TNP and MANT-nucleotides are 
environmentally sensitive fluorescent probes, however MANT-nucleotides 
have a high basal fluorescence and the MANT-group isomerizes between the 
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2’ and the 3’ position of the ribosyl moiety of the nucleotide (Gille et al., 2004; 
Mou et al., 2005). In contrast, TNP-nucleotides are more rigid molecules 
attached to both the 2’ and the 3’ position of the ribose moiety and their basal 
fluorescence is almost negligible (Hiratsuka, 2003).  
     A detailed analysis of the substrate binding site in the crystal structure of 
C1/C2 with TNP-ATP suggests that TNP-ATP may hamper important 
movement of protein loops, preventing a conformational change from the 
inactive and open state to the active and closed state (Mou et al., 2006) 
(Figure 2-1). TNP-ATP makes several contacts with residues on both C1 and 
C2.  The two amino groups of TNP-ATP form hydrogen bonds with the amino 
groups of N1022 and N1025 of C2 and the backbone oxygen of A409 of C1. 
K1029 of C2 interacts with phosphates of the substrate ATP to promote 
formation of the active, closed conformation and catalysis. TNP-nucleotide-
binding prevents this interaction. N6 and N7 of the adenine ring of TNP-ATP 
hydrogen bonds with S1028 of C2. Metal ion A is coordinated by D396 and 
D440 of C1. Metal ion B is coordinated by the β and γ phosphates of TNP-
ATP and three residues on C1, D396, I397 and D440 (Mou et al., 2006).  
     An inhibitory effect of TNP-nucleotides on purified C1/C2 has been 
observed in the Seifert laboratory (Gille et al., 2004). Since, UTPγS and 
CTPγS inhibited ACs (Gille et al., 2004), we examined the effect of TNP 
pyrimidine nucleotides on C1/C2. TNP purine and pyrimidine nucleotides are 
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moderately potent inhibitors of C1/C2 (Ki in the nanomolar range) (Table 2-1). 
TNP-nucleotide triphosphates (TNP-ATP, TNP-GTP, TNP-UTP and TNP-
CTP) are more potent compared to TNP-ADP, TNP-GDP and TNP-AMP. 
TNP-nucleotides were more potent when C1/C2 was maximally activated, i, e 
in the presence of both Gαs and FS when compared to submaximal activation 
(only FS, no Gαs). This effect was more pronounced with some TNP-
nucleotides compared to others. The phosphate chain of TNP-nucleotides 
played an important role in inhibition. We observed that removal of the γ-
phosphate of TNP-ATP caused a six fold decrease in affinity for C1/C2. 
Removal of both the β and γ phosphates caused an additional thirteen fold 
decrease in affinity for C1/C2. From the crystal structure of C1/C2 with bound 
TNP-ATP, it is clear that metal ion B interacts with the β and γ phosphates of 
TNP-ATP. Since metal ions are critical for catalysis (Tesmer et al., 1997 and 
1999), removal of these phosphates explains the decrease in affinity of TNP-
ADP and TNP-AMP for C1/C2. Compared with Ki values for other proteins 
inhibited by TNP-ATP, TNP-ATP has the lowest Ki (81 nM) for AC and thus a 
higher affinity than previously observed (Hiratsuka, 1982; Broglie and 
Takahashi, 1983; Thomas et al., 1991).  
     Differential regulation, localization and function of AC isoforms suggest a 
possible way for development of potent AC isoform specific inhibitors 
(Sunahara et al., 1996; Hanoune and Defer, 2001). We have observed that 
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MANT-nucleotides are potent inhibitors of C1/C2. However isoform-specific 
inhibition of MANT-nucleotides was not clearly observed (Gille et al., 2004). 
This chapter primarily focuses on the inhibitory effects of TNP-nucleotides on 
holo-AC isoforms and identification of potent AC isoform-specific inhibitors for 















Figure 2-1 Crystal structure of C1/C2-FS-  Gαs-TNP-ATP (Mou et al., 2006) 
     A detailed analysis of the substrate binding site of C1/C2 is shown here. 
C1 in tan, C2 in mauve and Gsα  is shown grey. FS, TNP-ATP and metal ions 
occupy the cleft formed by C1 and C2. TNP-ATP making contacts with 
important amino acid residues in C1 and C2 are also highlighted. FS and 
TNP-ATP are shown as stick models. Colors of atoms are depicted as C = 
gray, N = blue, O = red and P = green. The two Mn2+ ions are depicted as 





Table 2-1 Inhibition of the Catalytic activity of C 1/C2 by TNP-nucleotides 




2.2 Specific Aims and hypothesis 
   Although from earlier studies, it is clear that TNP-nucleotides inhibit C1/C2 
with great affinity (Ki in the nanomolar range) (Mou et al., 2006), the inhibitory 
properties of TNP-nucleotides for understanding AC isoform-specific inhibition 
has not yet been studied. In the present study, we examine: 1) How TNP- 
purine and pyrimidine nucleotides effect the catalytic activity of C1/C2 in its 
native form i.e., in the absence of the activators Gαs and or Forskolin (FS); 2) 
The inhibitory effect of TNP-nucleotides on holo-AC isoforms, mainly focusing 
on AC1, AC2 and AC5;  3) The conformational changes in C1/C2 due to 
binding of TNP-nucleotides observed by fluorescence spectroscopy; 4) DMB-
FS-induced conformational changes in C1/C2 probed by TNP-nucleotides; 5) 
The specificity of TNP substituted adenine and guanine nucleotides, TNP-
ATP and TNP-GTP for G-proteins in view of the fact that guanine nucleotides 
and adenine nucleotides bind to Gαs- and Gαi- with high affinity and low 
affinity respectively (Gilman, 1987; Birnbaumer et al., 1990). 6) How the TNP-
nucleotide interacts with C1/C2 compared to those of the MANT-nucleotides 
as indicated by fluorescence spectroscopy and enzymatic analysis.  
Based on previous studies using purified C1/C2 and studies carried out in 
our laboratory, we hypothesize that TNP-nucleotides bind with low affinity to 
C1/C2 alone in the absence of its activators, Gαs and or FS, and that both 
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purine and pyrimidine TNP-nucleotides bind to and bring about a major 
conformational change in the C1/C2 catalytic core. 
   In earlier studies of the interaction of MANT-nucleotides with C1/C2, we 
observed that there are subtle differences in binding of MANT-ATP to C1/C2 
compared to MANT-GTP (Mou et al., 2005; Mou et al., 2006). Therefore, we 
predict that there might be similar differences in binding of TNP-ATP to C1/C2 
compared to TNP-GTP and that such differences might be exploited  for the 












2.3 Materials and methods 
2.3.1 Materials 
     VC1, IIC2 and Gαs-GTPγS proteins kindly provided by Drs. S.Sprang and 
T.C.Mou (University of Texas Southwestern Medical Center, Dallas, TX), 
were expressed, purified and stored as described previously (Taussig et al., 
1994; Sunahara et al., 1997; Tesmer et al., 2002).  Baculoviruses encoding 
ACs 1, 2 and 5 were generously donated by Drs. A.G. Gilman and 
R.K.Sunahara (University of Texas Southwestern Medical Center, Dallas, 
TX). Sf9 cells were obtained from the American Type Cell Culture Collection 
(Rockville, MD). TNP-ATP, TNP-ADP and TNP-AMP were purchased from 
Invitrogen. TNP-GTP, TNP-GDP, TNP-UTP, TNP-CTP, MANT-ADP and 
MANT-GDP were obtained from Jena Bioscience (Jena, Germany). An 
overview of the structure of all the TNP-nucleotides (except TNP-AMP) is 
shown in Figure 2-2. FS and DMB-FS (water-soluble analog of FS) were 
obtained from Calbiochem (La Jolla, CA) or Sigma-Aldrich (St.Louis, MO). 
2’5’ dd 3’ATP, myokinase, creatine phosphate (CP), creatine kinase (CK) and 
nucleoside diphosphokinase (NDPK) were obtained from Sigma. [α-32P] ATP 
(6000 Ci/mmol) and [γ-32P]GTP were purchased from PerkinElmer Life 
sciences. Sources of cell culture reagents and other materials have been 
described elsewhere (Gille and Seifert, 2003; Pinto et al., 2008). Construction 
of cDNA, cell culture and membrane preparation of formyl peptide receptor 
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(FPR) coupled to Gαi proteins and the β2-adrenoreceptor coupled to Gαs 
splice variants are as described previously (Wenzel-Seifert et al., 1999; 
Seifert et al., 1998).  
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Figure 2-2 Structure of TNP-nucleotides 
Chemical structure of TNP-nucleotides utilized in this chapter and chapter 3.  
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2.3.2 Experimental methods  
      - Cell culture, expression and membrane prepa ration of recombinant         
holo-AC isoforms 
     Cell culture, expression and membrane preparation were carried out as 
described previously (Seifert et al., 1998; Gille et al., 2002; Houston et al., 
2002). Briefly, Sf9 cells were cultured in SF 900 II medium with 5% (vol/vol) 
FBS and 0.1 mg/ml gentamycin. High-titer baculoviruses were produced in 
two amplification steps as described elsewhere (Houston et al., 2002) and the 
supernatant fluid from each step was harvested and stored at 4˚C. Sf9 cells 
were then infected with the corresponding baculovirus encoding different ACs 
and cultured for 48 hours (1:10 – 1:10,000 dilutions incase of high titer virus 
stocks). Membranes from uninfected Sf9 cells and each AC construct were 
prepared as described previously (Seifert et al., 1998). Briefly, cells were 
harvested and suspensions centrifuged for 10 mins (1,000 x g at 4˚C). Pellets 
were resuspended in lysis buffer following lysis using a Dounce homogenizer. 
Lysis buffer contained 1 mM EDTA, 0.2 mM phenylmethyl-sulfonyl fluoride, 10 
µg/ml each of leupeptine and benzamide with a pH of 7.4. The resultant 
suspension was centrifuged for 5 mins (500 x g at 4˚C) for nuclei 
sedimentation. The supernatant fluid containing the cell membranes was 
transferred to 30 ml tubes and centrifuged for 20 mins (30,000 x g at 4˚C). 
The resultant pellet was then collected and resuspended in buffer containing 
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75 mM Tris/HCl, 12.5 mM MgCl2 and 1mM EDTA, pH 7.4. Protein 
concentration for each membrane was measured using Bio-Rad DC protein 
assay kit (Bio-Rad, Hercules, CA). 0.5 to 1 ml of membrane aliquots were 
prepared and stored at -80C. 
- AC activity assay 
      AC activity assays using C1/C2 was determined as described previously 
(Mou et al., 2005 and 2006). To carry out AC activity assays with C1/C2, 
assay tubes contained 7 nM VCI and 35 nM IIC2 respectively. For inhibition 
experiments with TNP and MANT-nucleotides, concentrations of the 
nucleotides ranging from 1 nM to 100 µM were added to the assay tubes 
before addition of the protein. Reactions were conducted in the presence and 
absence of 45 nM Gαs-GTPγS and 100 µM FS. After an initial preincubation 
for 2 min at 30˚C, 20 µl of reaction mixture containing 100 µM cAMP, 40 µM 
ATP, 10 mM MnCl2, 100 µM KCl, 25 mM Na+ HEPES pH 7.4 and 1 – 1.5 
µCi/tube [α-32P]ATP were added to the assay tubes. After incubation for 20 
min at 30˚C, reactions were terminated by adding 20 µl of 2.2 N HCl. 
Denatured protein was sedimented by a 1-min centrifugation at 25˚C and 
15,000 x g followed by application of 65 µl of the supernatant onto disposable 
alumina columns (1.3 g neutral alumina, Sigma A-1522, super I, WN-6). To 
separate [32P]cAMP from [32P]ATP, 4 ml of 0.1 M ammonium acetate was 
added for elution of [32P] cAMP. Recovery of [32P]cAMP was approx. 80% as 
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assessed with [3H]cAMP set as standard. [32P]cAMP was determined by liquid 
scintillation counting using Ecolume scintillation cocktail or Cerenkov 
radiation. AC assays in the absence of FS and Gαs were carried out using 6 – 
6.5 µCi/tube [α-32P] ATP and incubated for 1 hour at 30˚C before stopping the 
reaction.  
     AC assays using membranes from Sf9 cells expressing AC1, 2 and 5 were 
conducted as described previously (Gille 2004). Membranes were first 
centrifuged for 15 min (15,000 x g at 4˚C) and the pellets were resuspended 
in binding buffer. Each assay tube contained membrane expressing AC (15 – 
20 µg of protein/tube), 10 µM GTPγS, 40 µM ATP, 100 µM FS, 1 mM MnCl2 
and 100 µM cAMP and increasing concentrations of TNP-nucleotides ranging 
from 1 nM to 100 µM. Reactions were carried out as described above for 
C1/C2.  
     In AC experiments shown in Table 2.8,  the AC5 isoform was used and 
additionally reaction mix contained NTP-regenerating system consisting of 2.7 
mM mono(cyclohexyl)ammonium phosphoenol pyruvate,  0.125 IU pyruvate 
kinase and 1 IU myokinase was used as described previously (Gille 2004) to 
study the effect of phosphorylation of TNP-NDPs. In AC experiments with 
nucleoside-diphosphate kinase (NDPK), 1 IU NDPK was added either to the 
protein mix (C1/C2/ Gαs) or to the reaction tubes with nucleotides and 
preincubated for 15 minutes before addition of C1/C2. No major differences 
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were observed between the two conditions. AC experiments with 1 IU CP/CK 
(creatine phosphate/creatine kinase) were carried out in the same manner.  
- Fluorescence spectroscopy 
     All experiments were carried out using a Cary eclipse fluorescence 
spectrophotometer at 25C (Varian, Walnut Creek, CA). Measurements were 
performed using a quartz fluorescence microcuvette (Hellma, Plainview, NY) 
and the final assay volume was 150 µl. For TNP-nucleotides, steady-state 
emission spectra were recorded at low speed with  λex = 405 nm (λem = 500 – 
600 nm). Reaction mixture containing 100 mM KCl, 10 mM MnCl2 in 25 mM 
HEPES/NaOH pH 7.4 was added followed by sequential addition of TNP-
nucleotide, VCI/IIC2 and DMB-FS (water soluble analog of FS) to final 
concentrations of 5 µM, 4 µM/25 µM and 100 µM respectively. All the 
experiments were also carried out in the presence of 10 mM MgCl2. For the 
TNP-nucleotides, measurements were also carried out in the kinetic mode 
with the range 405-550 nm to measure the rate of binding of TNP-nucleotides 
to C1/C2.  For competition experiments with 2’5’ dd 3’ ATP, experiments were 
carried out similarly except that 2’5’ dd 3’ ATP was added in place of DMB-
FS. Reactions were also carried out in the kinetic mode to observe the 





- Steady-state GTPase assay  
     GTPase assays were carried out as described previously (Gille et al., 
2004). Membranes with β2AR- Gαs and FPR- Gαi fusion proteins were thawed 
and centrifuged for 15 min (15,000 x g at 4˚C) to eliminate any endogenous 
nucleotides. Pellets were resuspended in Tris-HCl, pH 7.4.  Assay tubes 
contained, in a final volume of 80 µl, 10 µg of protein/tube, 1 mM AppNHp, 
100 nM unlabeled GTP, 100 µM unlabeled ATP, 1 mM MgCl2, 100 µM EDTA, 
0.2% (mass/vol) bovine serum albumin, 5 mM creatine phosphate, 40 µg 
creatine kinase in 50 mM Tris-HCl, pH 7.4, TNP-ATP or TNP-GTP at varying 
concentrations and 10 µM isoproterenol  and N-formyl-L-methionyl-L-leucyl-L-
phenylalanine (FMLP) to fully activate β2AR- Gαs and FPR- Gαi fusion 
proteins respectively.  Assay tubes were incubated for 3 min at 25˚C following 
addition of 20 µl of [γ-32P]GTP (0.2 µCi/tube). Reactions were carried out for 
20 min at 25˚C and terminated by adding 900 µl of slurry (5% mass/vol) 
activated charcoal and 50 mM NaH2PO4, pH 2.0). Charcoal terminated 
reaction mixtures were centrifuged for 15 min (15,000 x g at room 
temperature). 700 µl of supernatant liquid were removed from each assay 
tube and 32Pi was determined by liquid scintillation counting. In the presence 
of 1 mM unlabelled GTP, non-enzymatic degradation of [γ-32P]GTP was 




- Molecular Docking and scoring method 
    Docking studies were carried out in collaboration with Mou’s group. The X-
ray crystal structure of VC1:IIC2:FSK:Gαs-GTPγS in complex with TNP-ATP 
and two Mn2+ ions (PDB ID:1GVD) was used as a model for docking other 
TNP-nucleotides. TNP-ATP and all the other atoms and associated residues 
within 5 Å of the ligand were used to define the active site of the mAC 
catalytic core complex. In the first step, modeled TNP-ATP was aligned to the 
one in the crystal structure. Using the rigid docking method, several 
conformations were generated and the most aligned TNP-ATP model was 
used since it closely mimics the actual TNP-ATP in the crystal structure. 
Similar conformations were generated for all the other TNP-nucleotides using 
the rigid docking procedure.  
- Data Generation and Statistics 
   All the enzymatic assays with saturation curves for inhibitors, were analyzed 
by nonlinear regression using Prism 4.0 software (Graphpad, San Deigo, CA). 
Ki  values expressed in nM were calculated using non-linear regression. Data 
shown are the mean values ± standard deviations of 3-4 experiments 
performed in duplicate. In GTP hydrolysis assays, Ki values expressed as µM 
or µmol/L (???) and 95% confidence intervals were also calculated using 
nonlinear regression.  
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    Fluorescence recordings were analyzed using the spectrum package of the 
Cary Eclipse software and final graphs were prepared using Graphpad prism 
4.0 software. Similar results were obtained from 3 – 4 independent 
experiments using three different batches of VCI and two different batches of 
IIC2.  
    Docking calculations were carried out using the GOLD 3.0.1 docking 
software. The Goldscore and Chemscore scoring functions were used to rank 
different binding poses. GOLD 3.0.1 GA parameter was used to encode the 














2.4 Results and discussion 
2.4.1 Enzymatic analysis of the interaction of TNP-n ucleotides with 
C1/C2 
     As was reported previously (Mou et al., 2006) the purine-substituted 
nucleotides TNP-ATP, TNP-GTP and the pyrimidine-substituted nucleotides 
TNP-UTP, TNP-CTP potently inhibited C1/C2 when maximally stimulated by 
FS, Gαs and Mn
2+ (Ki values in the 100 nM range) (Table 2-1). It is also very 
clear that with the elimination of γ phosphate in TNP-ATP and TNP-GTP, the 
Ki values increased several fold. With the elimination of both the β and γ 
phosphates in TNP-ATP, the Ki value was further increased.  
     In order to fully understand the structure-activity relationship for the 
inhibition of C1/C2 by different TNP-nucleotides, the potencies of TNP-
nucleotides in inhibiting C1/C2 in the absence of both the activators, Gαs and 
FS, was determined (Table 2-2). By omission of the activators the Ki 
increased several-fold. This is in accordance with earlier findings that FS and 
Gαs together and separately change the relative conformation of C1/C2 and 
promote catalysis (Sunahara et al., 1997). This indicates that FS, a non 
physiological activator, and Gαs, a physiological activator, are important for 
mAC catalysis. Furthermore, in the absence of Gαs and FS, the reduced 
apparent affinity for C1/C2 was different for different TNP-nucleotides. Even 
in the absence of Gαs and FS, TNP-ATP was the most potent inhibitor (Ki = 
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3.3 µM) of C1/C2 compared to other TNP-nucleotides. This reduced affinity of 
TNP-nucleotides for C1/C2 can also be explained by the fact that FS and Gαs 
binding to C1/C2 gives rise to a tighter binding and change in conformation. 
Therefore, in the absence of these activators, C1/C2 is in its native state with 
a completely different conformation prior to Gαs and FS binding.  
   It must be noted that in our AC experiments Mn2+ was used because Mn2+ 
is a more effective activator than Mg2+ (Dessauer and Gilman, 1997; Johnson 
et al., 1989). We have also observed that the inhibitor affinity is greatly 
reduced when Mn2+ is replaced by Mg2+(data not shown). 
     Though TNP-ATP and TNP-GTP have very similar potencies for C1/C2 in 
the presence of FS and Gαs, we shall explore the differences in their binding 









Table 2-2 Inhibitory potencies of TNP-nucleotides u nder different 
experimental conditions 
     Catalytic activity assays of C1/C2 were performed as described in section 
2.3.2. Assay tubes contained 7 nM VCI and 35 nM IIC2. Concentrations of 
TNP-nucleotides ranging from 1 nM to 100 µM were added to the assay tubes 
before addition of the protein. Reactions were conducted in the presence and 
absence of 45 nM Gαs-GTPγS and 100 µM FS.  Reaction mixture (20 µl) 
containing 100 µM cAMP, 40 µM ATP, 10 mM MnCl2, 100 µM KCl, 25 mM 
HEPES/NaOH pH 7.4 and 1 – 1.5 µCi/tube [α-32P]ATP were added to the 
assay tubes.  AC assays in the absence of FS and Gαs were carried out using 
6-6.5 µCi/tube [α-32P] ATP (25 µl) and incubated for 1 h at 30˚C before 
stopping the reaction. All enzymatic assays with saturated inhibition curves 
were analyzed by nonlinear regression using Prism 4.0 software (Graphpad, 
San Deigo, CA). Ki  values are expressed in nM and data shown are the mean 









C1/C2+ Mn2++FS+ Gαs  C1/C2+ Mn
2+  
TNP-ATP 100 ± 30 81 ± 27 3,300 ± 1400  
TNP-ADP 2,000 ± 660 1,300 ± 280 11,400 ± 5900  
TNP-AMP 21,000 ± 7,200 17,000 ± 6,000 -  
TNP-GTP 430 ± 130 83 ± 22 6,420 ± 2000  
TNP-GDP  8,100 ± 2,900 9,400 ± 1,800 15,200 ± 400  
TNP-UTP 92 ± 9 92 ± 36 14,300 ± 0  
TNP-CTP 110 ± 16 310 ± 76 8,570 ± 0  
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Figure 2-3 Inhibition of catalytic activity of C1/C 2 by TNP-nucleotides 
under different experimental conditions 
    Saturation curves for different TNP-nucleotides under three different 
experimental conditions are shown. A, in the presence of FS (sub maximal 
activation of C1/C2.  B, in the presence of Gαs and FS (maximal activation of 
C1/C2). C, in the absence of both Gαs and FS (C1/C2 in native state). 
Catalytic activity assays of C1/C2 inhibited by TNP-nucleotides were carried 
out as described in section 2.3.2. Saturated curves shown are representative 















2.4.2 Enzymatic analysis of the interaction of TNP-n ucleotides with holo-
AC isoforms 
   Crystallographic studies have provided us with insight into TNP-ATP 
binding and interaction with important amino acid residues in the catalytic 
pocket formed by C1 and C2 (Mou et al., 2006). Enzymatic studies have 
helped to show that TNP-nucleotides are potent inhibitors of C1/C2. However 
it is important to examine the effects of TNP-nucleotides on holo enzymes in 
membrane preparations to identify isoform-specific inhibitors. 
Baculovirus encoded AC1, 2 and 5 isoforms were expressed in Sf9 
cells. Sf9 cells have been widely used to express recombinant proteins and 
are excellent expression systems for mACs (Feinstein et al., 1991; Tang et 
al., 1991; Taussig et al., 1993). Since Sf9 cells express an unidentified 
endogenous membrane AC, it is also important to measure basal AC activity 
in uninfected Sf9 AC membranes to make sure that cAMP signaling is partly 
(??) due to endogenous ACs in Sf9 and not due to over-expression of 
mammalian ACs (Tang et al., 1991; Mouillac et al., 1992; Houston et al., 
2002). Furthermore, in order to ensure a smaller background activity, Sf9 
cells with virus encoded GAIP protein was used to study AC activity. GAIP 
protein is a GTPase-activating protein that interacts with GαI and is irrelevant 
with respect to AC regulation (De Vries et al., 1995). Moreover, Sf9 cells do 
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not express Gi, GAIP proteins act as controls when measuring AC activity in 
Sf9 membranes, both infected and uninfected.  
    Before examining the effects of TNP-nucleotides on recombinant AC 
isoforms, it was important to confirm that the AC isoform retained its natural 
properties, i,e, if it is activated by mediators such as FS and Gαs. 
Experiments were carried out under four different conditions: 1, Basal AC 
activity; 2, AC activity with FS as activator; 3, AC activity with GTPγS; 4, AC 
activity with both FS and GTPγS. ACs 1, 2 and 5 were compared in parallel 
with uninfected Sf9 membranes and GAIP membranes.  Membranes were 
analyzed in duplicate and three different batches of membranes were used.  
Membranes expressing AC1, 2 and 5 when activated by both FS and GTPγS 
showed maximal AC activity. In addition, as expected, AC activity was several 
fold higher in membranes with AC1, 2 and 5 isoforms (266 ± 12, 120 ± 8, 108 
± 7 pmol/mg/min respectively) when compared to uninfected Sf9 membrane 








Figure 2-4 AC activity in membranes from uninfected  Sf9 cells and 
membranes from Sf9 cells expressing GAIP, AC1, AC2 and AC5 under 
different experimental conditions 
    AC activity was measured in membranes from uninfected Sf9 cells, GAIP 
and holo-AC isoforms under four different experimental conditions: 1, Basal 
condition with no activation; 2, 100 µM FS; 3, 10 µM GTPγS; 4, 100 µM FS/10 
µM GTPγS. Each assay tube contained ~20 µg membrane/tube, 40 µM 
unlabelled ATP, 5 mM MnCl2, 100 µM cAMP and 1 – 1.5 µCi/tube [α-
32P]ATP. AC activity assay was carried out as described in section 2.3.2. AC 
activity measured in pmol/mg/min was calculated by non-linear regression. 
Data were obtained from 2-3 independent experiments from different 















    A systematic analysis of the structure-activity relationship of TNP-
nucleotides with holo-AC1, AC2 and AC5 isoforms was carried out to identify 
possible isoform-specific inhibitors and for a detailed comparison with results 
from C1/C2 inhibition described in section 2.4.1  
    In general, all four TNP-NTPs, i,e, TNP-ATP, TNP-GTP, TNP-UTP and 
TNP-CTP are potent inhibitors of AC1, 2 and 5 isoforms (Ki values in the 
nanomolar range). Among all AC isoforms studied, AC1 exhibited the highest 
sensitivity to inhibition by TNP-nucleotides and AC2 showed lower inhibitor 
sensitivity when compared AC1 and AC5. TNP-ATP and TNP-UTP were the 
most potent inhibitors of AC1 isoform (Ki = 9 and 7 nM respectively). TNP-
ATP was the most potent inhibitor for AC5 and was at least 25-fold more 
potent at inhibiting AC5 than AC2. TNP-UTP was the most potent inhibitor for 
AC2. Although most TNP-nucleotides showed a higher selectivity for AC5 
compared to AC2, the differences between specificities of TNP-UTP for AC1, 
AC2 and AC5 were negligible. TNP-CTP also showed very small differences 
in selectivity between AC1, AC2 and AC5 indicating that TNP-pyrimidine 
nucleotides probably bind to AC isoforms in a different manner compared the 
TNP-purine nucleotides. Also, since pyrimidine nucleotides are smaller in 
size, it is possible that they could fit into smaller catalytic pockets in AC 
isoforms when compared to purine nucleotides.  
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     Upon comparing soluble C1/C2 and holo-AC isoforms, a common 
similarity between the two is that holo-AC isoforms are also highly sensitive to 
inhibition by TNP-NTPs than TNP-NDPs. For example, in the case of AC1, 
removal of the γ-phosphate in TNP-ATP reduces the inhibitor affinity by 15-
fold. Removal of both the β- and γ− phosphates of TNP-ATP reduces the 
affinity by an additional 33-fold. We have observed a similar pattern in Table 
2-2 in the case of C1/C2.  A major difference between C1/C2, and holo-AC 
isoforms in general, is that C1/C2 is several-fold less sensitive to inhibition by 
TNP-nucleotides. This difference in sensitivity could be attributed to the fact 
that holo-AC isoforms have transmembrane domains that probably orient the 
catalytic domains in a position favorable for tighter binding and better 
inhibition by TNP-nucleotides. Since C1/C2 are soluble catalytic subunits 
without the transmembrane domains, the positioning of the hydrophobic 
pocket may be relatively different than in the holo-AC isoforms. It must also 
be noted that C1 and C2 subunits are from AC5 and AC2 respectively. 
Therefore, it is also possible that C2(AC2) dominates C1(AC5) and confers 
low inhibitor affinity to the cyclase since TNP-nucleotides have a lower affinity 
for AC2. 
    TNP-nucleotides also differ in their AC-inhibition pattern compared to 
MANT-nucleotides. C1/C2 are more sensitive to inhibition by MANT-
nucleotides compared to holo-AC isoforms whereas the reverse is true for 
TNP-nucleotides. TNP-nucleotides are also more isoform-selective in their 
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inhibition compared to MANT-nucleotides.  Earlier, crystallographic studies 
have shown differences in MANT-ATP, MANT-GTP and TNP-ATP binding to 
the catalytic site of C1/C2 (Mou et al., 2006). Although all three nucleotides 
bind to a common site in C1/C2, there are slight differences in their 
orientations. It is not clear if these differences in orientation may also exist in 
holo-AC isoforms. It is, however, possible that MANT and TNP-nucleotides 
have different binding modes to AC isoforms thus giving rise to properties 











Table 2-3 Inhibition of catalytic activity of AC1, AC2 and AC5 isoforms 
by TNP-nucleotides 
    AC assays using membranes from Sf9 cells expressing AC1, 2 and 5 were 
conducted as described previously (Gille et al., 2004) and in section 2.3.2. 
Each assay tube contained membrane expressing AC (15 – 20 µg of 
protein/tube), 10 µM GTPγS, 40 µM ATP, 100 µM FS, 1 mM MnCl2, 100 µM 
cAMP, 1 – 1.5 µCi/tube [α-32P] ATP and increasing concentrations of TNP-
nucleotides ranging from 1 nM to 100 µM in a final volume of 50 µl. Ki values 
are expressed in nM and were calculated by non-linear regression. Data 
shown are mean values ± S.D. of 3-5 experiments performed in duplicate with 











 TNP-nucleotides           AC1          AC2         AC5  
   TNP-ATP  9 ± 4  99 ± 2  3.7 ± 2  
   TNP-ADP  143 ± 17  1105 ± 176  367 ± 45  
  TNP-AMP  4801 ± 1000  7383 ± 518  4784 ± 1191  
   TNP-GTP  23 ± 2  216 ± 30  27 ± 4  
   TNP-GDP  410 ± 76  3355 ± 1262  1179 ± 277  
   TNP-UTP  7 ± 3  24 ± 12  15 ± 2  











Figure 2-5 AC activity inhibition in AC1, AC2 and A C5 isoforms by TNP-
nucleotides 
   Shown are saturation curves of the relative inhibitory activities of TNP-
nucleotides on the catalytic activity of AC1, AC2 and AC5. AC assays using 
membranes from Sf9 cells expressing AC1, 2 and 5 were conducted as 
described previously (Gille et al., 2004) and in section 2.3.2. Each assay tube 
contained membrane expressing AC (15 – 20 µg of protein/tube), 10 µM 
GTPγS, 40 µM ATP, 100 µM FS, 1 mM MnCl2, 100 µM cAMP, 1 – 1.5 
µCi/tube [α-32P] ATP and increasing concentrations of TNP-nucleotides 
ranging from 1 nM to 100 µM in a final volume of 50 µl. AC activity was 
calculated by non-linear regression and is expressed in pmol/mg/min. Data 
shown are representative of 3-5 experiments performed in duplicate with at 





























































































2.4.3 Characterization of C1/C2 interaction with TNP -nucleotides by 
fluorescence spectroscopy.  
      TNP-nucleotides are environmentally sensitive probes with a λmax 
emission at 550 nm and are weakly fluorescent in aqueous solutions 
(Hiratsuka 1982 and 2003).  However, when placed in a hydrophobic 
environment, the quantum yield of TNP-nucleotides greatly increases making 
them suitable for studying the active site or nucleotide binding sites of 
proteins. TNP-nucleotide binding, particularly TNP-ATP, has been studied in 
relation to myosin, protein kinases, ATPases, enzymes and nucleotide 
binding proteins to monitor conformational changes in these systems 
(Grubmeyer and Penefsky, 1981; Cheng and Koland, 1996; Weber and 
Senior, 1996). In this study, we monitor the binding of TNP-nucleotides to 
C1/C2 catalytic subunits of mAC. 
      Fluorescence emission spectra from TNP-nucleotides were measured in 
the presence and absence of C1/C2 and DMB-FS. TNP-nucleotides show a 
fluorescence peak at 550 nm when excited at 405 nm. The experiments were 
conducted in the presence of either Mn2+ or Mg2+. With the addition of C1/C2, 
the fluorescence increases 3-5 fold with TNP-ATP, TNP-GTP, TNP-CTP and 
TNP-UTP and 50-100-fold in the case of TNP-ADP and TNP-GDP indicating 
a strong interaction between the nucleotide and C1/C2 (Figure 2-6). 
Crystallographic studies of C1/C2 in complex with TNP-ATP (Mou et al., 
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2006) have shown that the amino groups of TNP-ATP form hydrogen bonds 
with A409 on C1 and N1022 and M1025 on C2. It is possible that this 
interaction is responsible for the increase in fluorescence and stabilization of 
TNP-ATP in the hydrophobic pocket of C1/C2. In addition to a several-fold 
increase in fluorescence, we observed that the emission peak shifted to a 
shorter wavelength. The blue shift is due to the binding of the nucleotide in a 
strongly hydrophobic pocket formed by the C1/C2. The magnitude of the blue 
shift was different for different TNP-nucleotides. The adenine nucleotides 
(TNP-ATP and TNP-ADP) and the pyrimidine nucleotides (TNP-UTP and 
TNP-CTP) showed a larger blue shift when compared to the guanine 
nucleotides (TNP-GTP and TNP-GDP) (Table 2-4). Furthermore, there was a 
decrease in fluorescence observed when DMB-FS was added. This reduction 
in fluorescence was most apparent for the adenine and the pyrimidine 
nucleotides and least apparent with the guanine nucleotides (Figure 2-6).  
     All of the nucleotide binding experiments were carried out in the presence 
of Mn2+. When Mg2+was used in place of Mn2+, only a small increase in TNP 
fluorescence was observed when C1/C2 was added (Figure 2-7) and the blue 
shift and decrease in TNP fluorescence upon addition of DMB-FS was less 
pronounced.  Collectively, enzymatic, crystallographic and fluorescence data 
indicate that TNP-nucleotides bind to C1/C2 with higher affinity in the 
presence of Mn2+ than in the presence of Mg2+.  
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    In comparison with MANT-nucleotides, several similarities and differences 
in TNP binding to C1/C2 were observed. Differences in the magnitude of the 
blue shift and in fluorescence amplitude due to FS binding indicate that TNP-
adenine nucleotides interact differently with C1/C2 compared to TNP-guanine 
nucleotides. These results are similar to those obtained for MANT-nucleotides 
where it has been observed that there are slight differences in the interaction 
of MANT-ATP and MANT-GTP with C1/C2 (Mou et al., 2006). Also, the 
apparent affinity of MANT and TNP-nucleotides for C1/C2 is higher in the 
presence of Mn2+ than Mg2+. However, a reduction in TNP-nucleotide 
fluorescence due to FS binding is in striking contrast to MANT-nucleotides 
where an increase in fluorescence was observed with addition of DMB-FS. 
This difference is likely due to the fact that, although MANT-nucleotides and 
TNP-nucleotides bind to a common site in C1/C2, slight differences in their 
orientations may cause a change in the relative conformation of C1/C2 which 
in turn can influence the positioning of DMB-FS.  
    In order to measure the displacement of bound TNP-nucleotides from 
C1C2, a competitive P-site inhibitor of C1/C2, 2’ 5’ dd 3’ ATP, was added 
(Desaubry et al., 1996). 2’ 5’ dd 3’ ATP almost completely displaced TNP-
ATP from the catalytic site of C1/C2 in a concentration dependent manner. 
However not all TNP-ATP was displaced indicating that some of the TNP-
ATP interaction with C1/C2 is may be non-specific.  It is also possible that the 
inhibited conformation of C1/C2 by TNP-ATP is somewhat different from the 
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conformation of C1/C2 in the presence of 2’5’ dd 3’ ATP. This incomplete 
displacement of bound TNP-ATP has also been observed in other nucleotide 
binding proteins (karkaria and Rosen, 1991; Liu and Sharom, 1997) and 
though it has been difficult to explain why this happens, it is still clear that 
TNP-ATP binding is largely reversible and competes with ATP or ATP 














Figure 2-6 Fluorescence emission spectra of TNP-nuc leotides in the 
absence and presence of C1/C2 and DMB-FS  
    Fluorescence experiments were conducted as described in section 2.3.2. 
Steady state emission spectra of TNP-nucleotides were recorded at λex = 405 
nm (λem = 500 – 600 nm). Cuvettes containing 4 µM/25 µM of VCI/IIC2, 100 
µM DMB-FS, and10 mM MnCl2 were equilibrated for 10 min at 25˚C with 5 
µM TNP-nucleotide in a final volume of 150 µl. Representative fluorescence 
emission spectra are shown for TNP-nucleotide alone (dashed line), TNP-
nucleotide in the presence of C1/C2 (bold line), TNP-nucleotide in the 
presence of C1/C2 and DMB-FS (dotted line). Fluorescence intensities are 
measured as percentage of the maximum emission. Fluorescence recordings 
were analyzed using the spectrum package of the Cary Eclipse software. 








              
TNP-ATP - C1/C2 + FS (Mn +2)





























TNP-ADP - C1/C2 + FS (Mn +2)





























TNP-GTP - C1/C2 + FS (Mn +2)





























TNP-GDP - C1/C2 + FS (Mn +2)





























TNP-CTP - C1/C2 + FS (Mn +2)





























TNP-UTP - C1/C2 + FS (Mn +2)































Table 2-4 Blue shift of TNP-nucleotides in the pres ence of C1/C2 
    Fluorescence experiments were conducted as described in section 2.3.2. 
Steady state emission spectra of TNP-nucleotides were recorded at λex = 405 
nm (λem = 500 – 600 nm) in the presence of 4 µM/25 µM of VCI/IIC2, 5 µM 
TNP-nucleotide and 10 mM MnCl2 in a final volume of 150 µl. The magnitude 
of the blue shift was calculated by the difference between the normal 
emission maxima (550 nm) and the emission maxima of TNP-nucleotides in 
the presence of C1/C2. Fluorescence recordings were analyzed using the 
spectrum package of the Cary Eclipse software. Similar results were obtained 
from 3 – 4 independent experiments. 
Nucleotides  Emission peak (nm)  Blue shift by  (nm)  
TNP-ATP 531.5 ± 2 13.5 ± 2 
TNP-ADP 532 ± 1 13 ± 1 
TNP-GTP 537 ± 1 8 ± 1 
TNP- GDP 540 ± 0 5 ± 0 
TNP-CTP 532.5 ± 0.7 12.5 ± 0.7 




Figure 2-7 A comparison of emission spectra of TNP- ATP and TNP-GTP 
in the absence and presence of C1/C2 and DMB-FS and  with Mn 2+ or 
Mg2+ 
    Fluorescence experiments were conducted as described in section 2.3.2. 
Steady state emission spectra of TNP-nucleotides were recorded at λex = 405 
nm (λem = 500 – 600 nm). Cuvettes containing 4 µM/25 µM  of VCI/IIC2 and 
100 µM DMB-FS in the presence of 10 mM MnCl2 or 10 mM MgCl2 were 
equilibrated for 10 min at 25˚C with 5 µM of TNP-nucleotide in a final volume 
of 150 µl.  Representative fluorescence emission spectra are shown for TNP-
nucleotide alone (dotted line), TNP-nucleotide in the presence of C1/C2 (bold 
line), TNP-nucleotide in the presence of C1/C2 and DMB-FS (dashed line). A 
and C are emission spectra of TNP-ATP and TNP-GTP respectively in the 
presence of Mn2+. B and D are emission spectra of TNP-ATP and TNP-GTP 
in the presence of Mg2+. Fluorescence intensities are shown in arbitrary units. 
Fluorescence recordings were analyzed using the spectrum package of the 









Figure 2-8 Displacement of bound TNP-ATP from C1/C2  by 2’5’ dd 3’ 
ATP 
     Fluorescence experiments were conducted as described in section 2.3.2. 
Steady state emission spectra of TNP-nucleotides were recorded at λex = 405 
nm (λem = 500 – 600 nm). Cuvettes containing 4 µM/25 µM of VCI/IIC2 in the 
presence of 10 mM MnCl2 were equilibrated for 10 min at 25˚C with 5 µM 
TNP-ATP and concentrations of 2’5’ dd 3’ ATP varying from 10 mM to 200 
mM. Panel A shows the kinetics of TNP-ATP displacement by 2’5’ dd 3’ ATP 
from C1/C2 in a concentration dependent manner. Fluorescence intensity in 
arbitrary units is measured as a function of time in min. Panel B shows the 
fluorescence emission spectra of TNP-ATP alone (dotted line), TNP-ATP in 
the presence of C1/C2 (bold line), TNP-ATP in the presence of C1/C2 and 
2’5’ dd 3’ ATP (dashed line). Fluorescence intensities are shown as 
percentage of the emission maxima in the respective experiment. 
Fluorescence recordings were analyzed using the spectrum package of the 











2.4.4. Molecular modeling of C1/C2 with bound TNP-A TP and TNP-GTP  
     To explore differences in the interaction of TNP-ATP and TNP-GTP with 
C1/C2, molecular docking experiments were carried out in collaboration with 
Dr. Mou (University of Texas Southwestern Medical Center). TNP-nucleotides 
were rigidly docked into the AC receptor derived from the crystal structure of 
C1/C2 in complex with TNP-ATP in the presence of Gαs, FS and Mn
2+. 
Docking calculations were performed using GOLD 3.0.1 docking software 
(Table 2-5). TNP-GTP was the top-scoring structure (indicating the best-
aligned TNP-nucleotide model) for docking into the catalytic site of C1/C2. 
This is surprising in view of the fact that TNP-ATP is the most potent inhibitor 
of C1/C2 as well as for holo-AC isoforms compared to TNP-GTP. However, it 
should be stressed that docking calculations were made using the C1/C2 
structure in the presence of Gαs and FS. Therefore it must be noted that in 
the presence of Gαs and FS, there is no difference in the Ki values of TNP-
ATP and TNP-GTP at inhibiting C1/C2 (Mou et al., 2006). Furthermore, 
though all four TNP-NTPs have relatively small differences in their docking 
scores, their scores are higher than their corresponding TNP-NDPs. This 
observation also corroborates with our data that TNP-NTPs are more potent 
compared to their respective TNP-NDPs. Also, TNP-UTP and TNP-CTP were 
docked with high scores indicating a strong interaction of these pyrimidine 
nucleotides with the catalytic site of C1/C2.  
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    Using the rigid docking procedure, models of TNP-ATP and TNP-GTP 
docked into C1/C2 were generated. A superimposition of the TNP-ATP 
conformer with the TNP-GTP conformer indicates that though both these 
nucleotides occupy a common site in the catalytic pocket of C1/C2, small but 
significant differences in their interaction can be observed (Figure 2-9). It is 
observed that TNP-ATP and TNP-GTP interact with several amino acid 
residues on C1 and C2, i.e. N1025, K1065 and D1018. These results are 
similar to our crystallography data indicating that these amino acid residues 
are important for binding, stabilization and fluorescence of TNP-nucleotides 
(Mou et al., 2006). Though the TNP-groups and the phosphate chains of 
TNP-ATP and TNP-GTP are aligned along the same sub-sites in C1/C2, 
there is a small difference in the orientation of the purine moiety of TNP-ATP 
and TNP-GTP in the purine binding subsite. A closer look at the purine 
binding site of TNP-GTP docked in the C1/C2 catalytic core indicates that the 
N-2 atom of the guanine ring of TNP-GTP could hydrogen bond with D1018 
(Figure 2-10). It is possible that these differences in TNP-ATP and TNP-GTP 
binding are responsible for the differences observed in fluorescence 
emission, interaction with FS and the blue shift. Collectively, our enzymatic, 
fluorescence and modeling data suggests that TNP-ATP and TNP-GTP 
interact differently at the catalytic site of C1/C2, nonetheless all TNP-NTPs 
are potent inhibitors of C1/C2 because C1/C2 has a spacious base binding 
pocket that can accommodate different purine and pyrimidine nucleotides. 
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Table 2-5 Docking scores of TNP-nucleotides with C1 /C2. Comparison 
with K i values obtained from AC inhibition assays under th ree different 
conditions   
     Docking studies were carried out in collaboration with Mou’s group. The X-
ray crystal structure of VC1:IIC2:FSK:Gαs-GTPγS in complex with TNP-ATP 
and two Mn2+ ions (PDB ID:1GVD) was used as a model for docking other 
TNP-nucleotides. TNP-ATP and all the other atoms and associated residues 
within 5 Å of the ligand were used to define the active site of the mAC 
catalytic core complex. In the first step, modeled TNP-ATP was aligned to the 
one in the crystal structure. Using the rigid docking method, several 
conformations were generated and the most aligned TNP-ATP model was 
used since it closely mimicked the actual TNP-ATP in the crystal structure. 
Docking calculations were carried out using the GOLD 3.0.1 docking 
software. The Goldscore and Chemscore scoring functions were used to rank 
different binding poses. GOLD 3.0.1 GA parameter was used to encode the 
ligand hydrogen-bonding interactions. Docking scores are compared side-by-
side with Ki values of TNP-nucleotides obtained from AC inhibition assays 






(Arbitrary score)  
TNP-
nucleotides  
     C1/C2 
  + Mn2++FS  
      C1/C2 
+ Mn2++FS+ Gαs 
C1/C2 
+ Mn2+  
1 (122.94) TNP-GTP 430 ± 130 83 ± 22 6,420 ± 2000  
2 (122.78) TNP-CTP 110 ± 16 310 ± 76 8,570 ± 0  
3 (111.05) TNP-UTP 92 ± 9 92 ± 36 14,300 ± 0  
4 (105.61) TNP-ATP 100 ± 30 81 ± 27 3,300 ± 1400  
5 (105.10) TNP-GDP  8,100 ± 2,900 9,400 ± 1,800 15,200 ± 400  
6 ( 95.43 ) TNP-ADP 2,000 ± 660 1,300 ± 280 11,400 ± 5900  
7 ( 78.47 ) TNP-AMP 21,000 ± 7,200 17,000 ± 6,000 -  
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Figure 2-9 Models of superimposed TNP-ATP and TNP-G TP docked into 
the active site of C1/C2 
     Docking studies were carried out in collaboration with Mou’s group. The X-
ray crystal structure of VC1:IIC2:FSK:Gαs-GTPγS in complex with TNP-ATP 
and two Mn2+ ions (PDB ID:1GVD) was used as a model for docking other 
TNP-nucleotides. TNP-ATP and all the other atoms and associated residues 
within 5 Å of the ligand were used to define the active site of the mAC 
catalytic core complex. In the first step, modeled TNP-ATP was aligned to the 
one in the crystal structure. Using the rigid docking method, several 
conformations were generated and the most aligned TNP-ATP model was 
used since it closely mimicked the actual TNP-ATP in the crystal structure. 










A. Models of the superimposed inhibitor TNP-ATP and TNP-GTP docked 
to the active site of mAC catalytic core. Ligands are shown as stick 
models; carbon atoms are gray for TNP-ATP and cyan for TNP-GTP. 
Nitrogen, oxygen and phosphorus are shown in blue, red, and green 
respectively. Mn2+ ions are shown in orange. (The same coloring 
scheme is shown in B and in Figure 2-10). Important amino acid 








B. TNP-ATP and TNP-GTP docked to the active site of mAC catalytic 
core. The molecular surface was calculated using the program PYMOL 










Figure 2-10 Model of the purine binding site of TNP -GTP docked into the 
C1/C2 catalytic core 
    Models of the purine binding sites of the superimposed inhibitor TNP-ATP 
and TNP-GTP docked to the active site of mAC catalytic core. Ligands are 
shown as stick models; carbon atoms are gray for TNP-ATP and cyan for 
TNP-GTP. Nitrogen, oxygen and phosphorus are shown in blue, red, and 
green respectively. Mn2+ ions are shown in orange. The N-2 of the guanine 












2.4.5 Effects of TNP-ATP and TNP-GTP on G αs - and G αi -protein 
mediated signaling 
    Heterotrimeric G-proteins (αβγ) mediate signaling from GPCRs to effector 
systems such as ACs (Gilman, 1987; Birnbaumer et al., 1990). Ligand-bound 
GPCRs activate Gα by catalyzing GTP binding to Gα. Gα−GTP then 
dissociates itself from GPCRs as well as from the βγ subunits.  After 
activation of ACs, Gα returns to its ground state when its GTPase activity 
causes hydrolysis of GTP to release GDP and Pi. GTP and ATP bind to G-
proteins with high and low affinity respectively (Gilman, 1987; Birnbaumer et 
al., 1990). To answer the question whether TNP-nucleotides bind to ACs with 
high specificity, we examined the functional effects of TNP-ATP and TNP-
GTP on Gαs - and Gαi -protein mediated signaling. 
     Fusion proteins of β2AR with Gαss, GαsL and Gαsolf respectively and 
fusion proteins of FPR with Gαi1, Gαi2 and Gαi3 respectively expressed in 
Sf9 cells, were studied as models to examine the effects of TNP-ATP and 
TNP-GTP. Steady-state GTPase activity was carried out and we found that 
TNP-ATP and TNP-GTP bind to Gαs - and Gαi -proteins with low affinities 
(Table 2-6). Gαs - and Gαi -proteins bound to TNP-ATP with several-fold 
lower affinity than TNP-GTP. Our results are not surprising in view of the fact 
that although G-proteins can bind ATP and GTP, the nucleotide binding 
pocket of Gα is tight (Rens-Domiano and Hamm, 1995; Sprang, 1997; Zera et 
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al., 1996). Therefore, substitution of the TNP-group at the ribose moiety 
yielding TNP-ATP and TNP-GTP hinders proper binding of these nucleotides 
to the binding pocket of G-proteins and reduces the affinities of ATP and GTP 
for G proteins. Our results are very similar to those obtained for MANT-
nucleotides. MANT-nucleotides are also highly specific for ACs and MANT-
GTPγS and MANT-GppNHp bind to Gαs - and Gαi- with low affinities (Gille 
and Seifert, 2003). Collectively, it is clear that TNP-ATP and TNP-GTP are 
highly specific for ACs and bind to G-proteins with low affinity and therefore 












Table 2-6 Affinities of TNP-ATP and TNP-GTP for G αs - and G αi- proteins  
    GTPase assays were carried out as described previously (Gille et al., 
2004) and in section 2.3.2. Briefly, assay tubes contained 10 µg of 
protein/tube (fusion proteins), increasing concentrations of TNP-ATP or TNP-
GTP ranging from 1 µM to 1 mM, unlabelled ATP and GTP. Additionally 
assay tubes contained 10 µM isoproterenol  and N-formyl-L-methionyl-L-
leucyl-L-phenylalanine (FMLP) to fully activate β2AR- Gαs and FPR- Gαi 
fusion proteins respectively. Data was analyzed by non-linear regression and 
95% confidence intervals have been reported. Ki values are reported in µM 











 TNP-ATP  TNP-GTP  
β2AR- GαsS  
95% confidence interval  
    53  
27 to 104.8 mmol/l  
    12  
7.9 -19  
β2AR- GαsL  
95% confidence interval  
   164.1 mmol/l  
90 to 296.2 mmol/l  
    17.4  
8.8 - 34  
β2AR-Gαolf  
95% confidence interval  
    50  
34 to 74  
    26  
19 - 35  
FPR- Gαi1  
95% confidence interval  
332 mmol/l  
244.5 mmol/l to 451 mmol/l  
    12  
9.6 - 15  
FPR- Gαi2  
95% confidence interval  
263 mmol/l  
112 mmol/l to 616.3 mmol/l  
    6.9  
5.2 - 9.3  
FPR- Gαi3  
95% confidence interval  
329 mmol/l  
174 mmol/l to 621 mmol/l  
    10  





2.4.6 Effect of kinases on the potency of MANT and TNP-NDPs at 
inhibiting ACs 
     A nucleoside triphosphate (NTP) regenerating system was used previously 
in AC assays routinely conducted in our laboratory, primarily to help reduce 
the degradation of NTPs by phosphatases especially in membrane 
preparations thereby keeping the NTP concentrations constant (Johnson, 
1980). It is possible that, in the presence of an NTP-regenerating system, 
MANT-NDPs and TNP-NDPs get phosphorylated to MANT-NTPs and TNP-
NTPs in AC assays, therefore rendering both NDPs and NTPs equally potent.  
     To examine the effect of the NTP regenerating system on the potency of 
MANT and TNP-NDPs at inhibiting ACs, three different systems were used. 
Experiments were carried out with MANT-ADP, MANT-GDP, TNP-ADP and 
TNP-GDP using C1/C2 in the presence and absence of creatine kinase (CK) 
and nucleoside-diphosphate kinase (NDPK) respectively. CK catalyzes the 
phosphorylation of ADP to ATP in the presence of creatine phosphate 
(Tanzer and Gilwarg, 1959).  With C1/C2, in the presence of CK, MANT-ADP 
and TNP-ADP are at least 19-fold and 2-fold respectively more potent than in 
the absence of CK indicating that MANT-ADP and TNP-ADP serve as good 
substrates for CK. However, no change was observed in the affinities of 
MANT-GDP and TNP-GDP for CK in the presence of C1/C2. This 
demonstrates that CK is highly selective towards adenine nucleotides and 
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can phosphorylate MANT-ADP and TNP-ADP to MANT-ATP and TNP-ATP 
respectively.  
     Sf9 cell membranes possess NDPK that catalyzes the conversion of NDP 
to NTP (Gille et al., 2002; Otero, 1990). With C1/C2, using NDPK, there was 
no change in the potencies of MANT- and TNP-NDPs indicating that these 
nucleotides do not serve as substrates for NDPK (Table 2-7).  
     Experiments were carried out with TNP-AMP, TNP-ADP and TNP-ATP 
using AC5 isoform in the presence and absence of a regenerating system 
consisting of pyruvate kinase and myokinase. Pyruvate kinase catalyzes the 
following reaction (Johnson, 1980): 
phosphoenol pyruvate + ADP                     pyruvate + ATP 
     It was observed that TNP-AMP was at least 500-fold more potent in the 
presence of the regenerating system than in its absence (Table 2-8). TNP-
ADP was found to be 50-fold more potent in the presence of the regenerating 
system. As expected, there was no change in the affinity of TNP-ATP in the 
presence and absence of the regenerating system. These data indicate that 
with AC5, pyruvate kinase catalyzes phosphorylation of both TNP-AMP and 
TNP-ADP to TNP-ATP, thus accounting for high potencies of TNP-AMP and 
TNP-ADP at inhibiting AC5. TNP-nucleotide analysis with AC5 was 
conducted in the absence of external NDPK-regenerating system. It must 
however be noted that though AC5 membrane preparations may contain 
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NDPK, the phosphorylation of TNP-AMP and TNP-ADP in this case is solely 
due to pyruvate kinase because we earlier observed that TNP- and MANT-
nucleotides do not serve as substrates for NDPK.  
    Collectively, these studies indicate that in the presence of a regenerating 
system, the potencies of TNP and MANT-NDPs must be more carefully 
analyzed. Also, this furthers shows that both β and γ phosphates of TNP and 
MANT-nucleotides are important for inhibiting C1/C2 as well as holo-AC 












Table 2-7 Inhibitory effects of MANT-ADP, MANT-GDP,  TNP-ADP and 
TNP-GDP on C1/C2 in the presence of a NTP-regenerat ing system  
    AC assays using C1/C2 with CPK and NDPK were conducted as described 
previously (Gille 2004) and in section 2.3.2. Assay tubes contained 7 nM VCI 
and 35 nM IIC2. For experiments with NDPK, concentrations of TNP and 
MANT-nucleotides ranging from 1 µM to 100 µM were added to the assay 
tubes before addition of the protein. For experiments with CPK, 1 nM to 100 
µM concentrations of TNP and MANT-nucleotides were added in the assay 
tubes. One IU NDPK or CPK was added to half the reaction tubes and 
preincubated for 15 minutes before addition of C1/C2. Reactions were 
conducted in the presence of 45 nM Gαs-GTPγS and 100 µM FS. Saturated 
curvesd for Inhibition and 95% confidence intervals were analyzed by 
nonlinear regression using Prism 4.0 software (Graphpad, San Deigo, CA). Ki  







   Control        CPK      Control         NDPK  
MANT-ADP  
95% confidence interval 
3.4 (+) 
1.6 – 6.8  
0.18 (+++) 
0.93 – 0.36  
3.8 (+) 
1.5 – 9.2  
4.3 (+) 
2.7 – 6.9  
MANT-GDP 
95% confidence interval 
1.27 (+) 
0.3 – 4.05  
2.6 (+) 
1.8 – 3.6  
1.02 (+) 
0.4 – 2.5  
1.67 (+) 
0.85 – 3.3  
TNP-ADP 
95% confidence interval 
1.09 (+) 
0.5 – 2.09  
0.516 (+++) 
0.29 – 0.92  
0.51 (+) 
0.2 – 1.2  
1.9 (+) 
1.5 – 2.4  
TNP-GDP 
95% confidence interval 
2.7 (+) 
1.4 – 5.1  
2.6 (+) 
1.1 – 5.8  
3.3 (+) 
2.5 – 4.2  
5.6 (+) 
2.7 – 12  
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Table 2-8 Inhibitory effects of TNP-AMP, TNP-ADP an d TNP-ATP on AC5 
in the presence of an NTP-regenerating system 
     AC assay was carried out as described previously (Gille et al., 2004) and 
in section 2.3.2. Each assay tube contained 32 µg of AC5 protein, 10 µM 
GTPγS, 40 µM ATP, 100 µM FS, 5 mM MnCl2 and 100 µM cAMP. TNP-
nucleotides at final concentrations varying from 0.1 nM to 1 µM were added to 
the assay tubes. Additionally, the reaction mix contained an NTP-
regenerating system consisting of 2.7 mM mono(cyclohexyl)ammonium 
phosphoenol pyruvate,  0.125 IU pyruvate kinase and 1 IU myokinase. 
Experiments were performed in duplicate and data were analyzed by non-
linear regression. Ki values are expressed in nM and numbers with +++ sign 
indicate more potency.  
       Control   Pyruvate kinase  
TNP-AMP  4784 (+)  9.7 (+++)  
TNP-ADP  367 (++)  4.4 (+++)  







     Enzymatic, fluorescence and molecular modeling studies of ACs with 
TNP-nucleotides as probes reveal that TNP-nucleotides are a novel class of 
potent AC isoform-selective inhibitors. A systematic inhibitor analysis of 
purified C1/C2 with TNP-nucleotides under various conditions confirm that 
ACs have a broad base specificity and can accommodate different purine and 
pyrimidine nucleotides. Our studies also show that TNP-NTPs are more 
potent compared to their respective NDPs and NMPs, highlighting the role of 
the β− and the γ-phosphate in AC inhibition. Furthermore, we observed that 
FS and Gαs bring about a dramatic change in the conformation of C1/C2 thus 
allowing TNP-nucleotides to bind and inhibit AC activity much more potently 
than in the absence of the activators. In the absence of FS and Gαs, it was 
observed that TNP-nucleotides weakly bind to C1/C2 bringing us back to the 
question: what the native conformation of C1/C2 is? Since the crystal 
structure of C1/C2 in the absence of FS and Gαs is not yet available, future 
biochemical and crystallographic studies in this area of AC research must be 
carried out to understand the exact conformational change in C1/C2 that 
occurs upon FS and Gαs binding.  
     Enzymatic studies also highlight an important role of TNP-nucleotides in 
isoform-selective inhibition. TNP-ATP and TNP-UTP are the most potent 
inhibitors of the AC1 isoform. For the AC2 isoform, we have observed that the 
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pyrimidine nucleotides TNP-UTP and TNP-CTP are more potent compared to 
purine nucleotides. As indicated earlier that AC2 may have a smaller catalytic 
pocket compared to AC5, we predict that pyrimidine TNP-nucleotides are 
better at inhibiting AC2 due to their smaller size compared to purine TNP-
nucleotides. AC1 and AC2 play an important role in learning, memory and 
synaptic plasticity (Wu et al., 1995; Jourdan et al., 2001). Therefore, the 
inhibitory properties of TNP-nucleotides can be very important for isoform-
specific inhibition of AC1 and AC2. 
     TNP-ATP is the most potent inhibitor of AC5 known so far. Intriguingly, the 
AC5 KO in mouse reduces development of cardiac failure and enhances 
longevity (Okumura et al., 2003; Yan et al., 2007). Thus, AC5 inhibitors may 
become of therapeutic relevance in the future. We have also observed that 
TNP-nucleotides have a higher specificity for holo-AC isoforms compared to 
purified C1/C2 indicating an important role for transmembrane domains in AC 
catalysis. Collectively, since both purine and pyrimidine TNP-nucleotides 
display isoform-selective inhibition, they serve as excellent starting points for 
development of potent isoform-specific AC inhibitors.  
     We have also observed that TNP-nucleotides are highly specific to some 
kinases. Our data clearly show that TNP-nucleotides serve as substrates for 
creatine kinase and pyruvate kinase. Since these enzymes are expressed in 
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several tissues, TNP-nucleotides can be used as prodrugs of AC inhibitors 
and can be valuable in studying AC isoform-selective inhibition in intact cells.  
     Fluorescence spectroscopic studies showed an enhancement in TNP-
nucleotide fluorescence when bound to C1/C2 confirming that TNP-
nucleotides bind to a hydrophobic/non-polar site in the C1/C2 catalytic core. 
Our fluorometric data fit with our crystallographic studies carried out earlier 
showing that TNP-nucleotides interact and form hydrogen bonds with 
important amino acid residues on C1 and C2. This interaction of TNP-
nucleotides with C1 and C2 is responsible for stabilization and fluorescence 
of TNP-nucleotides in the C1/C2 catalytic core. Furthermore, fluorescence 
studies also revealed differences between the interactions of TNP and MANT-
nucleotides with C1/C2. Our data clearly show that FS binding to C1/C2 
causes a decrease in TNP fluorescence and an increase in MANT 
fluorescence indicating their differential interaction with C1/C2. This 
observation is also supported by our crystallographic studies showing that 
MANT-nucleotides are stabilized by interacting with a completely different set 
of amino acid residues on C1 and C2 compared to TNP-nucleotides. 
Additionally, our fluorescence studies have highlighted differences between 
TNP-ATP and TNP-GTP, especially differences in their binding to C1/C2 and 
in the blue shift in fluorescence. This further allowed us to explore their 
differences through molecular modeling. The modeling data revealed that 
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there is a small difference in the orientation of TNP-ATP and TNP-GTP and 
we predict that TNP-GTP but not TNP-ATP may hydrogen bond with D1018.  
   Finally, these studies identified TNP-nucleotides as potent isoform-selective 
inhibitors similar yet different from MANT-nucleotides and as important 
probes to study conformational changes in ACs. It is anticipated that TNP-
nucleotides will be used as valuable tools in understanding regulation of ACs 
and will aid in identification and development of cell permeable isoform-
selective inhibitors.  
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Chapter 3: Biochemical and Biophysical analysis of 
the C1 and C2 catalytic subunits of Mammalian 
Adenylyl Cyclase 
3.1 INTRODUCTION 
    Mammalian adenylyl cyclases (mACs) that catalyze the conversion of ATP 
to cAMP play an important role in the G-protein signaling cascade (Tang and 
Hurley, 1998; Ishikawa and Homcy, 1997; Hanoune and Defer, 2001). Upon 
activation of G-protein coupled receptors (GPCRs) by extracellular signals 
such as hormones or neurotransmitters, GPCRs transmit signals to G-
proteins which in turn activate ACs thus producing cAMP (Cooper et al., 
1995; Defer et al., 2000). Though originally known to act as monomers, it is 
now well accepted that GPCRs can form dimers or oligomers as part of their 
normal function (Jordan and Devi, 1999; Marshall, 2001; George et al., 2002). 
However it is not clearly known if ACs can dimerize or oligomerize and if this 
dimerization of ACs could play an important role in the complex cAMP 
signaling system.  
  Nine different isoforms of mAC have been characterized (AC1-9) and 
all the isoforms share a common topology (Sunahara et al., 1996; Sunahara 
and Taussig, 2002). The AC molecule typically possesses two 
transmembrane domains, TM1 and TM2, and two associated cytoplasmic 
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domains, C1 and C2 respectively (Zhang et al., 1997; Tesmer et al., 1997). 
The C1 and C2 domains share a high degree of sequence homology and are 
further divided into C1a and C1b, C2a and C2b regions respectively. C1a and 
C2a together form the catalytic core of the enzyme as well as sites for 
activation by Gαs and FS. Previous studies have shown that C1a or C2a are 
catalytically inactive but when expressed separately and then mixed together, 
they retain the properties of the original enzyme such as conversion of ATP to 
cAMP and activation by Gαs and FS (Tang and Gilman, 1995; Whisnant et al., 
1996; Dessauer et al., 1998). 
     Hydrodynamic properties of holo-ACs studied using gel filtration and 
density-gradient ultracentrifugation showed  that ACs have a molecular 
weight of ~220 kDa, though the normal molecular weight is ~120 kDa (Haga 
et al.,1977). This indicated that ACs may form dimeric complexes or higher 
order assemblies with other signaling proteins.  Target-size analysis of ACs in 
hepatic membranes demonstrated that ACs in both the ground (no activators 
bound) and active state can form multimeric complexes with regulatory 
proteins such as Gαs as well as receptor proteins (Schlegel et al.,1979). 
Several independent studies using a variety of techniques have demonstrated 
that ACs may exist in dimeric or oligomeric forms interacting with G-proteins 
and GPCRs (Neer et al., 1984; Yeager et al., 1985; Smigel, 1986). In 
addition, ACs belong to the ABC (ATP-binding cassette) transporter protein 
family. Several members of this family such as glutamate transporter and 
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cystic fibrosis transmembrane conductance regulator (CFTR), are multimeric 
in their active forms (Krupinski et al., 1989; Haugeto et al., 1996; Wang et al., 
2000). Coimmunoprecipitation and fluorescence resonance energy transfer 
(FRET) evidence suggests that ACs may undergo dimerization via their 
transmembrane domains, TM1 and TM2 (Gu et al., 2001 and 2002; Cooper 
and Crossthwaithe, 2006). The transmembrane domains are thought to 
function as sites for regulation and oligomerization and the catalytic domains 
constitute the site for AC enzyme activity (Figure 3-1). Baragli et al., (2008) 
have shown that AC2 and AC5 can form heterodimers and this AC2/5 
complex retains all the properties of the original enzyme including activation 
by Gαs and forskolin. In addition, there is also growing evidence that ACs in 
other organisms dimerize via their catalytic domains. FRET measurements of 
Bordetella pertussis AC toxin have revealed their oligomeric behavior in 
solution (Lee et al., 2005). In Mycobacterium tuberculosis, Rv1625c is an AC 
enzyme that shows a high degree of sequence similarity to mammalian ACs 
(Shenoy et al., 2003). The Rv1625c AC is a transmembrane protein with a 
single cytosolic catalytic domain and is known to homodimerize to give rise to 
the functionally active form of the enzyme with two catalytic centers. In 
simpler organisms such as Trypanosoma brucei, AC dimerization occurs 
through their catalytic domains (Beiger and Essen, 2001). Therefore, it cannot 




     Based on sequence similarity between the C1 and C2 catalytic subunits of 
mAC, a crystal structure of C2 homodimer was determined and used as a 
model for the AC catalytic core (Zhang et al., 1997). These studies suggest 
that dimerization of monomers must occur for catalysis, a process further 
promoted by FS. FS is thought to play a key role in bringing the two 
monomers together as well as in interacting with the active site of the 
enzyme. Using gel filtration and sedimentation equilibrium centrifugation 
approaches, Sunahara and group (1997) have shown that C1 and C2 
subunits of mammalian AC may individually exist as homodimers in solution. 
However, when mixed together they found that C1 and C2 subunits have a 
higher propensity to form heterodimers in a manner that is dependent on the 
presence of FS and Gαs (Sunahara et al., 1997). Earlier studies have also 
shown that C1 homodimers may exist but they are catalytically inactive. In 
contrast, a C2 homodimer was shown to have very low catalytic activity and 
could bind ATP analogues (Mitterauer et al., 1998).  
This chapter primarily focuses on analyzing the nucleotide binding and 
catalytic properties of C1 (AC5, C1a region) and C2 (AC2, C2a region) 
domains of mammalian AC using a variety of approaches such as 
fluorescence studies, enzymatic assays, native gel electrophoresis and 
molecular modeling to understand the dimerizing/oligomerizing properties of 
C1 and C2.  
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Figure 3-1 A schematic representation of intra and inter-molecular 
heterodimerization between two AC8 isoforms.  
     Shown here are two AC8 isoforms with transmembrane domains as TM1 
and TM2 and cytosolic domains as C1a, C1b, C2a and C2b. C1a and C2a 
form the catalytic core of the enzyme (from Cooper and Crossthwaithe, 2006). 
FRET analysis also showed that AC8 is capable of intra (between TM1 and 
TM2 of the same molecule) and inter-molecular heterodimerization (between 





3.2 Specific aims and hypothesis 
     ACs dimerize via their transmembrane domains, however, we still do not 
know if the catalytic subunits C1 and C2 play an important role in this 
dimerization. The research described in this chapter aims at answering the 
following questions.   
1. Do C1 and C2 subunits homodimerize in solution?  
2. If C1 and C2 homodimerize, are they catalytically active?  
3. If C1 and C2 homodimerize, do they have a functional nucleotide 
binding site? 
4. If C1 and C2 homodimerize, what is the possible physiological role 
of this dimerization event in vivo?  
Using MANT and TNP-nucleotides as probes, we have studied the 
binding, conformational changes and catalytic activities of C1 and C2.  Based 
on the available evidence, we hypothesize that C1 and C2 homodimerize and 
that the homodimerization may have an important functional significance in 
AC regulation since production and regulation of cAMP is central to several 





3.3 Materials and Methods 
3.3.1 Materials 
     C1, C2 and Gαs-GTPγS were kindly donated by TC.Mou and S.Sprang 
(University of Texas Southwestern Medical Center, Dallas, TX). FS and DMB-
FS were obtained from Sigma and Calbiochem respectively. TNP-nucleotides 
and MANT-nucleotides were obtained from Jena Bioscience (Jena, Germany) 
(Figure 2-2 and 3-2). [α-32P]ATP (3000 Ci/mmol) was obtained from Perkin 
Elmer Life Sciences. Novex® Tris-Glycine native gels (4-12%) and SDS-
PAGE gels were obtained from Invitrogen. Sources of all other materials have 



















3.3.2 Experimental methods 
-     AC activity assay 
      AC activity assays were performed as described in chapter 2. To carry out 
assays with C1 alone and C2 alone, assay tubes contained 1 µM CI and/or 5 
µM C2. Reactions were conducted in the presence and absence of 5 µM Gαs-
GTPγS and 100 µM FS. Twenty µl of reaction mixture containing 100 µM 
cAMP, 40 µM ATP, 10 mM MnCl2, 100 µM KCl, 25 mM HEPES/NaOH pH 7.4 
and 6 – 6.5 µCi/tube [α-32P]ATP were added to each assay tube. For 
inhibition experiments with TNP and MANT-nucleotides, nucleotides at final 
concentrations ranging from 1 nM to 100 µM were added to the assay tubes 
before addition of the protein.   
 
- Fluorescence spectroscopy 
     All experiments were carried out at 25˚C using a Cary Eclipse fluorescence 
spectrophotometer (Varian, Walnut Creek, CA). Measurements were 
performed using a quartz fluorescence microcuvette (Hellma, Plainview, NY). 
Reaction mixture containing 100 mM KCl, 10 mM MnCl2 in 25 mM 
HEPES/NaOH, pH 7.4 was added to the cuvette and the final assay volume 
was 150 µl. For TNP-nucleotides, measurements were carried out as 
described in chapter 2 with 4 µM CI or 25 µM C2 and 100 µM DMB-FS. 
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     For experiments with MANT-nucleotides, steady-state emission spectra 
were recorded with λex = 280 nm (λem = 300 – 500 nm) and λex = 350 nm (λem 
= 370 – 500 nm). Assays were performed as described above except that 
final concentration of 1 µM of MANT-nucleotide, 5 µM C1 and 35 µM C2 were 
used. In order to measure the binding stoichiometry between C1 and TNP-
ATP/GDP, experiments were carried out in the kinetic mode with 4 µM C1 
and increasing concentrations of TNP-ATP and TNP-GDP. Kd values were 
calculated after correction for the inner filter effect based on absorbance of 
the TNP-nucleotides (Lakowicz, 1999). 
 
     -    Native and SDS gel electrophoresis  
C1 and C2 were electrophoresed on 4-12% Novex ® Tris-Gylcine gels 
under native conditions and 10% Bis-Tris gels under denaturing conditions. 
Proteins were visualized using coomassie blue staining.  
 
- Molecular modeling studies 
     Molecular models of the C1 homodimer and C1/C2 heterodimer were 
generated in collaboration with Dr. G. Lushington (University of Kansas, 
Lawrence). To generate the C1+C1 homodimer, the first C1 unit was obtained 
from the crystal structure solved by Tesmer et al. (1997), and the second C1 
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unit was obtained via homology modeling.  Sequence alignment between the 
C1 target and the C2 template was performed via the Clustal-W program 
(Thompson et al., 1994), using the BLOSUM-30 substitution matrix (Henikoff 
and Henikoff, 1993), and standard gap penalties of 10 for opening and 0.1 for 
extension.   
 
- Data Generation and statistics  
    For AC activity assays and inhibition experiments, Vmax, Km, turn over 
number, Ki values and saturation curves for inhibitors were analyzed by 
nonlinear regression using Prism 4.0 software (Graphpad, San Diego, CA). 
The Ki values calculated are apparent Ki values since the protein 
concentration is higher than the ligand concentrations in the experiments 
performed.  
    Fluorescence recordings were analyzed using the spectrum package of the 
Cary Eclipse software and final graphs were prepared using Graphpad prism 
4.0 software. Similar results were obtained from 3 – 4 independent 






3.4 Results and Discussion 
3.4.1 Kinetic studies of C1 and C2 subunits of mAC 
     Previous biochemical studies have shown that C1 is catalytically inactive 
and C2 possesses low catalytic activity (Zhang et al., 1997; Mitterauer et al., 
1998). Since C1 and C2 domains were highly homologous, the C2 
homodimer crystal structure solved by Zhang et al (1997) was used as the 
preliminary model for C1/C2 interaction. However, the structure of C1 has not 
been solved and studies of C1 have been limited to biochemical and 
biophysical approaches.  
To study the properties of the individual subunits C1 and C2, AC 
activity expressed as turnover numbers for C1 and C2 was first determined. 
The catalytic properties of C1 and C2 were examined under four different 
conditions as indicated in Table 3-1. AC activity was observed only in the 
presence of both the activators, Gαs and FS. Catalytic rates for both C1 and 
C2 were very low although significant.  Interestingly, the activity of C1 was 
more than 20-fold higher than that of C2. This is surprising in view of the fact 
that C2 was shown previously to display exceedingly low catalytic activity 
whereas C1 was essentially inactive (Mitterauer et al., 1998).  The same 
group further showed that C2 alone could bind ATP analogs and this binding 
was further enhanced by Mn2+. 
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     The Vmax and Km values for C1 were calculated in the presence of the 
activators, Gαs, FS and Mn
2+ (Figure 3-2). The Km values for C1 ranged 
between 32 and 70 µM and the Vmax value was 110 pmol/mg/min. The Vmax 
value for C1 was much lower than that of the C1/C2 heterodimer (Gille et al., 
2004). Compared to the C1/C2 heterodimer (Gille et al., 2004), the Km value 
of C1 for ATP was several-fold lower, indicating that, although C1 has a very 













Table 3-1 AC activity of C1 and C2 in the presence and absence of FS 
and Gαs 
     AC assays were carried out under four different conditions: 1) Basal; 2) In 
the presence of FS; 3) In the presence of Gαs; and 4) in the presence of both 
FS and Gαs.  Assay tubes contained 1 µM C1 or 5 µM C2. Reactions were 
carried out in the presence or absence of 5 µM Gαs-GTPγS and 100 µM FS. 
20 µl of reaction mixture containing 100 µM cAMP, 40 µM ATP, 10 mM 
MnCl2, 100 µM KCl, 25 mM HEPES/NaOH pH 7.4 and 6 – 6.5 µCi/tube [α-
32P]ATP was added to each assay tube. AC activity was calculated as 
turnover numbers and analyzed by non-linear regression using the Prism 4.0 
software (Graphpad, San Diego, CA). Data shown are the mean values ± SD 
of 2-3 experiments performed in duplicate.  
Additions  C1 (AC activity/min)  C2 (AC activity/min)  
Basal  ND ND 
FS  ND ND 
Gαs  ND ND 




Figure 3-2 C1 AC activity – K m and Vmax determination 
     C1 AC activity assays were performed as described in section 3.3.2. 
Assay tubes contained 1 µM C1, 5 µM GαsGTPγS, 100 µM FS and 10 mM 
MnCl2. Vmax is expressed in pmol/mg/min, Km is expressed in µM and 95% 
confidence intervals were analyzed by non-linear regression using Prism 4.0 
software (Graphpad, San Deigo, CA). 
 
Vmax 
95% confidence interval 
110 pmol/mg/min  
102-117 
Km 
95% confidence interval 




3.4.2 Inhibition of C1 AC activity by MANT and TNP- nucleotides 
     Since C2 AC activity was too small to measure reliably, we examined the 
inhibitory properties of MANT-GTP, TNP-ATP and TNP-GDP on C1 AC 
activity (Figure 3-3). The reason for selection of MANT-GTP and TNP-ATP 
was due to the fact that earlier studies had shown MANT-GTP is the most 
potent inhibitor (Ki = 11 nM) of C1/C2 among the MANT substituted 
nucleotides (Gille et al., 2004; Gille and Seifert, 2003; Mou et al., 2005) and 
TNP-ATP was reported as the most potent (Ki = 81 nM) when compared to 
other TNP-nucleotides (Mou et al., 2006). TNP-GDP was selected because, 
though TNP-GDP poorly inhibited C1/C2 (Ki = 9.4 µM), it showed the largest 
fluorescence change (Figure 3-5) upon binding to C1 alone compared to 
other TNP-nucleotides.  
     MANT-GTP was the most potent inhibitor of C1 activity with a Ki value of 
4.6 nM following maximal activation by Gαs, FS and Mn
2+ (Figure 3-3). TNP-
ATP also potently inhibited C1 with a Ki value of 8.9 nM. TNP-GDP inhibited 
C1 activity with a Ki value of 645 nM. We observed that all three nucleotides 
show higher affinity for C1 when compared to C1/C2. This again points to our 
earlier observation that though C1 has low catalytic activity, it has a high 
affinity for substrate ATP and ATP analogues modified at the ribosyl moiety. It 
must be noted that all the Ki values reported in these experiments are 
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apparent Ki values due to the fact that the concentrations of C1 and C2 were 

















Figure 3-3 Inhibition of C1 AC catalytic activity b y TNP and MANT-
nucleotides 
     Experiments aimed at measuring C1 AC activity inhibition by TNP-ATP, 
TNP-GDP and MANT-GTP were performed as described in section 3.3.2. 
Assay tubes contained 1 µM C1, 5 µM Gαs-GTPγS and 100 µM FS. 
Concentrations of the TNP and MANT-nucleotides ranging from 1 nM to 100 
µM were added to the assay tubes before addition of the protein. Ki values 
(nM) and 95% confidence intervals were analyzed by non-linear regression 
using Prism 4.0 software (Graphpad, San Deigo, CA).  
Nucleotides Ki values 
MANT-GTP  
95% confidence intervals  
4.6 
3.7 – 5.6  
TNP-ATP 
95% confidence intervals  
8.9 
6.7 – 11  
TNP-GDP 
95% confidence intervals  
645 









3.4.3 Fluorescence analysis of the interaction of T NP-nucleotides with 
C1 and C2 
     TNP and MANT-nucleotides bind to a hydrophobic site formed by C1/C2 
as monitored by fluorescence spectroscopy (Mou et al., 2005; Chapter 2). 
Crystal structures of C1/C2 with bound TNP-ATP or MANT-GTP/ATP have 
shown that these nucleotides have slightly different orientations but bind to a 
common site at the C1/C2 interface (Mou et al., 2006). Mitterauer et al., 
(1998) have observed that TNP-ATP fluorescence increases in the presence 
of C2 alone and fluorescence is further enhanced by the addition of MnCl2. 
However, experiments with C1 alone have not been reported so far and it is 
not known if C1 alone can bind TNP and MANT-nucleotides. If so, then it is 
important to see if the nucleotides bind to C1 monomer or a dimer.  
      When TNP-GDP, TNP-ATP and TNP-UTP were excited at 408 nm, they 
emitted a fluorescence peak at ~550 nm (Figure 3-5). With the addition of C1 
to the cuvette containing TNP-nucleotides in the presence of Mn2+, a 3-6-fold 
increase in fluorescence was observed (Figure 3-5 A, B and C). The 
fluorescence increase was dependent on the specific nucleotide studied. A 6-
fold increase in fluorescence was observed with TNP-GDP when bound to C1 
(Figure 3-5A). Additionally, a blue-shift in the emission maximum of TNP-
nucleotides was observed indicating that the TNP-group resided in a 
hydrophobic pocket. The magnitude of the blue-shift was dependent on the 
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respective nucleotide studied. TNP-GDP fluorescence shifted to ~ 537 nm 
from 550 nm (Fig. 3-5A). Similarly with TNP-ATP and TNP-UTP in the 
presence of C1, the emission peak shifted to  ~ 533 nm (Figure 3-5B) and ~ 
530 nm (Figure 3-5C) respectively. Furthermore, upon addition of DMB-FS, a 
decrease in fluorescence was observed and was dependent on the specific 
nucleotide studied. Collectively, the data indicate that all three nucleotides 
bind to C1 but interact in slightly different ways with residues within the 
hydrophobic site on C1.  
    With the addition of C2 to the cuvette containing TNP-nucleotides alone, 
there was no increase in fluorescence observed irrespective of the specific 
nucleotide studied (Figure 3-6 A, B and C). Moreover, there was no change in 
fluorescence observed with the addition of DMB-FS. These results are in 
striking contrast to earlier studies (Mitterauer et al., 1998) which showed an 
increase in fluorescence of TNP-ATP with C2. Therefore our data indicate 
that none of the three TNP-nucleotides studied bind tightly to C2 in the 
absence of C1.  
     To estimate the affinity of TNP-nucleotides for C1, fluorescence 
experiments were carried out with increasing concentrations of TNP-ATP and 
TNP-GDP in the presence of a constant concentration of C1. Kd values were 
calculated after correction for the inner filter effect and substraction of 
baseline TNP-nucleotide-fluorescence in the absence of C1. Apparent Kd 
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values of 0.51 µM and 0.07 µM were calculated for TNP-ATP and TNP-GDP 
respectively at 4 µM C1 (Figure 3-7). These values do not match with the Ki 
values calculate for these nucleotides. It is possible that that this approach 
underestimates the actual affinity of TNP-nucleotides for C1 because higher 
concentrations of C1 are required to observe changes in fluorescence. Also, a 
difference in the binding of TNP-GDP and TNP-ATP to C1 was observed. At a 
constant concentration of C1 (4 µM), with 2 µM TNP-GDP, an increase in 
fluorescence was observed. Beyond 2 µM concentration of TNP-GDP, 
fluorescence intensity constantly decreased. In the case of TNP-ATP, with 2 
µM concentration, an increase in fluorescence intensity was observed. Higher 
concentrations of TNP-ATP did not decrease the fluorescence intensity. 
Based on our observation in chapter 1 that TNP adenine nucleotides interact 
differently with C1/C2 compared to TNP guanine nucleotides, it may be 
possible that TNP-adenine nucleotides interact differently with C1 compared 
to TNP-guanine nucleotides. Nonetheless, saturation of 4 µM C1 was 
observed with 2 µM of TNP-ATP or TNP-GDP. The 1:2 binding stoichiometry 






Figure 3-5 Fluorescence analysis of the interaction  of TNP-nucleotides 
with C1  
     The buffered solution consisted of 100 mM KCl, 10 mM MnCl2 in 25 mM 
HEPES/NaOH pH 7.4. 5 µM (final concentration) of TNP-GDP, ATP or UTP 
(A, B and C respectively - green trace) was added followed by addition of 4 
µM C1 (red trace). 100 µM DMB-FS was added following C1 addition (blue 
trace). Emission spectra were recorded in the emission range 500-600 nm 
with an excitation wavelength of 405 nm. Fluorescence is shown as arbitrary 
units (a.u.). Baseline fluorescence (buffer alone) was subtracted from each 
curve. Similar data were obtained from 3-4 independent experiments using 








Figure 3-6 Fluorescence analysis of the interaction  of TNP-nucleotides 
with C2 
     The buffered solution consisted of 100 mM KCl, 10 mM MnCl2 in 25 mM 
HEPES/NaOH pH 7.4. 5 µM (final concentration) of TNP-nucleotide (3-6 A, B 
and C respectively, green trace) was added followed by addition of 25 µM C2 
(red trace). 100 µM DMB-FS was added following addition of C2 (blue trace). 
Emission spectra were recorded in the emission range of 500-600 nm with an 
excitation wavelength of 405 nm. Fluorescence is shown as arbitrary units 
(a.u.). Baseline fluorescence (buffer alone) was subtracted from each curve. 
Similar data were obtained from 3-4 independent experiments using three 













Figure 3-7 Fluorescence spectra of increasing conce ntrations of TNP-
ATP and TNP-GDP in the presence of C1.  
     4 µM C1 was incubated in buffer containing 100 mM KCl, 10 mM MnCl2 in 
25 mM HEPES/NaOH, pH 7.4 followed by increasing concentrations of TNP-
ATP or TNP-GDP as indicated.  















3.4.4 Fluorescence analysis of the interaction of M ANT-nucleotides 
with C1 and C2 
     In previous studies we have observed that MANT-nucleotides bind to a 
hydrophobic site on C1/C2 as indicated by an increase in fluorescence at 350 
nm (Mou et al., 2005 and 2006). With the addition of DMB-FS, a further 
increase in fluorescence was observed. In addition, at 280 nm, fluorescence 
resonance energy transfer (FRET) was observed between the aromatic 
amino acid residues such as W1020 residue of C2 and the MANT group. 
FRET is a distance-dependent interaction occurring between a donor and an 
acceptor. If the donor and acceptor lie between 10 – 100 Å, a transfer of 
energy occurs from the donor to the acceptor (Lacowicz, 1999). In this case, 
when the MANT-nucleotide in the presence of C1/C2 is excited at 280 nm, 
energy from neighboring groups such as W1020 is transferred to the MANT 
group which in turn gets excited and subsequently emits at ~420 nm (Figure 
3-8). However, it is not known if MANT-nucleotides bind to C1 and C2 alone. 
Therefore, fluorescence experiments were conducted to analyze the changes 
both in intrinsic protein fluorescence via FRET and changes in MANT-






- Interaction of MANT-nucleotides with C1 – FRET meas urements 
     For FRET measurements, we used MANT-GTP and its analogs, 2’ MANT 
3’d GTP and 3’ MANT 2’d GTP. When excited at 280 nm, a small increase in 
fluorescence of MANT-nucleotide was observed around 450 nm (Fig 3-9 A, B 
and C). With the addition of C1, tyrosine and tryptophan fluorescence 
occurred at 350 nm (red trace). Additionally a smaller peak was observed at 
around 430 nm due to FRET from C1 to the MANT-nucleotide. A C1 alone 
trace without bound nucleotide (green trace, Figure 3-9 A, B and C) was 
superimposed on the graphs to indicate the magnitude of FRET. The 
magnitude of FRET was dependent on the specific nucleotide studied. MANT-
GTP showed the lowest FRET compared to 2’ MANT 3’d GTP and 3’ MANT 
2’d GTP.  
     For FRET to occur, the MANT-nucleotide must lie close between 10-100 Å 
of tyrosine/tryptophan residue of C1. When FRET measurements were 
performed using 295 nm as the excitation wavelength (tryptophan specific 
excitation, Lakowicz, 1999), we observed a 2-fold decrease in fluorescence at 
350 nm as well as a decrease in FRET at 430 nm (data not shown). Thus, 
both tyrosine and tryptophan residues must be excited in order to obtain the 
maximum FRET. Based on the primary structure of C1, it is clear that the 
MANT-nucleotide lies in the vicinity of tryptophan residues W502, W507 and 
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tyrosine residues Y383, Y442, Y443, Y535, Y540 and Y557 and these are the 
most likely candidate residues contributing to the observed FRET.  
     We also observed that, in the presence of 2’ MANT 3’d GTP, the intrinsic 
C1 fluorescence decreased at 350 nm with a corresponding increase at 430 
nm (FRET) (3-9 B, red trace). However, in the case of MANT-GTP and 3’ 
MANT 2’d GTP, although FRET was observed, there was no decrease in 
intrinsic C1 fluorescence (Figure 3-9 A and C, red trace). The data indicates 
that the three MANT-nucleotides studied interact differently with C1.  
     We also observed that with the addition of DMB-FS (Blue trace, Figure 3-9 
A, B and C) there was a slight decrease in intrinsic C1 fluorescence and 
FRET. These results are in striking contrast to our earlier studies with C1/C2. 
When DMB-FS was added to C1/C2, a decrease in intrinsic C1/C2 
fluorescence with corresponding increase in FRET was observed (Mou et al., 
2005 and 2006). 
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Figure 3-8 Schematic representation of fluorescence  resonance energy 
transfer (FRET) 
     A schematic representation of FRET between C1/C2 and the MANT group of 
MANT-ATP is shown. Upon excitation at 280 nm (intrinsic protein fluorescence), 
tryptophan and tyrosine residues of C1/C2 emit at 350 nm. From the crystal 
structure of C1/C2 in complex with MANT-ATP, it is clear that the MANT group lies 
in the vicinity of W1020 of C2. Therefore, an energy transfer from W1020 to the 
MANT group causes MANT-ATP to emit at 420 nm.  
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Figure 3-9 FRET analysis of MANT-GTP and its 2’ and  3’ analogs in the 
presence of C1 and DMB-FS 
     Fluorescence measurements were conducted as described in section 
3.3.2. A, B and C are FRET measurements with 1 µM MANT-GTP, 2’ MANT-
3’-d-GTP or 3’ MANT-2’-d-GTP respectively. Steady-state emission spectra 
were recorded at λex = 280 nm (λem = 300 – 500 nm). Five µM C1 and 100 µM 
DMB-FS were included as indicated. Representative emission spectra of 
MANT-nucleotide alone (purple trace), C1 alone (green trace), MANT-
nucleotide in the presence C1 (red trace) and MANT-nucleotide in the 
presence of both C1 and DMB-FS (blue trace) are shown. Fluorescence 
intensity is measured as percentage of the maximal emission spectra 
recorded in the respective experiments. Fluorescence tracings are 
representative for three or four independent experiments using different 












- Interaction of MANT-nucleotides with C1 – Direct fl uorescence 
measurements 
     When excited at 350 nm, MANT-GTP, 2’ MANT 3’d GTP and 3’ MANT 2’d 
GTP emit at 450 nm (green trace, Figure 3-10 A, B and C). With the addition 
of C1 (red trace, Figure 3-10 A, B and C), an increase in fluorescence was 
observed. Additionally, the emission maxima of the MANT-nucleotides 
studied showed a shift to shorter wavelengths (Blue shift). The emission 
maxima for MANT-GTP, 2’ MANT 3’d GTP and 3’ MANT 2’d GTP shifted to 
439 nm, 441 nm and 432 nm respectively. An increase in fluorescence is 
indicative of MANT-nucleotides binding to C1 and the blue shift is indicative of 
MANT-nucleotide residing in a hydrophobic pocket of C1. With the addition of 
DMB-FS (blue trace, Figure 3-10 A, B and C), there was no change in 
fluorescence observed. It was observed previously that addition of DMB-FS to 
C1/C2 caused an increase in fluorescence (Mou et al., 2005 and 2006). The 
lack of effect of DMB-FS observed here with C1 indicates that DMB-FS 








Figure 3-10 Direct fluorescence analysis of MANT-GT P and its 2’ and 3’ 
analogs in the presence of C1 and DMB-FS 
     Fluorescence measurements were conducted as described in section 
3.3.2.  A, B and C are direct fluorescence measurements with MANT-GTP, 2’ 
MANT-3’-d-GTP and 3’ MANT-2’-d-GTP respectively. Steady state emission 
spectra was recorded at λex = 350 nm (λem = 370 – 500 nm). Final 
concentrations of 1 µM MANT-nucleotide, 5 µM C1 and 100 µM DMB-FS 
were used. Representative emission spectra of MANT-nucleotide (green 
trace), MANT-nucleotide in the presence of C1 (red) and MANT-nucleotide in 
the presence of C1 and DMB-FS (blue) are shown.  Fluorescence intensity is 
measured as percentage of the maximal emission spectra recorded in the 
respective experiments. Black arrows indicate the emission maxima of 
MANT-nucleotides alone and in the presence of C1 and DMB-FS. 
Fluorescence tracings are representative for three – four independent 






 - Interaction of MANT-nucleotides with C2 – FRET and direct 
fluorescence measurements  
     MANT-ATP and MANT-GTP were used as probes for FRET 
measurements of C2. With the addition of C2 to the cuvette containing 
MANT-ATP or MANT-GTP, an increase in fluorescence was observed at 350 
nm when excited at 280 nm (red trace, Figure 3-11 A and B). However, there 
was no FRET observed from C2 to MANT group as in the case of C1. A C2 
alone trace (black trace, Figure 3-11 A and B) was superimposed to observe 
the magnitude of FRET, if any. There was no change in fluorescence 
observed with the addition of DMB-FS (blue trace, Figure 3-11 A and B).  
     In direct fluorescence measurements, when MANT-ATP or MANT-GTP 
were excited at 350 nm, the emission maximum was observed at 450 nm 
(green trace, Fig. 4C and D). When C2 was added, there was no change in 
fluorescence observed for MANT-ATP (red trace, Fig. 4C). A slight decrease 
in fluorescence was observed for MANT-GTP (red trace, Fig. 4D). This 
decrease is probably due to the presence of MANT-GTP in a hydrophilic 
environment. With the addition of DMB-FS (blue trace, Fig. 4C and D), again 
there was no change in fluorescence observed. Collectively, these studies 




Figure 3-11 FRET and direct fluorescence analysis o f MANT-ATP and 
MANT-GTP in the presence of C2 and DMB-FS 
     Fluorescence measurements were conducted as described in 3.3.2. A and 
B are FRET measurements; C and D are direct fluorescence measurements. 
A and C are measurements with MANT-ATP; B and D are measurements 
with MANT-GTP. Steady state emission spectra was recorded at λex = 280 
nm (λem = 300 – 500 nm) in A and B; λex = 350 nm (λem = 370 – 500 nm) in C 
and D. Final concentrations of 1 µM MANT-nucleotide, 35 µM C2 and 100 µM 
DMB-FS were used. Representative emission spectra of MANT-ATP/MANT-
GTP only (green trace) and C2 only (black trace) in A and B, MANT-
nucleotide in the presence C2 (red trace) and MANT-nucleotide in the 
presence of both C2 and DMB-FS (blue trace) are shown.  Fluorescence 
intensity is measured as arbitrary units (a.u).  Fluorescence tracings are 
representative for three – four independent experiments using different 
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3.4.5 Native and SDS gel electrophoresis of C1, C2 and C1/C2 
     C1 and C2 are each 25 kDa and together form a 50 kDa heterodimer 
which constitutes the catalytic core of the enzyme (Sunahara et al., 1997). 
C1, C2 and C1/C2 were resolved on Tris-glycine gels under native conditions 
(Figure 3-12 A). We observed that C1 alone (lane 2, Figure 3-12 A) and C2 
alone (lane 3, Figure 3-12 A) migrated with different electrophoretic mobility.  
C1/C2 did not migrate together as one band (lane 4, Figure 3-12A). Under 
native conditions, proteins migrate based on their charge: mass ratio. 
Therefore it is clear that C1 and C2 have different charge densities causing 
them to migrate differently. In case of C1/C2 together, it is not surprising that 
they do not migrate as one band. This is probably due to the fact that they are 
loosely associated in the absence of activators such as Gαs and FS. Our 
results indicate that C1 and C2, under native conditions, exist in different 
forms. As a control, we carried out gel electrophoresis experiments under 
denaturing conditions, as expected, C1 and C2 each migrated at ~25 kDa 







Figure 3-12 Native and SDS gel electrophoresis of C 1, C2 and C1/C2 
     A and B are electrophoresis under native and denaturing conditions 
respectively. Lane 1 is a protein marker, Lane 2 is 4.5 µg C1, lane 3 is 5 µg 
C2 and lane 4 is 2 µg C1 plus 2 µg C2. Proteins were visualized using 
coomassie staining. Shown here are representative results from 3-4 
independent experiments performed with 3 different batches of C1 and C2.  















3.4.6 Molecular modeling of C1 homodimer and C1/C2 heterodimer 
     We have observed that, although C1 exhibits low catalytic activity and C2 
possesses almost no measurable catalytic activity, TNP and MANT-
nucleotides bind to C1 with high affinity. In fluorescence assays, we have 
seen that TNP and MANT-nucleotides bind to C1 with an increase in 
fluorescence and FRET that are indicative of a hydrophobic binding site in C1 
formed probably due to dimerization. The crystal structure of C1 has not been 
solved yet and we know that C2 exist as dimers. Therefore, in collaboration 
with Dr.G. Lushington (Molecular modeling laboratory, University of Kansas, 
Lawrence), based on the crystal structure of C1/C2 (Tesmer et al., 1997), a 
C1 dimer was obtained using homology modeling (Figure 3-13). A 
straightforward explanation for our observation of strong ligand affinity to 
C1C1 but a low catalytic activity is that the R1029 residue in C1.C2 is 
replaced in C1.C1 by a histidine. R1029 is critical for catalysis as it is the 
immediate destination of the proton stripped from the ribosyl 3-hydroxy that 
initiates the cyclization reaction (Tesmer et al., 1997).  The reason for low 
catalytic activity in C1/C1 is probably due to histidine because it may be too 
weak a base to serve this role and, perhaps more importantly, has a shorter 




       Interestingly, Tesmer et al (1997), claim that an alanine mutation of 
R1029 does not diminish the Km of 2', 3’ d-ATP. This indicates that, from the 
perspective of P-site inhibition, stronger interactions of 2’, 3’d-ATP with 
R1029 (both van der Waals and electrostatic) actually correlate with 
somewhat weaker observed affinity.  Therefore, the presence of a smaller 
and electrostatically weaker histidine may actually improve non-catalytic 
binding affinity. 
Molecular modeling studies predict that MANT-nucleotides are stabilized by 
hydrophobic and hydrophilic interactions with C1 homodimer. Based on the 
hydrophobic pocket formed by C1/C1, within a distance of 3 Å and 20 Å, the 
MANT-group can be predicted to interact with lipophilic residues A409, L413, 
W507 and polar residues Q410, S508 and N509. Furthermore, between a 
distance of 3 Å and 20 Å, MANT-group is predicted to interact with the 
tryptophan residues W502, W507 and tyrosine residues Y383, Y442, Y443, 
Y535, Y540 and Y557 of C1. Therefore these are the most likely amino acid 






Figure 3-13 Computational modeling of C1/C1 homodim er and C1/C2 
heterodimer 
     Molecular modeling of C1 homodimer and C1/C2 heterodimer was 
undertaken in collaboration with Dr.Gerald Lushington (University of Kansas, 
Lawrence). To generate the C1+C1 homodimer, based on the crystal 
structure solved by Tesmer et al (1997), the first C1 unit was retained and the 
second C1 unit was mapped to the framework via homology modeling.  
Sequence alignment between the C1 target and the C2 template was effected 
via the Clustal-W program (Thompson et al., 1994), using the BLOSUM-30 
substitution matrix (Hanikoff and Hanikoff, 1993), and standard gap penalties 
of 10 for opening and 0.1 for extension. In the graphic, the ligand shown is 
2’3’ d-ATP bound to C1/C2 heterodimer alternated by C1/C1 homodimer. 
Carbon atoms of R1029 in C1/C2 dimer and the corresponding histidine 























     In this chapter, using a variety of approaches, we have provided a 
demonstration that soluble catalytic subunits of mAC, C1 and C2 can exist as 
homodimers in solution. This homodimerization of C1 and C2 subunits may 
play an important physiological role in signaling.  
Based on our earlier studies of the C1/C2 heterodimer with bound MANT-
ATP, MANT-GTP or TNP-ATP, we have observed that the C2 domain 
contributes a site for purine binding and the C1 domain accommodates 
nucleotide phosphates and metal ions. The MANT or the TNP-group binds at 
the interface between C1 and C2 (Mou et al., 2006). However, we have 
observed an increase in fluorescence and FRET when TNP or MANT-
nucleotide binds to C1. Keeping in mind the fact that C1 accommodates only 
the nucleotide phosphates, it is almost impossible for TNP or MANT-
nucleotide to bind to a monomer of C1. Therefore, we predict that TNP and 
MANT-nucleotides bind to a hydrophobic site formed by two subunits of C1.  
     In our fluorescence assays with C1 alone, we found that FRET occurred 
between C1 and MANT-nucleotide indicating that MANT-nucleotide was in 
close proximity to tyrosine and tryptophan residues of C1. It is interesting to 
note that none of the C1 amino acid residues were responsible for FRET to 
occur between the C1/C2 heterodimer and bound MANT-nucleotide. In fact 
W1020 of C2 was most likely to be mainly responsible for FRET to the MANT 
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group (Mou et al., 2005). This indicates that C1 alone is in an altogether 
different conformation when compared to C1/C2 dimer thus making tyrosine 
and tryptophan residues more accessible for interaction with MANT-
nucleotides. On the contrary, in the case of C2 with MANT-nucleotide, we did 
not observe any FRET between C2 and the MANT group indicating that 
W1020 is not accessible for interaction with MANT-nucleotides. This also 
suggests that the C2/C2 dimer does not have a nucleotide binding site. It 
would be extremely important to solve the crystal structure of C1 homodimer 
and carry out site-directed mutagenesis studies to identify the important 
residues involved in nucleotide binding and the residues responsible for 
FRET to the MANT group of MANT-nucleotides. 
     In addition to the above mentioned differences between C1 homodimers 
and C1/C2 heterodimer, we have also observed that FS interacts differently 
with the C1 homodimer when compared to the C1/C2 heterodimer. In 
enzymatic assays, in the case of C1/C2, submaximal activation of catalytic 
activity was observed in the presence of either Gαs or FS. When both Gαs 
and FS were present together, maximal activation of catalytic activity was 
observed. However, in the case of C1 homodimers or C2 homodimers, to 
observe measurable catalytic activity, both Gαs and FS must be present. In 
fluorescence experiments, addition of DMB-FS increased fluorescence of 
MANT-nucleotides when bound to C1/C2 (Mou et al., 2005 and 2006). In 
striking contrast, we found that when DMB-FS was added, a decrease or no 
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change in MANT-nucleotide fluorescence was observed when bound to C1 
homodimer and C2 homodimer respectively. All these differences point to the 
fact that FS induces different conformational changes in homodimers vs. the 
heterodimers. 
 
     Based on our enzymatic studies, it is also clear that C1 shows low catalytic 
activity but a high affinity for substrate ATP, and C2 has extremely low 
catalytic activity. Our molecular modeling data support the above observation 
of strong ligand binding affinity to the C1 homodimer but an absence of 
catalytic activity due to replacement of Arg1029 in C1/C2 with a histidine in 
C1/C1. In electrophoresis experiments, C1 forms higher order aggregates in 
native PAGE, probably dimers but the interaction is probably unstable under 
the electrophoresis conditions. However based on the observed results, we 
predict that a dimer is a minimum that C1 can form with a low catalytic activity 
but a functional nucleotide binding site. 
      Earlier studies by Mitterauer et al. have shown that TNP-ATP can bind to 
C2 (Mitterauer et al., 1998). These results were surprising because our 
fluorescence experiments suggest that TNP-nucleotides do not bind to C2. 
There have been some differences in the experimental protocols, namely, the 
C2 used by Mitterauer et al, had a hexa-His tag at the N-terminus whereas 
the C2 used in our experiments was C terminal His-tagged. Also, the 
concentrations of TNP-nucleotide used were different, since fluorescence 
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assays are extremely sensitive and concentration dependent, we have used 5 
µM TNP-nucleotide final concentration versus 100 µM TNP-ATP used by 
Mitterauer et al. However, it is not entirely clear if positive results obtained by 
Mitterauer et al. can be attributed to the above mentioned differences. 
      In previous studies with AC6 (Ding et al., 2005) and AC8 isoforms (Gu et 
al., 2001), it was observed that AC6 dimerizes via the TM1 domain and AC8 
via the TM2 domain. In both cases, the dimerized forms showed lower 
plasma membrane expression and AC activity when compared to full length 
AC6 or AC8. The lower AC activity in AC6 is probably because when the two 
TM1 domains dimerize, the C1 subunits attached to TM1 domains may also 
dimerize to form a site with low catalytic activity but high affinity for ATP. 
Similarly, in the case of AC8, when TM2 regions dimerize, C2 domains may 
form dimers with low catalytic activity. 
 
- Physiological relevance of C1 and C2 homodimers and  isoform-
specific heterodimers 
     Preformed homodimers of C1 and C2 may play several important roles. 
Since C1 and C2 must dimerize to convert ATP to cAMP, dimerization of 
individual subunits of C1 and C2 may play an autoinhibitory role to serve as a 
checkpoint for excessive cAMP production. Since our studies were carried out 
using only C1a and C2a regions, an important role for C1b regions and the 
TM regions cannot be ruled out. In an intact molecule, it is well possible that 
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TM regions may prevent or promote homodimerization of C1 and C2 
domains. 
     So far, we have seen that AC isoforms prefer to dimerize with their own 
kind instead of different isoforms (Cooper and Crossthwaithe, 2006). 
However, using a combination of approaches, recent studies have shown that 
a functional heterodimer of AC2/AC5 was localized on the plasma membrane 
in live cells (Baragli et al., 2008). AC2 and AC5 alone and together were co-
expressed with Gαs in HEK293 cells and treated with FS. It was observed that 
cAMP accumulation in cells expressing both AC2 and AC5 was 6 times 
higher when compared to cells expressing either of the two AC isoforms. This 
production of cAMP was further enhanced by treatment with FS. These 
properties of the AC2/AC5 heterodimer are very similar to the soluble C1/C2 
used as a model for AC catalysis and regulation over the last several years. 
This indicates the possibility of cross-talk between C1 of AC5 and C1 of AC2 
or an interaction between the two C2 subunits in the AC2/AC5 heterodimer.  
     Furthermore, it has been found that AC2 and AC5 are co-localized in 
cardiac tissues (Baragli et al., 2008). It has also been demonstrated that AC2 
and AC5 in rat ventricular cardiomyocytes are localized in the nuclear 
membranes (Boivin et al., 2006). This indicates that heterodimers are 
probably a special and distinct class of ACs with a more complex regulation. 
Colocalization of two different isoforms such as AC2 and AC5 in cardiac 
tissues also indicates an intriguing possibility of other tissue-specific 
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heterodimerization such as AC1 and AC2 in the brain, AC5 and AC6 in the 
heart and AC3 and AC8 in the pancreas. AC1 and AC2 in the brain are 
localized in regions important for learning and memory and play an important 
role in synaptic plasticity (Wu et al., 1995; Abdel-Majid et al., 1998; Furuyama 
et al, 1993). AC5 and AC6 in the heart play an important role in cardiac 
stress. AC6 is known to be cardioprotective, whereas AC5 antagonists are 
important for cardiac stress (Phan et al., 2007; Yan et al, 2007; Krishnan et 
al., 2008). AC3 and AC8 in the pancreas are implicated in glucose-mediated 
insulin secretion (Guenifi et al., 2000). Therefore, it would be extremely 
important to understand if these isoforms in these specific tissues formed 
heterodimers. It would also be important to study the role of C1 and C2 
subunits in the overall regulation of the AC heterodimers.  
Future studies in this area of research, using techniques such as FRET 
and BRET, (bioluminescence resonance energy transfer) will be required to 
understand the cross-talk between two similar or different AC isoforms. It will 
also be interesting to study chimeric ACs with TM domains from AC X and 
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Chapter 4: Molecular analysis of edema factor, a 
Bacillus anthracis adenylyl cyclase toxin and its 
interaction with calmodulin using MANT-nucleotides 
as probes.  
4.1 Introduction 
     Edema Factor (EF), one of the exotoxins released by Bacillus anthracis, 
contributes considerably to both cutaneous and systemic forms of anthrax 
(Leppla, 1982; Dixon et al., 1999). EF, a ~90 kDa protein, consists of a 
protective antigen binding domain (PABD, ~30 kDa) and an adenylyl cyclase 
domain (ACD, ~60 kDa) (Drum et al., 2000; Bhatnagar et al, 2001). After 
protective antigen (PA)- mediated entry into host cells, EF is activated by 
calmodulin (CaM), a calcium sensor protein and catalyzes the conversion of 
adenosine 5’-triphosphate (ATP) to adenosine 3’:5’-cyclic monophosphate 
(cAMP) (Drum et al., 2002; Shen et al., 2002).  Binding of calmodulin to EF 
causes a major conformational change in EF giving rise to excessive 
intracellular levels of cAMP which in turn disrupts several signaling pathways 
(Shen et al., 2005). EF can severely impair host defenses and suppress 
innate immune responses (Firoved et al., 2007; Kammer et al., 1988; Kyriakis 
et al., 2001). 
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     EF plays a crucial role in causing anthrax and therefore, several studies 
have been carried out to identify potent inhibitors of EF catalytic activity. 
Using a variety of approaches, several studies have traditionally identified 
both fluorescent and non-fluorescent analogs of the substrate ATP as potent 
inhibitors of EF. Johnson et al. (1990) identified polyadenylate (IC50 in the mM 
range) and 2’d 3’ AMP (IC50 in the µM range) as low - moderate potency 
inhibitors of EF and CyaA, an adenylyl cyclase toxin from Bordetella pertussis 
(Confer and Eaton, 1982; Hewlett et al., 1989; Ladant and Ullmann, 1999). 
The crystal structure of EF in complex with CaM and 3’d-ATP helped to gain 
insight into the activation and catalytic mechanism of EF (Drum et al., 2002). 
Shen et al., (2004a) have observed that adenosine 5’-(α, β-methylene)-
triphosphate (AMPCPP) inhibits EF with low potency (Ki = 0.85 mM) and 
possesses an alternative binding mode in the catalytic pocket of the EF-CaM 
complex.  Shen et al (2004b) also observed that the antiviral drug, adefovir 
dipivoxil potently inhibits EF AC activity (Ki = 27 nM). Adefovir, approved for 
treatment of chronic hepatitis B virus infection, is an acyclic nucleotide analog 
of adefovir monophosphate and is phosphorylated into its active metabolite, 
adefovir diphosphate (PMEApp). Furthermore, the fluorescent nucleotide 3’-
anthraniloyl-2’-deoxy-ATP (3’ANT-2’d-ATP) can bind to both EF and CyaA 
(Sarfati et al., 1990; Gallay et al., 2004). As monitored by fluorescence 
spectroscopy, the Kd for 3’ANT-2’d-ATP binding to EF-CaM is1 µM. 
Additionally, the crystal structure of EF-CaM in complex with 3’ANT-2’d-ATP 
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was comparable to that of EF-CaM-3’d-ATP complex (Drum et al., 2002; 
Shen et al., 2002). Furthermore, N-methylanthraniloyl (MANT)-substituted 
nucleotides are potent inhibitors of mammalian ACs and bacterial ACs 
including EF and CyaA (Gille et al., 2004).  
     Several small molecules structurally dissimilar to ATP analogs and peptide 
based inhibitors also potently inhibit the catalytic activity of EF. Based on the 
crystal structure of EF, molecular docking experiments were carried out with 
~200,000 commercially available small molecules and identified a specific 
quinazoline compound that does not affect EF-CaM binding but specifically 
inhibits EF AC activity (Ki = 20 µM) (Soelaiman et al., 2003). This compound 
also efficiently inhibited CyaA (Ki = 20 µM). A specific anti-protective antigen 
(anti-PA) branched peptide called MAP3 V/A was also capable of inhibiting 
EF catalytic activity in several cell lines (Pini et al., 2006). Very recently, 3 out 
of 19 diverse compounds were identified that are capable of inhibiting EF 
catalytic activity in cell-based assays (Chen et al., 2008). Based on crystal 
structures of EF alone and in complex with CaM and several inhibitors, they 
generated a 3D-pharmacophore model for EF. Using a fragment-based 
screening approach, at least 10,000 compounds from the ZINC database 
were virtually docked onto the 3D-pharmacophore model. Out of 19 
compounds selected, 3 were chosen for cell based assays depending on 
various factors such as toxicity, solubility and penetration into the cell.  
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     Although, most of the inhibitor development studies have aimed at 
blocking EF catalytic activity, it is also important to focus on studying EF-CaM 
binding. After entry of EF into cells, the EF-CaM interaction is the first step in 
the intoxication mechanism of EF (Deisseroth et al., 1998; Drum et al., 2000, 
Leppla, 1982). CaM, composed of 148 residues, possesses N and C terminal 
globular domains connected by a long α-helix (Babu et al., 1985; Zhang et al., 
1995). Each domain consists of two Ca2+ binding sites. CaM exists in three 
different Ca2+ loading states namely-a Ca2+ free apo-form, a two Ca2+ions- 
bound C-terminal domain and a four Ca2+ -bound form with both N and C-
terminal domains being loaded (Ikura, 1996; Nelson et al., 1998). Although 
lower Ca2+ concentrations are required for activation and catalysis of EF, 
higher Ca2+ concentrations inhibit EF catalysis (Shen et al., 2002). EF-CaM 
binding can alter the Ca2+ loading state of CaM. EF interacts with N-CaM in a 
calcium independent manner but forms a tighter interaction with C-CaM only 
in the presence of calcium (Ulmer et al., 2003; Shen et al., 2005). 
Furthermore, FRET experiments with a double-labeled CaM molecule 
demonstrated that CaM binds to EF in an extended conformation (Drum et al., 
2000). A two-cysteine CaM mutant was generated in which T34 and T110 in 
the N and C-terminal domains of CaM respectively, were replaced with 
cysteine residues. The distance between the two cysteine residues in the 
presence of EF was ~49 Å indicating an extended conformation compared to 
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the compact CaM conformation in complex with several effector proteins (~16 
Å).  
     Though several crystallographic, biochemical and structural studies have 
helped to understand the EF-CaM interaction, in practice it has been 
extremely difficult to identify small molecules inhibitors of protein-protein 
interaction (IPPI) the block EF-CaM binding. Using a combination of 
spectroscopic and cell-based approaches, a benzene sulfonamide derivative 
(10506-2A) was identified as an IPPI for the EF-CaM interaction. This 
compound was capable of binding to EF and preventing activation of EF by 
CaM thereby blocking EF catalytic activity (Lee et al., 2004).  
     To promote development of inhibitors for EF catalytic activity and of the 
EF-CaM interaction, a systemic study of these processes is needed. In this 
chapter, we study the inhibitory properties of fluorescent nucleotides and 








4.2 Specific aims and hypothesis 
     This chapter will deal with two different aspects of EF. Firstly, several 
crystallographic, biochemical, structural and cell-based approaches have 
revealed the catalytic mechanism of EF and have identified potent inhibitors 
of EF catalytic activity. Studies conducted in our laboratory have identified 
MANT-nucleotides as potent inhibitors of mAC and CyaA (Gille and Seifert, 
2003; Gille et al., 2004; Gottle et al., 2007). Furthermore, 3’ MANT-2’d-ATP 
was identified as a potent inhibitor of EF. However, in order to fully exploit the 
properties of MANT-nucleotides as potent EF inhibitors, a systematic analysis 
of MANT-ATP and MANT-GTP analogs was undertaken. The study is aimed 
at answering the following questions. 
- If MANT-ATP and MANT-GTP analogs inhibit EF in the presence of 
CaM?  
- If MANT-ATP and MANT-GTP analogs bind to EF, as monitored by 
fluorescence spectroscopy? 
- If CaM induced-conformational changes in EF could be probed by 
MANT-ATP and MANT-GTP analogs? 
- If MANT-ATP and MANT-GTP analogs demonstrate a differential 
binding to EF/CaM? 
220 
 
     It is known that EF binds to an extended conformation of CaM (Drum et 
al., 2000). It has also been observed that the EF-CaM interaction and 
catalysis are dependent on physiological calcium concentrations and 
depending on the Ca2+ loading state, EF binds differentially to N- and C-CaM 
(Shen et al., 2002 and 2005). However, molecular analysis of a Ca2+ 
dependent/independent interaction between EF and CaM has not yet been 
probed by fluorescent nucleotides.  
     Furthermore, oxidation of CaM can alter its binding to effector proteins 
(Bartlett et al., 2003; Gao et al., 1998). Paritally oxidized CaM can alter the 
activation and binding to CaM-dependent kinase II (Robison et al., 2007). In 
the case of bacterial infections, the primary targets are neutrophils, which 
when activated, produce reactive oxygen species causing oxidation of both 
intracellular proteins and foreign proteins. Additionally, CyaA-CaM complex is 
resistant to oxidation to a certain extent indicating that CyaA can still exert its 
toxic effect even when CaM is oxidized (Vougier et al., 2004). However, it is 
not known if oxidized CaM can bind and activate EF. In this chapter, the 
following questions will be examined in detail.  
- Role of calcium in CaM-EF interaction as monitored by fluorescence 
spectroscopy. 
- Effect of CaM oxidation on EF-CaM interaction. 
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     Previous studies have demonstrated that CyaA has a spacious catalytic 
site that can accommodate 2’ (-3’)-substituted nucleotides (Gottle et al., 
2007). Furthermore, as mentioned in chapters 1 and 2, we have generated a 
three-site pharmacophore model of the mAC catalytic site with a broad-base 
specificity, i.e, it can bind to both purine and pyrimidine nucleotides (Mou et 
al., 2006). Therefore, we predict that 
- MANT-nucleotides potently inhibit EF catalytic activity. 
- Calcium plays an important role in binding and activation of EF. 
- Oxidation of CaM alters its binding to EF. 
     Based on our studies, we expect to obtain a clear understanding of the 
properties of the MANT-nucleotide and EF-CaM binding processes which will 









4.3 Materials and methods 
4.3.1 Materials 
     EF (full length) and EF3 (catalytic domain only) were kindly donated by Dr. 
W.J.Tang (Ben May Department for Cancer Research, University of Chicago, 
IL). MANT-nucleotides (MANT-ATP, 2’MANT-3’d-ATP, 3’MANT-2’d-ATP, 
MANT-GTP, 2’MANT-3’d-GTP, 3’MANT-2’d-GTP) were obtained from Jena 
Bioscience (Jena, Germany). An overview of the structure of MANT-
nucleotides is shown in Figure 4-1. In the case of MANT-ATP and MANT-
GTP, the MANT-group isomerizes between the 2’ and 3’ position of the ribose 
ring. In other MANT-nucleotides, the MANT-group is fixed either at the 2’ or 3’ 
position due to the lack of the neighboring hydroxyl group. Calmodulin purified 
from bovine brain and calmidazolium chloride were purchased from 
Calbiochem (La Jolla, CA). 2’5’ dd 3’ATP was obtained from Sigma (St. Louis, 
MO). [α-32P]-ATP (6000 Ci/mmol) was purchased from PerkinElmer Life 
Sciences. Microcon centrifugal filter devices (YM-30) were obtained from 
Millipore Corporation. Sources of other materials were described previously 
(Gille et al., 2004; Mou et al., 2005 and 2006; Gottle et al., 2007) and in 




Figure 4-1 Structure of MANT-nucleotides 
     Chemical structures of MANT-ATP, MANT-GTP and its analogs are shown. 
The MANT-group which spontaneously isomerizes between the 2’ and the 3’ 
position of the ribose moiety in the case of MANT-ATP and MANT-GTP but not in 




4.3.2 Experimental methods  
- EF AC activity assay 
     EF AC activity assays were conducted as described previously (Gille et al., 
2004) and in chapter 2. For determination of potencies of MANT-nucleotides 
as EF inhibitors, assay tubes contained 10 pM EF/EF3 and 10 µl of MANT-
nucleotides with concentrations ranging from 10 nM to 100 µM to obtain 
inhibition curves. Additionally, reaction mixtures containing 100 µM KCl, 40 
µM unlabelled ATP, 5 mM Mn2+ or Mg2+, 100 µM EGTA, 100 nM CaM, 100 
µM cAMP, 100 µM Ca2+ and [α-32P]ATP were added to the assay tubes. AC 
activity was carried out as described in section 2.3.2 of chapter 2.  
- Fluorescence spectroscopy 
     All experiments were carried out using a Cary Eclipse fluorescence 
spectrophotometer at 25˚C (Varian, Walnut Creek, CA). Measurements were 
performed using a quartz fluorescence microcuvette (Hellma, Plainview, NY). 
Steady-state emission spectra were recorded with λex = 280 nm (λem = 300 – 
500 nm) for intrinsic protein fluorescence and λex = 350 nm (λem = 370 – 500 
nm) for MANT-nucleotide fluorescence. Reaction mixtures containing 100 mM 
KCl, 10 mM MnCl2 or MgCl2 and 25 mM HEPES/NaOH, pH 7.4 were added to 
the cuvette and the final assay volume was 150 µl. Three hundred nM each of 
MANT-nucleotide, EF/EF3 and CaM were included.  
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     For EF saturation experiments, MANT-nucleotides ranging from 165 nM to 
1.3 µM were used to obtain saturation curves. All EF saturation experiments 
were performed in the presence of 10 mM Mn2+  300 nM each of EF3 and 
CaM respectively. For determination of Kd values, MANT-nucleotide 
fluorescence was first corrected for the inner filter effect by recording the 
absorbance spectra of the respective MANT-nucleotide at the highest 
concentration in the presence of EF3 and CaM. Since the absorption 
wavelength depends on the emission properties of the respective nucleotide 
studied, it varied from nucleotide to nucleotide. The absorption wavelength 
was then subtracted depending on the concentrations of the MANT-
nucleotides used in the saturation experiments. 
     For competition studies with 2’5’ dd 3’ ATP and calmidazolium chloride, 
experiments were carried out similarly except that 2’5’ dd 3’ ATP or 
calmidazolium chloride was added in place of CaM. Reactions were first 
carried out in the kinetic mode to observe the displacement of MANT-
nucleotides by increasing concentrations of 2’5’ dd 3’ATP. Since 
calmidazolium chloride inhibits CaM, the rate of change in EF-CaM 
fluorescence was observed.  
     To probe Ca2+ dependent/independent EF3-CaM interactions using 2’ 
MANT-3’d-ATP, experiments were carried out in the presence and absence of 
calcium under three different conditions namely (1) in the presence of 100 µM 
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Ca2+ and no EGTA (2) 100 µM EGTA and no Ca2+  and (3) no Ca2+ and no 
EGTA. Fluorescence emission spectra were recorded with both λex = 280 nm 
(λem = 300 – 500 nm) and λex = 350 nm (λem = 370 – 500 nm).  
     For fluorescence experiments with oxidized calmodulin  CaM (O), 10 µM 
CaM was incubated with 0.06% (vol/vol) of 8.8 M H2O2 for 24 h at 37˚C. Ten 
µM CaM in the absence of H2O2 (CaM (N)) was also incubated as control. 
After incubation, for desalting and efficient concentration of CaM, 25 µl each 
of normal and oxidized CaM and 175 µl of 25 mM HEPES pH 7.4 were added 
to microcon centrifugal filter devices (YM-30) and concentrated by 
centrifugation for 10 min at 11,000 x g. Filter device YM-30 helps desalt and 
concentrate proteins upto 30 kDa. After repeating the above steps 4-5 times, 
a Biorad assay was carried out to determine the concentrations of CaM (N) 
and CaM (O). Fluorescence emission spectra with CaM (O) and CaM (N) 
were recorded with both λex = 280 nm (λem = 300 – 500 nm) and λex = 350 nm 
(λem = 370 – 500 nm). Fluorescence experiments were also carried out in the 
kinetic mode to analyze the rate of binding of CaM (N) and CaM (O) to EF3.  
-Molecular modeling studies 
     Molecular docking studies were carried out in collaboration with Dr. G.H. 
Lushington (University of Kansas, Lawrence). The six MANT-nucleotides 
studied in this chapter and 12 MANT-nucleotides studied by Jennifer Schmidt 
(University of Regensburg, Germany) were used for docking studies. MANT-
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nucleotides were docked into the receptor model constructed using the crystal 
structure of EF3-CaM in complex with 3’-d-ATP as inhibitor (Drum et al., 
2002). Amino acid residues with atoms further than 12 Å from the inhibitor 3’-
d-ATP were truncated from the model. Except for the in situ Mn2+, all of the 
heteroatoms were omitted. The ligands were docked into the receptor 
structure and a quantitative structure-activity relationship (QSAR) model was 
generated. The highest computed binding energy for each ligand was chosen 
to study the specific interactions between the ligand and the amino acid 
residues in receptor EF3.  
- Data generation and statistics 
     Saturation inhibition curves for EF AC activity were analyzed by nonlinear 
regression using Prism 4.0 software (Graphpad, San Diego, CA). Free Ca2+ 
concentrations were calculated using 100 µM EGTA as calcium chelator with 
WinmaxC 2.05 version (www.stanford.edu/~cpatton/max-c.html). Ki  Values 
were calculated based on Km values determined previously for EF (Gille et al., 
2004). Data shown are the mean values ± SD of 5-6 experiments performed 
in duplicate. 
     Fluorescence recordings were analyzed using the spectrum package of 
the Cary Eclipse software and final graphs were prepared using Graphpad 
prism 4.0 software. Similar results were obtained from 3 – 4 independent 
experiments using 3-5 different batches of EF and EF3 respectively. Kinetics 
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of CaM (N) and CaM (O) binding to EF3 were analyzed by the one-phase 
exponential association equation in the Graphpad prism 4.0 software.  
     In Molecular modeling studies, the SYBYL program (SYBYL 7.2, The 
Tripos Associates, St. Louis, MO) was used to protonate the EF3-CaM 
receptor model. All the MANT-nucleotides were also sketched and protonated 
using SYBYL and relaxed via the molecular mechanics optimization settings 
in SYBYL using the Tripos Force Field (Clark et al., 1989). Ligand-receptor 
complexes were generated using the FLexX program via flexible docking 
simulations (Rarey et al., 1996). The QSAR model was generated via the 
Comparative Binding Energy (COMBINE) method (Ortiz et al., 1995). For 
each of the 16 ligands, several poses were generated and the pose with the 










4.4 Results and Discussion 
4.4.1 Inhibition of catalytic activity of EF3 by MA NT-nucleotides 
     In earlier studies carried out in the Seifert laboratory, we have observed 
that MANT-nucleotides potently inhibit mACs, EF and CyaA (Gille and Seifert, 
2003; Gille et al., 2004; Gottle et al., 2007). In mACs, MANT-GTP is more 
potent than MANT-ATP. Furthermore, crystallographic and molecular 
modeling studies have demonstrated that the MANT-group at the 2’-O-ribosyl 
position is in a more hydrophobic environment and therefore more favored 
compared to the MANT-group at the 3’-O-ribosyl position (Gille et al., 2004, 
Mou et al., 2005). In sharp contrast, in the case of both EF and CyaA, the 3’ 
analog of MANT-ATP is the most potent inhibitor reported so far (Ki = 13 nM 
and 0.2 µM for EF and CyaA respectively) (Gille et al., 2004; Gottle et al., 
2007). Additonally, MANT-GTP also moderately inhibits EF (Ki =1.6 µM) (Gille 
et al., 2004). However, a detailed analysis of the structure-activity 
relationships with 2’ and 3’-MANT-nucleotide isomers and EF has not been 
studied. Therefore, we examined the properties of 2’ and 3’-MANT analogs of 
ATP and GTP in inhibiting EF and EF3. Since, it is known that there are no 
major differences between EF and EF3 with respect to inhibition by MANT-




     In the presence of Mn2+ and in the presence of Ca2+/CaM, 3’ MANT-2’d-
ATP is the most potent inhibitor of EF3 (Ki = 11 nM), a result that is similar to 
results obtained earlier (Gille et al., 2004, Ki = 13 nM) (Table 4-1). The rank 
order of potency was 3’MANT-2’d-ATP > 2’ MANT-3’d-ATP = 2’ MANT-3’d-
GTP > 3’ MANT-2’d-GTP = MANT-ATP > MANT-GTP. Overall MANT-ATP 
analogs were more potent at inhibiting EF compared to MANT-GTP analogs. 
MANT-ATP was at least 9-fold and 33 fold less potent than 2’ MANT-3’d-ATP 
and 3’ MANT-2’d-ATP respectively. Similarly, MANT-GTP was also at least 2-
fold and 3-fold less potent than 2’ MANT-3’d-GTP and 3’ MANT-2’d-GTP 
respectively. Most strikingly, 3’MANT-2’d-ATP was 3.6-fold more potent than 
2’MANT-3’d-ATP, whereas 2’MANT-3’d-GTP was at least 7-fold more potent 
than 3’MANT-2’d-GTP. Though the 2’ analogs of both MANT-ATP and MANT-
GTP showed comparable affinities for EF, a huge difference in the potencies 
between the 3’ analogs of MANT-ATP and MANT-GTP were observed. 
    Under Mg2+ conditions, in the presence of Ca2+/CaM, an overall decrease 
in the affinity of MANT-nucleotides for EF3 was observed (Table 4-1). The 
rank order of potency was 3’ MANT-2’d-ATP > MANT-ATP > 2’ MANT-3’d-
ATP = 2’ MANT-3’d-GTP > MANT-GTP > 3’ MANT-2’d-GTP. Again, 3’ MANT-
2’d-ATP was the most potent inhibitor of EF in the presence of Mg2+. The 
affinities of 2’ MANT-3’d-ATP and 3’ MANT-2’d-ATP for EF3 were at least 
115-fold and 68-fold lower in the presence of Mg2+ when compared to those 
obtained in the presence of Mn2+ c. Similarly, 2’ MANT-3’d-GTP and 3’ MANT-
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2’d-GTP showed at least 86-fold and 27-fold lower potency in the presence of 
Mg2+. Surprisingly, it was observed that MANT-ATP and MANT-GTP had 
comparable affinities to 3’ MANT-2’d-ATP and 3’ MANT-2’d-GTP respectively 
for EF3 in the presence of Mg2+. This observation possibly indicates that in 
the presence of the physiological ligand, the 3’-O-ribosyl conformer of the 
MANT-group of both ATP and GTP is preferred over the 2’-O-ribosyl 
conformer.  
     Based on experiments of MANT-nucleotide affinities for EF3 under Mn2+ 
and Mg2+ conditions, it is clear that MANT-nucleotides bind and inhibit EF3 
with a higher affinity in the presence of Mn2+ than in the presence of Mg2+. 
This observation also corroborates available literature related to cyclases that 
indicate a higher sensitivity to inhibition in the presence of Mn2+ (Gille and 
Seifert, 2003; Brandwein et al., 1982; Shoshani et al., 1999; Tesmer et al., 
2000). Nonetheless, Mg2+ is more relevant under physiological conditions and 
therefore, it was important to study the inhibitory effects of MANT-nucleotides 
on EF3 in the presence of Mg2+. 
     In a detailed comparison of the potencies of MANT-nucleotides for EF3, 
and mACs, 3’ MANT-2’d-ATP was at least 35-fold more potent at inhibiting 
EF3 compared to C1/C2. Additionally, though MANT-GTP is the least potent 
inhibitor of EF3 (Ki = 1.08 µM) and the most potent inhibitor of C1/C2 (Ki = 4.2 
nM), 2’ MANT and 3’ MANT analogs of GTP were highly potent at inhibiting 
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EF3. Furthermore, all the MANT-nucleotides studied were more potent 
inhibitors of EF3 than CyaA (Gottle et al., 2007).  
     Overall, the 2’ and 3’ isomers of MANT-ATP and MANT-GTP were more 
potent at inhibiting EF3 when compared to mACs and CyaA indicating the 
possibility of structural differences in the catalytic sites of these enzymes. 
Therefore, the 2’ and 3’ isomers of MANT-ATP and MANT-GTP can be 














Table 4-1 Inhibitory potencies of MANT-nucleotides under Mn 2+and 
Mg2+conditions 
     EF AC activity assays were conducted as described previously (Gille et al., 
2004) and in section 2.3.2 of chapter 2. Assay tubes contained 10 pM EF/EF3 
and 10 µl of MANT-nucleotides with concentrations ranging from 10 nM to 
100 µM to obtain saturation inhibition curves. Additionally, reaction mixtures 
containing 100 µM KCl, 40 µM unlabelled ATP, 5 mM Mn2+ or Mg2+, 100 µM 
EGTA, 100 nM CaM, 100 µM cAMP, 100 µM Ca2+ and [α-32P]ATP were 
added to the assay tubes. Data were analyzed by nonlinear regression using 
the Prism 4.0 software (Graphpad, San Diego, CA) and Ki  values, expressed 
in µM were calculated based on Km values calculated previously for EF (Gille 
et al., 2004). Data shown are the mean values ± SD of 5-6 independent 








Nucleotides  Mn2+  
K i (µM) 
Mg2+  
K i (µM) 
MANT-ATP  0.36 ± 0.18 0.9 ± 0.07 
2’ MANT-3’d-ATP  0.04 ± 0.002 4.6 ± 0.2 
3’ MANT-2’d-ATP  0.011 ± 0.002 0.75 ± 0.04 
MANT-GTP 1.08 ± 0.4 8.8 ± 0.3 
2’ MANT-3’d-GTP  0.05 ± 0.01 4.3 ± 0.4 





Figure 4-2 Inhibition of the catalytic activity of EF3 by MANT-nucleotides 
under Mn 2+and Mg 2+conditions  
     EF AC activity assay was conducted as described previously (Gille et al., 
2004) and in chapter 2. Briefly, assay tubes contained 10 pM EF/EF3 and 10 
µl of MANT-nucleotides with concentrations ranging from 10 nM to 100 µM to 
obtain saturation inhibition curves. Additionally, reaction mixtures containing 
100 µM KCl, 40 µM unlabelled ATP, 5 mM Mn2+ or Mg2+, 100 µM EGTA, 100 
nM CaM, 100 µM cAMP, 100 µM Ca2+ and [α-32P]ATP were added to the 
assay tubes. Saturated inhibition curves were analyzed by nonlinear 
regression using Prism 4.0 software (Graphpad, San Diego, CA). EF AC 
activity is expressed in turnover numbers (s-1). Data shown are representative 
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4.4.2 Characterization of EF interaction with MANT-n ucleotides by 
fluorescence spectroscopy 
     MANT-nucleotides are environmentally sensitive probes utilized in the 
study of several nucleotide-binding proteins, structural proteins and enzymes 
(Hazlett et al., 1993; Bauer et al., 1997; Hiratsuka, 1983; Jameson and 
Eccleston, 1997). Specifically, MANT-nucleotides have been used to monitor 
conformational changes in mACs and CyaA (Mou et al., 2005 and 2006; 
Göttle et al., 2007). Crystallographic and fluorimetric data suggest that MANT-
nucleotides bind to a hydrophobic pocket formed by C1/C2 resulting in a 
several-fold increase in fluorescence. MANT-nucleotide interacts with several 
polar and hydrophobic amino acid residues and thereby is stabilized in the 
catalytic pocket of C1/C2. This interaction causes an increase in MANT 
fluorescence indicating the presence of MANT-nucleotide in a hydrophobic 
environment within C1/C2. Furthermore, the MANT-group lies close to W1020 
residue of C2 resulting in energy transfer from W1020 to the MANT-group 
(Mou et al., 2005 and 2006).  
      In CyaA, MANT-nucleotides interact with the hydrophobic residue F306 in 
the catalytic site. This interaction is likely to increase fluorescence signals. 
Additionally, FRET occurs between W69, W242 and multiple tyrosine 
residues and the MANT-group in CyaA (Göttle et al., 2007). Very similar to 
CyaA, crystallographic and fluorescence studies with EF have shown that 2’d-
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3’ANT-ATP interacts with F586 of EF, thereby stabilizing the EF-nucleotide 
interaction in the presence of CaM (Shen et al., 2002). 
     In contrast to mACs and CyaA, a detailed analysis of the conformational 
changes in EF3 monitored by the binding of the MANT-ATP and MANT-GTP 
analogs has not yet been presented. Therefore, In order to further investigate 
the mechanism of conformational changes in EF3 due to MANT-nucleotide 
binding, a systematic analysis of interaction of the defined 2’ and 3’ isomers 
of MANT-ATP and MANT-GTP with EF3 was carried out. 
     Fluorescence experiments were carried out with both EF and EF3. No 
major differences in the fluorescence properties between EF and EF3 were 
observed (data not shown). All experiments were carried out under Mn2+ and 
Mg2+ conditions. However, EF3 showed a preference for Mn2+ compared to 
Mg2+ (data not shown). Similarly, mACs and CyaA show a preference for 
Mn2+ in both fluorescence and enzymatic analysis using MANT and TNP-
nucleotides (Mou et al., 2005 and 2006; Chapter 2; Göttle et al., 2007). 
Experiments were carried out at an excitation wavelength of 280 nm to 
measure the tyrosine and tryptophan fluorescence of EF3 emitted at 350 nm 
and the possibility of FRET from these residues to the MANT-group, which is 
excited at 350 nm to emit light at around 420-450 nm. Fluorescence spectra 
were also recorded at 350 nm to observe possible changes in MANT-
nucleotide fluorescence upon binding to EF3. 
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- Interaction of MANT-nucleotides with EF3 – FRET exp eriments 
     When excited at 280 nm under steady-state conditions, EF3 strongly emits 
at around 339-340 nm in the absence of CaM (Figure 4-3 A, B, C and Figure 
4-4 A, B and C – red trace). As mentioned earlier, at 280 nm, though both 
tryptophan and tyrosine residues are excited, tryptophan residues have 
higher fluorescence amplitudes compared to tyrosine residues (Lacowicz, 
1999). Tryptophan residues alone can be excited at 294 nm. When EF3 was 
excited at 294 nm, a 50% decrease in fluorescence intensity was observed 
with the emission maximum at 340 nm (data not shown). Primary structure 
analysis of EF3 indicates the presence of six tryptophan and twenty-five 
tyrosine residues, all of which could potentially transfer energy to the 
nucleotide (www.pdb.org, structure 1k93). The emission maximum for EF3 
observed at ~340 nm indicates that the tryptophan residues are buried in the 
catalytic site. 
     In the presence of MANT-nucleotide, when CaM was added, a second 
prominent peak was observed at around 440 nm (Figure 4-3 A, B, C and 
Figure 4-4 A, B and C – blue trace). This indicated energy transfer (FRET) 
from the tryptophan and tyrosine residues to the MANT-group of the 
nucleotide. The magnitude of FRET varied among the nucleotides studied. 
The 2’ isomer of both MANT-ATP and MANT-GTP showed at least 3-fold 
larger FRET than their corresponding 3’ isomers. Though 3’MANT-2’d-ATP 
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was the most potent inhibitor of EF3 reported so far, the 2’ isomers of MANT-
ATP and MANT-GTP were more favorable for FRET. These findings indicate 
that the affinity differences do not account for the different fluorescent 
responses of the nucleotides studied. The fluorescence responses are 
entirely dependent on the local environment of the specific nucleotide in the 
catalytic pocket of EF3.  
     In addition to the emission peak observed at ~440 nm, a very slight shift of 
the emission maximum from ~340 nm to ~344 nm (± 2 nm) was observed 
upon the addition of CaM. This shift to longer wavelength reflects a change in 
the polarity of the tryptophan residues indicating a shift to a more solvent-
exposed environment in the presence of CaM. 
- Interaction of MANT-nucleotides with EF3 – direct  fluorescence 
experiments 
     MANT-nucleotides when excited at 350 nm emit at 450 nm (Figure 4-3 D, 
E, F and Figure 4-4 D, E and F – green trace). Steady-state emission spectra 
were recorded between 370 nm and 550 nm. No increase in MANT-
nucleotide fluorescence was observed with the addition of EF3 (Figure 4-3 D, 
E, F and Figure 4-4 D, E and F – red trace). Upon addition of CaM, an 
increase in fluorescence of more than 140% was observed for the 2’ isomers 
of MANT-ATP and MANT-GTP. In the case of MANT-ATP and MANT-GTP, a 
40% and a 10% increase in fluorescence was observed respectively. Also, a 
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70% increase in fluorescence was seen for the 3’ isomer of MANT-ATP and a 
very slight increase for the 3’ isomer of MANT-GTP (Figure 4-3 D, E, F and 
Figure 4-4 D, E and F – blue trace). In addition to increases in MANT-
nucleotide fluorescence, the emission maxima of MANT-nucleotides shifted to 
shorter wavelengths (blue shift) in the presence of CaM. This indicates that 
MANT-nucleotides bind to a hydrophobic pocket in the catalytic site of EF3 in 
the presence of CaM probably by interacting with the F586 residue in the 
EF3.   
     Qualitatively, 2’ MANT-3’d-ATP and 2’ MANT-3’d-GTP behave similarly in 
direct fluorescence and FRET experiments. The inhibitory properties of these 
nucleotides in AC assays are also similar. However, the 3’ isomers of MANT-
ATP and MANT-GTP do not have the same properties in direct fluorescence, 
FRET experiments and AC assays. It is possible that, although the 2’ position 
of the MANT-group is more favorable for FRET, the 3’ position of the MANT-
group is more favorable for inhibition of EF3 especially in the case of MANT-
adenine nucleotides. It is also clear that the defined 2’ and 3’ isomers of 
MANT-ATP and MANT-GTP are more favorable for inhibition of EF3 than the 
MANT-group isomerizing between the 2’ and 3’ position.  
     In comparison with CyaA, an increase of at least a 4-fold in the intrinsic 
fluorescence of EF3 was observed in the case of EF3 with the same 
concentration (300 nM). In direct fluorescence experiments, higher 
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concentrations of CyaA and CaM (2.4 µM each) were used in order to 
observe measurable increase in fluorescence. In sharp contrast, 300 nM EF3 
was sufficient to observe changes in MANT- nucleotide fluorescence. 
Furthermore, there was no difference observed between the defined 2’ and 3’ 
isomers of MANT-ATP in their interaction with CyaA in both FRET and direct 
fluorescence experiments (Göttle et al., 2007). However in EF3, higher FRET 
and fluorescence amplitude changes were observed with the 2’ isomer of 
MANT-ATP. The interaction of 2’ and 3’ isomers of MANT-GTP with CyaA 
has not been studied. Collectively, it is clear that MANT-nucleotides interact 











Figure 4-3 Analysis of MANT-ATP and its defined 2’ and 3’ isomers 
binding to EF3 using FRET and direct fluorescence m easurements  
      Shown here are FRET measurements (A, B and C) and direct 
fluorescence measurements (D, E and F) of MANT-ATP and its defined 2’ 
and 3’ isomers respectively. Steady-state emission spectra were recorded 
with λex = 280 nm (λem = 300 – 500 nm) for intrinsic protein fluorescence and 
λex = 350 nm (λem = 370 – 500 nm) for MANT-nucleotide fluorescence. 
Experiments were carried out with sequential addition of reaction mixtures 
containing 100 mM KCl, 10 mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4, 
300 nM MANT-nucleotide (green trace), 300 nM EF3 (red trace) and 300 nM 
CaM (blue trace). The final assay volume was 150 µl. Arrows in D, E and F 
indicate a blue shift in the emission spectra due to addition of CaM to 
EF3/MANT-nucleotide. Graphs were generated using Prism 4.0 software. 
Baseline fluorescence (buffer alone) was subtracted from the spectra. 
Fluorescence intensities in A, B and C are shown as percentage of the 
maximal emission data obtained for the respective experiment. Fluorescence 
intensity in D, E and F are shown as arbitrary units (a.u) to observe 
differences between the three nucleotides studied. Data shown are 
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Figure 4-4 Analysis of MANT-GTP and its defined 2’ and 3’ isomers 
binding to EF3 using FRET and direct fluorescence m easurements 
     Shown here are FRET measurements (A, B and C) and direct 
fluorescence measurements (D, E and F) of MANT-GTP and its defined 2’ 
and 3’ isomers respectively. Steady-state emission spectra were recorded 
with λex = 280 nm (λem = 300 – 500 nm) for intrinsic protein fluorescence and 
λex = 350 nm (λem = 370 – 500 nm) for MANT-nucleotide fluorescence. 
Experiments were carried out with sequential addition of reaction mixtures 
containing 100 mM KCl, 10 mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4, 
300 nM MANT-nucleotide (green trace), 300 nM EF3 (red trace) and 300 nM 
CaM (blue trace). The final assay volume was 150 µl. Arrows in D, E and F 
indicate a blue shift in the emission spectra due to addition of CaM to 
EF3/MANT-nucleotide. Graphs were generated using Prism 4.0 software. 
Baseline fluorescence was subtracted from the spectra. Fluorescence 
intensities in A, B and C are shown as percentage of the maximal emission 
spectra obtained for the respective experiment. Fluorescence intensities in D, 
E and F are shown as arbitrary units (a.u) to observe differences between the 
three nucleotides studies. Data shown are representative of 5-6 experiments 
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- Enzyme saturation experiments and determination of K d values 
     Enzyme saturation experiments were carried out to determine the 
apparent Kd values of the MANT-nucleotides for EF3 in the presence of Mn
2+. 
Kd values help understand the binding affinity of the ligand to the receptor and 
therefore FRET saturation experiments were carried out.  The excitation 
wavelength of 280 nm was used to measure intrinsic protein fluorescence and 
350 nm for MANT-nucleotide fluorescence. EF3 and CaM were added to the 
cuvette first and the emission spectra were recorded at 280 nm and 350 nm. 
Increasing concentrations of MANT-nucleotide were then added to observe 
increases in fluorescence until saturation was reached (Figure 4-5 A). 
Fluorescence spectra of increasing MANT-nucleotide concentrations were 
also recorded in the absence of EF3/CaM at 280 nm (Figure 4-5 B). These 
values were later subtracted from the FRET signals in the presence of 
EF3/CaM. After correction for the inner filter effect, saturation curves were 
generated for the specific MANT-nucleotide (Figure 4-6) and the apparent Kd 
values were calculated (Table 4-2). Slight inconsistencies between the Kd 
values and the Ki values obtained in AC assays were observed. The Ki and Kd 
values especially in the case of MANT-GTP isomers were more consistent 
compared to the other MANT-nucleotides studied. These slight differences in 
Ki and Kd values can be attributed to experimental conditions such as salt 
concentration, pH and temperature. Most importantly, since MANT-
nucleotides are extremely sensitive probes, the relative orientation and the 
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local environment of the nucleotide plays a very important role in any changes 
observed in fluorescence. Another important difference between Kd and Ki 
values is also the fact that the EF concentrations in AC assays and FRET 
assays were largely different. Higher EF concentrations were used in FRET 
assays. When the affinity of the ligand for EF is high, the higher protein 
concentrations largely underestimate the affinity of the ligand for EF. 
Nonetheless, the order of affinity of the MANT-nucleotides studied matched 
well with the Ki values obtained in AC assays. 3’ MANT-2’d-ATP showed the 
lowest Kd value (Kd = 0.065 µM) compared to other MANT-nucleotides 
indicating higher affinity for EF3/CaM. MANT-GTP showed the lowest affinity 
for EF3/CaM and the Kd value (Kd = 0.79 µM) was slightly lower compared to 
the Ki value obtained in AC assays (Kd = 1.08 µM).  
    Collectively, the results of the fluorescence and enzymatic studies indicate 
that the 2’ and 3’ isomers of MANT-ATP and MANT-GTP have different 
fluorescence and inhibitory properties for EF3. The MANT-group positioning 
and the base are extremely critical for binding and inhibition of EF3 catalytic 
activity. Furthermore, similar to mACs and CyaA, the catalytic core of EF3 in 
the presence of CaM is spacious enough to accommodate various MANT-
nucleotides with differences in the MANT-group positioning and the 
nucleobase  (Mou et al., 2006; Gottle et al., 2007). Knowledge of the 
inhibitory properties of the different MANT-nucleotide analogs should facilitate 
rational design of potent EF3 inhibitors. 
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Figure 4-5 EF3 saturation experiments using FRET me asurements 
probed by 2’ MANT-3’d-ATP in the presence of Mn 2+ 
     EF saturation experiments were carried out as explained in section 4.3.2  
in the presence of Mn2+ with sequential addition of buffer, 300 nM EF3, 300 
nM CaM and increasing concentrations of MANT-nucleotides ranging from 
165 nM to 1.3 µM (A). Steady-state emission spectra were recorded with λex = 
280 nm (λem = 300 – 500 nm) for FRET saturation measurements. 
Experiments were also carried out in the absence of EF3/CaM (B). Graphs 
were generated using Prism 4.0 software. Fluorescence intensity in A is 
shown as percentage of the maximal emission spectra obtained for the 
respective experiment. Fluorescence intensity in B is shown as percentage of 
the emission maximum obtained in A for comparison.  Data shown here are 
representative experiments with 2’ MANT-3’d-ATP. Similar results were 
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Figure 4-6 Nucleotide saturation curve for EF3 in t he presence of Mn 2+ 
     EF saturation experiments were carried out as explained in section 4.3.2 in 
the presence of Mn2+ with sequential addition of buffer, 300 nM EF3, 300 nM 
CaM and increasing concentrations of MANT-nucleotides ranging from 165 
nM to 1.3 µM. MANT-nucleotide fluorescence was first corrected for the inner 
filter effect by recording the absorbance spectra of the respective MANT-
nucleotide at the highest concentration in the presence of EF3 and CaM. The 
absorption wavelength was then subtracted depending on the concentrations 
of the MANT-nucleotides used in the saturation experiments. Additionally 
values from experiments conducted in the absence of Ef3/CaM (Figure 4-4 B) 
were subtracted from values obtained in Figure 4-4 A. Saturation curves were 
obtained by non-linear regression analysis using Prism 4.0 software. Fcorr is 
the fluorescence intensity in arbitrary units (a.u) after correction for the inner 
filter effect. Data shown are for a representative experiment with 2’ MANT-
3’d-ATP. Similar results were obtained for all the MANT-nucleotides studied in 







Table 4-2 Comparison of K d values in fluorescence assays and K i values 
in AC assays for MANT-nucleotides 
     Shown here is a comparison of Kd values and Ki values obtained in AC 
assays. Kd values of MANT-nucleotides for EF3 were determined as 
explained in section 4.3.2. Experiments were carried out in the presence of 
Mn2+ with sequential addition of buffer, 300 nM EF3, 300 nM CaM and 
increasing concentrations of MANT-nucleotides ranging from 165 nM to 1.3 
µM. MANT-nucleotide fluorescence was first corrected for the inner filter 
effect and values from experiments conducted in the absence of Ef3/CaM 
(Figure 4-4 B) were subtracted from values obtained in Figure 4-4 A. Kd 
values were determined by non-linear regression analysis using Prism 4.0 
software. Ki values were calculated in AC assays as described in section 
4.3.2. Kd and Ki values are expressed in µM. Similar results were obtained for 









Ki Values  
   (µM) 
      Kd values  
        (µM)  
MANT-ATP  0.36 ± 0.18 0.19 ± 0.2  
2' MANT 3' d ATP 0.04 ± 0.002 0.1 ± 0.03  
3' MANT 2' d ATP 0.011 ± 0.002 0.065 ± 0.005  
MANT-GTP 1.08 ± 0.4 0.7 ± 0.3  
2' MANT 3' d GTP 0.05 ± 0.01 0.06 ± 0.02  









-Fluorescence analysis of the nucleotide-binding sit e of EF3 by 
competition with 2’5’dd 3’-ATP  
     To confirm the presence of a single nucleotide-binding site in EF3, 
experiments were carried out with 2’5’-dd-3’-ATP to observe the displacement 
of MANT-nucleotide from the catalytic site of EF3. The non-fluorescent ATP 
analog, 2’5’-dd-3’-ATP, is a potent inhibitor of mACs (Desaubry et al., 1996) 
and displaces MANT- and TNP-nucleotides from the catalytic site of C1/C2 
(Gille et al., 2004; Chapter 2 data). Fluorescence experiments were carried 
out in the dual-kinetic mode to observe the rate of change in EF3 (λ = 280 – 
450 nm, Figure 4-6, red trace) and MANT-nucleotide fluorescence 
respectively (λ = 350-450 nm, Figure 4-6, blue trace). 2’5’dd-3’-ATP displaced 
2’ MANT-3’d-ATP almost completely from the catalytic site of EF3 in a 
concentration-dependent manner. This clearly indicates that the catalytic site 
of EF3 possesses a single nucleotide-binding site and MANT-nucleotides 
bind reversibly to the catalytic site of EF3. Steady-state emission spectra 
were also recorded at 280 nm for changes in intrinsic EF3 fluorescence and 
at 350 nm for MANT-nucleotide fluorescence. In FRET measurements, 10 µM 
concentration of 2’5’-dd-3’-ATP caused a decrease in intrinsic EF3 
fluorescence as well as a decrease in FRET from EF3 to the MANT-group in 
the presence of CaM (Figure 4-7 A, black trace). A decrease in FRET is 
reflective of longer distances between MANT-group and the tryptophan and 
tyrosine residues in EF3. In direct fluorescence measurements, a decrease in 
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MANT-fluorescence due to addition of 2’5’-dd-3’-ATP (Figure 4-7 B, black 
trace) indicates that the MANT-group is in a more polar environment and, 
therefore, displaced competitively by the non-fluorescent nucleotide from the 
catalytic pocket of EF3. Overall, it is clear that MANT-nucleotide binds to the 















Figure 4-7 Kinetic analysis of the displacement of bound 2’ MANT-3’d-
ATP from the catalytic site of EF3 by 2’5’-dd-3’-AT P 
     Fluorescence experiments were conducted as described in section 4.3.2. 
Kinetics of 2’ MANT-3’d-ATP displacement by 2’5’ dd 3’ ATP from the EF3 
catalytic site were carried out in dual-kinetic mode to observe the rate of 
change in EF3 (λ = 280 – 450 nm, red trace) and MANT-nucleotide 
fluorescence (λ = 350 – 450 nm, blue trace). Cuvettes contained 300 nM 
each of EF3, CaM and MANT-nucleotide in the presence of buffer 
containing10 mM MnCl2. Increasing concentrations of 2’5’- dd -3’-ATP varying 
from 1 µM to 10 µM were added until saturation was achieved.  In the graph, 
fluorescence intensity in arbitrary units is measured as a function of time in 
minutes. Fluorescence recordings were analyzed using the spectrum 
package of the Cary Eclipse software. Similar results were obtained from 3 – 












Figure 4-8 FRET and direct fluorescence measurement s of the 
displacement of 2’ MANT-3’d-ATP from EF3 catalytic site by 2’5’-dd-3’-
ATP 
     FRET and direct fluorescence experiments were carried out as described 
in section 4.3.2. Steady-state emission spectra were recorded with λex = 280 
nm (λem = 300 – 500 nm) for intrinsic EF3 fluorescence (Figure A) and λex = 
350 nm (λem = 370 – 500 nm) for MANT-nucleotide fluorescence (Figure B). 
Experiments were carried out with sequential addition of reaction mixtures 
containing 100 mM KCl, 10 mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4, 
300 nM 2’ MANT-3’d-ATP (green trace), 300 nM EF3 (red trace) and 300 nM 
CaM (blue trace), followed by addition of 10 µM 2’5’-dd-3’-ATP (black trace). 
The final assay volume was 150 µl. Graphs were generated using Prism 4.0 
software. Baseline fluorescence (buffer alone) was subtracted from the 
spectra. Fluorescence intensity in A and B are shown as percentage of the 
maximal emission obtained for the respective experiment. Data shown here 
are conducted with 2’ MANT-3’d-ATP and similar results were obtained from 







FRET measurements - Inhibition by 2'5'-dd-3'-ATP




























Direct fluorescence - Inhibition by 2'5'-dd-3'-ATP

































4.4.3 Molecular modeling studies of MANT-nucleotide  binding to EF3-
CaM 
     Enzymatic studies have shown that MANT-ATP and its 2’ and 3’ isomers 
are more potent at inhibiting EF3 than MANT-GTP and its analogs. 
Furthermore, 3’ MANT-2’d-ATP was 3-fold more potent than 2’ MANT-3’d-
ATP. In sharp contrast, 2’ MANT-2’d-GTP was at least 7-fold more potent 
than 3’ MANT-2’d-GTP. In fluorescence assays with EF3 and CaM, the 2’ 
isomers of MANT-ATP and MANT-GTP were more favorable for FRET and 
for showing the increase in direct fluorescence of the MANT-group compared 
to other MANT-nucleotides studied in this chapter. So far, several crystal 
structures of EF-CaM with fluorescent and non-fluorescent nucleotides have 
been solved, however, crystallographic studies of EF3-CaM in complex with 
MANT-nucleotides has not. Due to differences observed in enzymatic and 
fluorescence studies and a lack of crystal structure of EF3-CaM in complex 
with MANT-nucleotide, molecular modeling studies were carried out to predict 
the specific interaction of MANT-nucleotides with the amino acid residues in 
EF3.   
     Molecular docking studies carried out in collaboration with 
Dr.G.H.Lushington (University of Kansas) predict that MANT-nucleotides are 
stabilized in the catalytic pocket of EF3 by Van der Waals and electrostatic 
interactions with several residues in EF3. The NHCH3-group of MANT-ATP 
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interacts with F586, Q588 and N583 of EF3 (Figure 4-8). Amino acid residues 
T548 and T579 further enhance this interaction by stabilizing the base of the 
nucleotide. More specifically, the anthraniloyl ring of the MANT-group is 
aligned parallel to F586 and is stabilized by π−stacking interactions with F586 
in the catalytic site of EF3.  Furthermore, the distances between the MANT-
group and the tryptophan residues W357, W552, W608 and W645 in EF3 are 
predicted to be 16 Å, 22 Å, 14 Å and 17 Å respectively. This proximity 
between the tryptophan residues (donor) and the MANT-group (acceptor) 
explains the occurrence of significant FRET in our fluorescence experiments 
(Lakowicz, 1999).  
     The triphosphate chains of the MANT-nucleotides are stabilized by their 
interaction with residues R329, K346, K353, S354 and K372 of EF3 (Figure 4-
10). The γ-phosphate and the oxygen of the β-phosphate interact with R329, 
K353 and K372. The β-phosphate and the α,β-bridging oxygen are stabilized 
by interactions with S354 and K346. The β, γ-bridging oxygen is predicted to 
form hydrogen bonds with K353. As expected in the crystal structure of EF3, 
the metal atoms are coordinated by H577, a pair of conserved aspartate 
residues D491 and D493 and the non-bridging oxygens of the phosphate 
chain. 
     Molecular docking studies predicted differential binding of the MANT-ATP 
and MANT-GTP isomers in the active site of EF3. Residues T548 and T579 
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may interact with the adenine base. This may explain why MANT-ATP 
analogs are more potent than MANT-GTP analogs. Also, in the case of 
MANT-ATP analogs, the 3’ MANT isomer is more aligned to form π-stacking 
interactions with F586 explaining its greater affinity for EF3 (Figure 4-8). 
However, the orientation of the MANT-group of 3’ MANT-2’d-GTP placed it 
further away from F586 than its 2’ isomer (Figure 4-9). This is also consistent 
with our experimental data that indicated that the 2’ MANT isomer of MANT-
GTP is more potent in AC assays and is more favorable for FRET and direct 
fluorescence effects. This is especially surprising because in ACs, a 
preference for the 3’-conformation of MANT-ATP and MANT-GTP was 
observed (Gille et al., 2004; Mou et al., 2005). Therefore, a preference for the 
2’-conformation of MANT-GTP has been demonstrated for the first time. 
Since, molecular modeling studies only predict the interaction of the MANT-
nucleotides with the catalytic site of EF3, future crystallographic studies of 
EF3-CaM in complex with the isomers of MANT-ATP and MANT-GTP will be 







Figure 4-9 Predicted differential interaction of MA NT-ATP isomers with 
amino acid residues in the catalytic site of EF3 
     A superimposition of 2’ and 3’ isomers of MANT-ATP in the space filling 
model of EF3 is shown. Only important residues are shown in the model and 
the colors on the surface of EF3 are depicted as follows: Hydrophobic 
surfaces = yellow, acidic surfaces = red, basic regions = blue, neutral/polar = 
white. Ligands are depicted in stick form and are represented in the following 






Figure 4-10 Comparison of the predicted interaction  of 2’ and 3’ isomers 
of MANT-GTP with amino acid residues in the catalyt ic site of EF3 
     A plot of predicted 2’ MANT-3’d-GTP (stick with purple C-atoms) and 
3’MANT-2’d-GTP (stick with green C-atoms) binding conformers within the 
EF3 receptor is shown. Sterically important residues are indicated.  Gold-lined 
Connolly surfaces represent favorable Van der Waals interactions of residues 
with ligands and blue-lined surfaces depict unfavorable interactions. Except 
for carbon atoms, all the other atoms are depicted as follows: H = cyan, N = 
blue, O = red, P = orange. The MANT-group of 2’ MANT-3’d-GTP faces 
towards F586 whereas in the case of 3’ MANT-2’d-GTP, the MANT-group 




Figure 4-11 Predicted interaction of the triphospha te chain of MANT-
nucleotides with the amino acid residues in the cat alytic site of EF3 
A superimposition of the triphosphate chain of MANT-nucleotides in the space 
filling model of EF3 is shown. Only important residues are shown in the model 
and the colors on the surface of EF3 are depicted as follows: Hydrophobic 
surfaces = yellow, acidic surfaces = red, basic regions = blue, neutral/polar = 
white. Ligands are depicted in stick form and are represented in the following 




4.4.4 Characterization of the EF-CaM interaction pro bed by MANT-
nucleotides 
     Binding of CaM to EF is the first step in the toxic mechanism of EF. As 
mentioned in the introduction section of chapter 1, EF consists of three 
domains CA, CB and a helical domain connected to CA by a linker region. CA 
and CB domains form the catalytic core of EF. CaM binding to EF causes the 
helical, linker and CA domain to completely wrap around the CaM. In addition 
to these domains, switch sgments A, B and C of EF also undergo 
conformational changes due to CaM binding (Drum et al., 2002). Residues 
corresponding to switches A and C are most important for interaction with EF. 
The switch B region of EF consists of residues important for catalysis and 
makes extensive contacts with switch C. Several hydrophobic and hydrophilic 
contacts stabilize the interaction between EF and CaM. Extensive binding 
surface area between EF and CaM is observed in the crystal structure of the 
EF-CaM complex. The CA domain of EF binds to helices IV, V and VI of CaM.  
The helical domain of EF and residues corresponding to switch C interact with 
and stabilize the N-terminal domain of CaM. The K525 residue in EF was 
identified as a “hotspot” for binding to CaM and forms a salt bridge with E114 
of CaM. D647of EF can also form a salt bridge with R90 of CaM. Therefore it 
was proposed that CaM first binds with residues from switch A followed by 
interaction with residues from switch C. Switch B is disordered in the structure 
of EF alone. However in the structure of the EF-CaM complex, switch B is 
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ordered indicating that CaM-binding to switch C induces the ordering of 
switch B (Drum et al., 2002).    
     Furthermore, it has been observed that EF binds to the N-terminus of CaM 
in a closed and Ca2+ independent manner, whereas binding of EF to the C-
terminus of CaM is Ca2+ dependent. EF interacts weakly with a closed N-CaM 
in a Ca2+ independent manner to initiate a tighter interaction with an open and 
Ca2+ loaded C-CaM (Shen et al., 2002; Shen et al., 2005).  
     In addition to identifying inhibitors for EF AC activity, it is also important to 
identify inhibitors that block the binding of CaM to EF. It is difficult to inhibit 
CaM, since CaM is a ubiquitous protein that can bind to several effector 
proteins and plays an important role in signal transduction. Therefore, it is 
important to identify regions in EF that specifically bind to CaM. This study is 
aimed at understanding EF-CaM binding to help identify inhibitors that 
exclusively block this interaction.  
 - Inhibition of EF3-CaM interaction with Calmidazol ium chloride (Cz.Cl) 
probed by 2’ MANT-3’d-ATP 
     Calmidazolium chloride (Cz.Cl) is a classic inhibitor of CaM (IC50 = 10 nM) 
and can, therefore, inhibit CaM-activated enzymes. Cz.Cl binds specifically to 
CaM and is therefore not expected to compete with the MANT-nucleotide for 
the nucleotide-binding site of EF3. Binding of Cz.Cl to CaM and its indirect 
impact on the EF-CaM interaction was probed by 2’ MANT-3’d-ATP using 
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fluorescence spectroscopy. Fluorescence experiments were carried out in 
both steady-state and kinetic modes to observe changes in EF3 and MANT-
nucleotide fluorescence due to binding of Cz.Cl. In kinetic mode, with a 
sequential addition of Cz.Cl ranging from 1 nM to 300 nM, a gradual decrease 
in EF3 fluorescence was observed in the presence of CaM (Figure 4-11, red 
trace). However, with the addition of Cz.Cl, there was no change in MANT-
nucleotide fluorescence in the presence of CaM (Figure 4-11, blue trace). In 
steady-state fluorescence experiments, at an excitation wavelength of 280 
nm, with the addition of Cz.Cl to EF3/CaM and MANT-nucleotide, a decrease 
in EF3 fluorescence and a shift to longer wavelength at around 355 nm was 
observed (Figure 4-12 A, black trace). Shifts to longer wavelengths indicate 
the presence of tryptophan residues of EF3 in a more polar environment. 
Additionally, a decrease in FRET at around 440 nm was observed. This 
indicates that Cz.Cl binds and inhibits CaM that can in turn bring about 
conformational changes in EF3 causing a change in the local environment of 
the tryptophan residues in EF3. Furthermore, this change in the local 
environment of tryptophan residues also causes a decrease in FRET to 
MANT-nucleotide possibly due to an increased distance between them. 
      At an excitation wavelength of 350 nm, in the presence of EF3/MANT-
nucleotide, as expected, an increase in fluorescence was observed with the 
addition of CaM (Figure 4-12 B, blue trace). This is due to CaM-induced 
conformational changes in EF3 so that MANT-nucleotide can bind to a 
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hydrophobic site in EF3. Therefore with the addition of Cz.Cl, a decrease in 
MANT-nucleotide fluorescence can be expected because Cz.Cl inhibits CaM. 
However, it was surprising to observe that even in the presence of Cz.Cl, 
there was no change in MANT-nucleotide fluorescence (Figure 4-12 B, black 
trace). MANT- nucleotide was bound to a hydrophobic pocket in EF3 even 
after inhibition of CaM. Based on our experiments, two possibilities cannot be 
ruled out. One, CaM is not completely inhibited by calmidazollium and 
therefore can still bind to and induce conformational changes in EF3. Two, 
though it is too early to suggest that EF3 may possess an exposed/accessible 
nucleotide binding pocket that can accommodate a nucleotide in the absence 
of CaM, it is possible that MANT-nucleotide can bind to EF3 in a CaM-
independent manner. It is also possible that nucleotide binding to EF in the 
absence of CaM is an intermediate or transition state between EF alone and 
EF-CaM-nucleotide complex. Future biochemical, enzymatic, crystallographic 
and biophysical studies will be required to understand if substrate or substrate 







Figure 4-12 Kinetic analysis of the inhibition of E F3-CaM binding with 
calmidazolium chloride probed by 2’ MANT-3’d-ATP 
     Fluorescence experiments were conducted as described in section 4.3.2. 
Kinetics of inhibition of EF3-CaM binding by calmidazolium chloride was 
carried out in dual-kinetic mode to observe the rate of change in EF3 (λ = 280 
– 450 nm, red trace) and MANT-nucleotide fluorescence (λ = 350 – 450 nm, 
blue trace). Cuvettes contained 300 nM each of EF3, CaM and MANT-
nucleotide in the presence of buffer containing10 mM MnCl2. Increasing 
concentrations of calmidazolium chloride varying from 1 nM to 300 nM were 
added. In the graph, fluorescence intensity in arbitrary units is measured as a 
function of time in minutes. Fluorescence recordings were analyzed using the 
spectrum package of the Cary Eclipse software. Similar results were obtained 












Figure 4-13 FRET and direct fluorescence experiment s examining the 
effect of calmidazolium chloride on EF3-CaM binding probed by 2’ 
MANT-3’d-ATP 
     FRET and direct fluorescence experiments were carried out as described 
in section 4.3.2. Steady-state emission spectra were recorded with λex = 280 
nm (λem = 300 – 500 nm) for intrinsic EF3 fluorescence (Figure A) and λex = 
350 nm (λem = 370 – 500 nm) for MANT-nucleotide fluorescence (Figure B). 
Experiments were carried out with sequential addition of reaction mixtures 
containing 100 mM KCl, 10 mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4, 
300 nM 2’ MANT-3’d-ATP (green trace), 300 nM EF3 (red trace) and 300 nM 
CaM (blue trace) followed by addition of 300 nM calmidazolium chloride 
(black trace). The final assay volume was 150 µl. Graphs were generated 
using Prism 4.0 software. Baseline fluorescence (buffer alone) was 
subtracted from all spectra. Fluorescence intensity in A and B are shown as 
percentage of the maximal emission data obtained for the respective 
experiment. Data shown here are representative of 2 – 3 independent 
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-Calcium dependent/independent interaction of CaM wi th EF3 probed by 
2’ MANT-3’d-ATP  
     A high binding affinity of EF and CaM (Kd = 20 nM) is dependent on 
calcium (Shen et al., 2002 and 2005; Ulmer et al., 2003). CaM possesses four 
calcium binding sites (2 each in N and C-terminal domain) and exists in three 
calcium loading states namely apo-CaM (no Ca2+ bound), 2 Ca2+ state (2 Ca2+ 
ions bound to C-CaM and N-CaM in apo state) and a 4 Ca2+ state (both N and 
C-CaM bound to calcium). EF binds to CaM in a 2 Ca2+ loaded state with N-
CaM in apo state and C-CaM bound to calcium ions. Experiments with CaM 
mutants suggest that mutations in calcium binding sites 1 and 2 did not have 
an effect on EF-CaM activation. Mutations in calcium binding sites 3 and 4, 
especially 4 had a significant effect on EF-CaM activation (Shen et al., 2002). 
This clearly indicated that EF can bind to N-CaM irrespective of its calcium 
loaded state but EF binding to C-CaM is strongly dependent on calcium.  
    A combination of enzymatic, spectroscopic and NMR studies have 
demonstrated that EF activation by CaM requires a physiological calcium 
concentration of about 1 µM. In fluorescence experiments probed by 2’d-3’ 
ANT-ATP, up to 2 µM Ca2+ was required for EF-CaM activation. Higher 
calcium concentrations inhibit EF activity by competing with Mg2+ ion for the 
metal-ion binding site (Shen et al., 2002).  
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     The current study is aimed at understanding the importance of calcium 
ions in the EF-CaM interaction probed by 2’ MANT-3’d-ATP. Fluorescence 
experiments at excitation of 280 nm (Figure 4-13 A, B and C) and 350 nm 
(Figure 4-13 D, E and F) were carried out in three different conditions namely 
1, in the presence of 100 µM Ca2+ (Figure 4-13 A and D). 2, in the presence 
of 100 µM EGTA (to bind to any free Calcium ions) (Figure 4-13 B and E). 3, 
in the absence of both EGTA and calcium (Figure 4-13 C and F). EGTA is a 
calcium chelator and can effectively bind to free calcium if present in the 
experiment. Calcium or EGTA were added to the HEPES buffer to observe 
their effect on intrinsic EF3 or MANT-nucleotide fluorescence. Under all three 
conditions studied, no change in intrinsic EF3 fluorescence, FRET or direct 
MANT-nucleotide fluorescence was observed. This indicates that irrespective 
of the presence of calcium, MANT-nucleotide can bind to a hydrophobic site 
formed by CaM-bound EF3. Our results are surprising in view of the fact that 
CaM-dependent activation and catalysis of EF3 is dependent on optimal 
calcium concentrations. In EF AC inhibition studies, the affinity of MANT-
nucleotides depended on optimal free calcium concentrations. However, in 
fluorescence assays, no difference in MANT-nucleotide binding to EF3-CaM 
was observed in the presence or absence of calcium.  
     In experiments carried out with N-CaM and C-CaM separately, it was 
observed that N-CaM but not C-CaM partially activated EF (Shen et al., 
2002). Based on the observations that EF locks N-CaM in a calcium-
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independent manner, we predict that in experiments with 2’ MANT-3’d-ATP, 
the fluorescence changes in nucleotide binding to EF3 is almost entirely due 
to EF3 binding to N-CaM in a calcium independent manner.   
     Previous observations suggest that the helical domain and switch C of EF 
bind to N-CaM which later triggers a tighter interaction of other regions of EF 
with C-CaM (Drum et al., 2002; Shen et al., 2002). From molecular modeling 
and fluorescence studies, we predicted that the stabilization of the MANT-
group is due to π-stacking interactions with F586. It is also known that switch 
C makes large contacts with switch B and F586 is a residue in switch B. 
Therefore, we predict that binding and activation of EF3-CaM probed by 
2’MANT-3’d-ATP is a multi-step process as follows.  
1. The helical domain and switch C region of EF3 make initial contacts 
with N-CaM (calcium-independent) 
2. Switch C binding to N-CaM causes the ordering of switch B in EF3 
which can now accommodate  and stabilize the MANT-nucleotide in a 
hydrophobic pocket by π-stacking interactions with F586 
1. N-CaM binding to EF3 triggers a stronger interaction with C-CaM in a 
calcium dependent manner to fully activate EF3.   
     It is also clear that binding of CaM and activation of EF are two 
independent events where amino acid residues in EF3 responsible for binding 
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are completely different from the ones needed for nucleotide-binding and 
catalysis. Site-directed mutagenesis experiments with CaM, crystallographic 
studies of EF3-CaM in complex with 2’ MANT-3’d-ATP and molecular 
modeling approaches will be needed to completely understand the role of 















Figure 4-14 Calcium-dependent/independent-binding o f CaM to EF3 
probed by 2’MANT-3’d-ATP 
     FRET and direct fluorescence experiments were carried out as described 
in section 4.3.2 in three different conditions namely 1, in the presence of 100 
µM Ca2+  (Figure A and D). 2, in the presence of 100 µM EGTA (Figure B and 
E). 3, in the absence of both EGTA and calcium (Figure C and F). Steady-
state emission spectra were recorded with λex = 280 nm (λem = 300 – 500 nm) 
for intrinsic EF3 fluorescence (Figure A, B and C) and λex = 350 nm (λem = 
370 – 500 nm) for MANT-nucleotide fluorescence (Figure D, E and F). 
Experiments were carried out with sequential addition of reaction mixtures 
containing 100 mM KCl, 10 mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4, 
with calcium or EGTA followed by addition of 300 nM 2’ MANT-3’d-ATP 
(green trace), 300 nM EF3 (red trace) and 300 nM CaM (blue trace). The final 
assay volume was 150 µl. Graphs were generated using Prism 4.0 software. 
Baseline fluorescence (buffer alone) was subtracted from all spectra. 
Fluorescence intensities in A, B and C are shown as percentage of the 
maximal emission data obtained for the respective experiment. Fluorescence 
intensity in D, E and F are shown in arbitrary units (a.u). Data shown here are 
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Figure 4-15 Schematic representation of the propose d mechanism of 








- Modulation of EF-CaM interaction by oxidation of Ca M  
     Reactive oxygen species oxidize specifically the cysteine and methionine 
residues in proteins (Levine et al., 1999). CaM consists of nine methionine 
residues and these residues are particularly sensitive to ROS-induced 
oxidation (Yin et al., 2000). CaM (O) (oxidized CaM) cannot efficiently bind to 
and activate its effector proteins such as Ca2+-ATPase in the plasma 
membrane. Specifically, oxidation of M144 and M145 in CaM abolishes the 
CaM-dependent activation of Ca2+-ATPase (Bartlett et al., 2003). It has also 
been observed in nitric oxide synthases that CaM (O) has a decreased affinity 
for the enzyme (Montgomery et al., 2003). CaM (O) is also unable to activate 
CaM kinase II and prevents autophosphorylation (Robison et al., 2007). 
Clearly, the reduced state of methionine residues is crucial for interaction of 
CaM with its effector proteins. Fluorescence and circular dichroism (CD) 
studies have shown that the central helix in CaM loses its stabilizing 
interactions due to oxidation (Gao et al., 1998). Furthermore, compared to C-
CaM, increased local structural changes were observed in N-CaM due to 
oxidation of methionine residues.  
     CyaA, the AC toxin from Bordetella pertussis specifically targets 
neutrophils and macrophages by binding to CD11b/CD18 integrin during 
infection (Guermonprez et al., 2001). Neutrophil activation results in ROS 
production that can in turn oxidize a number of proteins including CaM. 
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Therefore it was important to determine whether oxidized CaM could bind to 
and activate CyaA. Activation of CyaA was completely abolished by CaM 
oxidation (Wolff et al., 1980). CyaA was activated by partially oxidized CaM 
indicating an important role for the toxin in exerting its pathophysiological 
effects even in the presence of CaM (O). Methionines 109, 124 and 145 were 
identified as important residues for binding and activation of CyaA enzymatic 
activity (Vougier et al., 2004).  
     EF and LF together inhibit NADPH oxidase activity that generates ROS to 
cause bacterial killing (Crawford et al., 2006). However, it is not known if 
stimulation of NADPH oxidase activity can cause oxidation of CaM and, 
therefore, result in inactivation of EF. The goal of this study is to understand 
the importance of methionine residues in EF-CaM binding and if they play an 
important role in CaM oxidation in the EF toxic mechanism.  
     In this study, a qualitative analysis of the binding of CaM (O) to EF3 
probed by MANT-nucleotides was carried out by fluorescence spectroscopy. 
CaM was oxidized as explained in Vougier et al., (2004) and in section 4.3.2. 
CaM without oxidation CaM(N), was used as control in all the experiments to 
compare the effects with CaM (O). In steady-state fluorescence experiments 
at an excitation wavelength of 280 nm, CaM (N) was added to EF3/MANT-
nucleotide (Figure 4-14 and 4-15 A and C). As expected, FRET occurred from 
the tryptophan and tyrosine residues to the MANT-group. In experiments with 
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CaM(O), in the presence of EF3/MANT-nucleotide, the intensity of FRET 
reduced several-fold (Figure 4-14 and 4-15 B and D). To monitor changes in 
MANT-nucleotide fluorescence, CaM (N) was added to EF3/MANT-nucleotide 
and excited at 350 nm (Figure 4-14 and 4-15 E and G). A several-fold 
increase in fluorescence was observed. With the addition of CaM (O) (Figure 
4-14 and 4-15 F and H), the intensity of MANT-nucleotide fluorescence was 
reduced compared to CaM (N).  
     In both FRET and direct MANT-nucleotide fluorescence measurements, 
with the addition of CaM (O), a decrease in fluorescence intensity compared 
to CaM (N) indicates that CaM (O) does not bind to EF3 efficiently. 
Additionally, we observed that a decrease in fluorescence intensity with 
CaM(O) varied for each nucleotide studied. A 63% and a 42% decrease in the 
intensity of FRET and direct fluorescence respectively was observed with 
CaM (O) in the presence of 2’ MANT-3’d-ATP (Figure 4-15, B and F). 
Irrespective of the nucleotide studied, an overall decrease in fluorescence 
intensity indicates that CaM (O) cannot bind properly to EF3 as compared to 
CaM (N).  
     Fluorescence experiments were carried out in the kinetic mode to monitor 
the rate of binding of CaM (N) and CaM (O) to EF3 (Figure 4-16). Irrespective 
of the MANT-nucleotide studied, binding of CaM (N) to EF3 showed a higher 
association rate constant (1.6 min-1 ± 0.2) compared to binding of CaM (O) to 
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EF3 (0.69 min-1 ± 0.4). This indicates that CaM (N) associates faster with 
EF3 compared to CaM (O). Furthermore, the t1/2 values obtained from the 
results are also reflective of the rate of binding of CaM to EF3. The half life in 
this case indicates the time taken for half of CaM to bind to EF3. Half life 
obtained for CaM (N) and CaM (O) are 0.4 min ± 0.1 and 0.9 min ± 0.2 
respectively. This shows that CaM (O) binds at least 50% slower than CaM 
(N) to EF3/MANT-nucleotide.  
    Collectively, a qualitative and a quantitative difference in the binding of 
CaM (N) and CaM (O) to EF3 was observed. It is clear that CaM (O) shows 
inefficient binding to EF3 and therefore, it can be suggested that methionine 
residues in CaM play an important role in the EF3-CaM interaction. However, 
it remains to be seen if CaM (O) can affect the catalytic activity of EF3. It is 
also not known if the oxidation of CaM can be reduced by the endogenous 
methionine sulfoxide reductases (Msr). Future experiments in this area of 
research must include identifying the specific methionine residues responsible 
for the EF3-CaM interaction.  In addition to design of inhibitors for EF catalytic 
activity, a clearer understanding of the mechanism EF3-CaM binding will aid 
in the developments of inhibitors to specifically block this protein-protein 




Figure 4-16 FRET and direct fluorescence measuremen ts of CaM (N) and 
CaM (O) binding to EF3 probed by MANT-ATP and MANT- GTP 
     CaM oxidation and fluorescence experiments were carried out as 
described in section 4.3.2. Steady-state emission spectra were recorded with 
λex = 280 nm (λem = 300 – 500 nm) for intrinsic EF3 fluorescence (Figure A, B, 
C and D) and λex = 350 nm (λem = 370 – 500 nm) for MANT-nucleotide 
fluorescence (Figure E, F, G and H). Figures A, B, E and F correspond to 
MANT-ATP and Figures C, D, G and H correspond to MANT-GTP. 
Experiments were carried out with sequential addition of reaction mixtures 
containing 100 mM KCl, 10 mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4 
followed by addition of 300 nM MANT-nucleotide (green trace), 300 nM EF3 
(red trace) and 300 nM CaM (N) or 300 nM CaM (O) (blue trace). The final 
assay volume was 150 µl. Graphs were generated using Prism 4.0 software. 
Baseline fluorescence (buffer alone) was subtracted from all spectra. 
Fluorescence intensities in A, B, C and D are shown as percentage of the 
maximal emission data obtained for the respective experiment. Fluorescence 
intensity in E, F, G and H are shown in arbitrary units (a.u). Data shown here 
are representative of 2 – 3 independent experiments for each MANT-
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Figure 4-17 FRET and direct fluorescence measuremen ts of CaM (N) and 
CaM (O) binding to EF3 probed by 2’MANT-3’d-ATP and  3’MANT-2’d-ATP 
     CaM oxidation and fluorescence experiments were carried out as 
described in section 4.3.2. Steady-state emission spectra were recorded with 
λex = 280 nm (λem = 300 – 500 nm) for intrinsic EF3 fluorescence (Figure A, B, 
C and D) and λex = 350 nm (λem = 370 – 500 nm) for MANT-nucleotide 
fluorescence (Figure E, F, G and H). Figures A, B, E and F correspond to 2’ 
MANT-3’d-ATP and Figures C, D, G and H correspond to 3’ MANT-2’d-ATP. 
Experiments were carried out with sequential addition of reaction mixtures 
containing 100 mM KCl, 10 mM MnCl2 and 25 mM HEPES/NaOH, pH 7.4 
followed by addition of 300 nM MANT-nucleotide (green trace), 300 nM EF3 
(red trace) and 300 nM CaM (N) or 300 nM CaM (O) (blue trace). The final 
assay volume was 150 µl. Graphs were generated using Prism 4.0 software. 
Baseline fluorescence (buffer alone) was subtracted from all spectra. 
Fluorescence intensities in A, B, C and D are shown as percentage of the 
maximal emission data obtained for the respective experiment. Fluorescence 
intensities in E, F, G and H are shown in arbitrary units (a.u). Data shown are 
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Figure 4-18 Kinetic analysis of the rate of binding  of CaM (N) and CaM 
(O) to EF3 
     Fluorescence experiments were carried out in the kinetic mode as 
described in section 4.3.2 to determine the rate of binding of CaM (N) and 
CaM (O) to EF3. Experiments were carried out with sequential addition of 
reaction mixtures containing 100 mM KCl, 10 mM MnCl2 and 25 mM 
HEPES/NaOH, pH 7.4 followed by addition of 300 nM MANT-nucleotide, 300 
nM EF3 and 300 nM CaM (N) or 300 nM CaM (O). Experiments were carried 
out in kinetic mode with wavelength ranging from 280-450 nm. Kinetics of 
CaM (N) and CaM (O) binding to EF3 were analyzed by the one-phase 
exponential association equation in Graphpad prism 4.0 software. Baseline 
fluorescence (buffer + nucleotide + EF3) and initial time before the addition of 
CaM was subtracted from the graph plotted between fluorescence intensity 
(a.u) and time (min). Independent experiments with CaM (N) and CaM (O) are 
plotted in the same graph for comparison. K is the association rate constant 
expressed in min-1 and half life expressed in min is the time required for CaM 
to bind 50% of the available EF3 molecules. Data shown here are 
representative of 2 independent experiments for MANT-ATP. Similar results 
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4.5 Conclusions  
     In conclusion, the 2’ and 3’ isomers of MANT-ATP and MANT-GTP 
respectively are useful probes in studying EF-CaM interaction and EF 
catalytic activity. MANT-GTP analogs have not been studied yet in other AC 
systems but clearly, enzymatic studies show that MANT-ATP analogs are the 
most potent inhibitors for EF compared to CyaA, C1/C2 and mAC isoforms 
(Gille et al., 2004; Gottle et al., 2007).  
     Though 2’ isomers of MANT-ATP and MANT-GTP  are more favorable for 
FRET and direct fluorescence studies, 3’ MANT-2’d-ATP is the most potent 
inhibitor of EF reported so far (Ki = 11 nM). Our molecular modeling studies 
predict that the 3’ MANT-substituent of ATP is better aligned to form π-
stacking interactions with F586 and thereby stabilizes itself in the catalytic site 
of EF3. However, the 2’ MANT-substituent of GTP was more potent than its 
corresponding 3’ MANT-substituent as an inhibitor in enzymatic studies. 
Molecular modeling studies also predict that the MANT-group of 2’MANT-3’d-
GTP is oriented towards F586 resulting in more stabilizing interactions with 
EF. Our studies clearly show that the MANT-group positioning is critical for 
binding and inhibition of EF3.  
     Enzymatic, fluorescence and molecular modeling approaches have shown 
that, though there are slight differences in the binding of the 2’ and 3’ isomers 
of MANT-ATP and MANT-GTP, the catalytic site of EF is spacious enough to 
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accommodate bulky purine nucleotides with modified ribose substituents. 
Crystallographic studies of the EF-CaM in complex with MANT-ATP and 
MANT-GTP analogs will help understand the differential binding of these 
nucleotides. Similar to the tripartite pharmacophore model for mACs (Mou et 
al., 2006), generation of a pharmacophore model for EF based on the crystal 
structures of EF-CaM in complex with various nucleotides will help in the 
design of potent EF inhibitors. 
     We observed that binding of CaM to EF is Ca2+independent while 
activation of EF catalytic activity was dependent on calcium. Therefore, a 
multi-step hypothesis was proposed stating that binding and activation of EF 
by interaction with CaM are two independent steps involving two different sets 
of amino acid residues in EF. Future studies, more specifically, experiments 
with CaM mutants with mutations at the calcium binding sites, will be required 
to test our hypothesis.  
     Methionine residues play an important role in recognition and binding of 
CaM to EF3. Oxidation of methionine residues in CaM resulted in inefficient 
and a slower binding of CaM to EF3. Based on the important role of 
methionine residues in EF-CaM interaction, three questions arise. 1. What are 
the specific methionine residues involved in the EF-CaM interaction? CaM 
consists of nine methionine residues with five residues in N-CaM and 4 
residues in C-CaM (pdb structure 2F3Z, 1J7O, 1J7P, Fallon et al., 2005; 
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Chou et al., 2001). In the case of CyaA, it was observed that methionine 
residues at 109, 124, 144 and 145 in C-CaM are important for interaction with 
CyaA AC (Vougier et al., 2004). Site-directed mutagenesis and Mass-
spectroscopic experiments will be required to identify the specific methionine 
residues involved in EF-CaM interaction. 2. Does CaM (O) alter the catalytic 
activity of EF? Though it is clear that CaM (O) shows a reduced binding 
affinity for EF, it is not known if CaM (O) can modulate EF AC activity. It has 
been observed that CyaA AC activity can be completely abolished by CaM 
(O) though CyaA can be resistant to partial oxidation of CaM (Wolff et al., 
1980; Vougier et al., 2004). This also indicated that even in the presence of 
CaM (O), CyaA toxin can exert its pathophysiological effect. Enzymatic 
studies of EF with CaM (O) will be required to observe the effect of CaM 
oxidation on EF AC activity. In addition, it will also be important to observe the 
reversal of CaM oxidation by the endogenous methionine sulfoxide reductase 
enzymes.  
     Collectively, these properties should help gain insights into EF-CaM 
interaction to aid in the design of specific EF-CaM inhibitors.  
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Chapter 5: Future directions 
5.1 Understanding AC regulation and inhibition 
5.1.1 Structural basis for the interaction of the T NP-nucleotides with 
C1/C2 and holo-AC isoforms 
     The work presented in chapter 2 clearly indicates that there are subtle 
differences in the interaction of TNP-GTP and TNP-ATP with C1/C2. Since 
the crystal structure of C1/C2-Gsα-FS in complex with TNP-ATP is already 
available (Mou et al., 2006), crystallographic studies of C1/C2 in complex with 
TNP-GTP should be carried out to compare and explain the differences in the 
interaction of these nucleotides with C1/C2.  
     Compared to other proteins studied with TNP-nucleotides as probes, TNP-
nucleotides have the highest affinity for mACs (Hiratsuka, 1982; Broglie and 
Takahashi, 1983; Thomas et al., 1991). TNP-nucleotides are known to bind to 
a number of nucleotide-binding proteins so it is challenging to establish their 
usefulness as specific inhibitors for ACs (Liu and Sharom, 1997; Stewart et 
al., 1998; Hiratsuka, 2003) Among the ACs, we have seen that TNP-
nucleotides are more potent at inhibiting mACs compared to bacterial AC 
toxins such as EF and CyaA (data not shown). From the crystal structure of 
C1/C2-Gsα-FS in complex with TNP-ATP (Mou et al., 2006), it is clear that 
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introduction of the bulky, aromatic TNP group at the 2’ and the 3’ position of 
the ribose moiety of ATP can give rise to a new class of inhibitors for mACs. 
Additionally, we have also observed that TNP-UTP and TNP-CTP are highly 
potent at inhibiting both C1/C2 (Ki = 92 nM and 310 nM respectively) and 
mAC isoforms indicating that a smaller base may also help in higher potency 
at AC inhibition. Since the TNP-pyrimidine nucleotides have not yet been 
reported to bind to, and inhibit other proteins, they can serve as starting 
points for development of potent inhibitors for mACs.  
    There are nine different AC isoforms with differential localization, regulation 
and interaction with different proteins (Sunahara et al., 1996; Hanoune and 
Defer, 2001). Therefore, it has been extremely difficult to identify potent 
isoform-specific activators and inhibitors of mACs. While studying the 
inhibitory effects of TNP-nucleotides on holo-AC isoforms, specifically AC1, 
AC2 and AC5, TNP-nucleotides inhibited the holo-ACs in an isoform-selective 
manner. TNP-ATP was the most potent inhibitor of the AC5 isoform reported 
so far (Ki = 4 nM). Furthermore, in our fluorescence assays, we have 
observed that all the TNP-nucleotides can be utilized as probes to study 
conformational changes in C1/C2.  
     We have also observed that TNP-NDPs can serve as substrates for 
selective kinases (Chapter 2). Therefore TNP-NDPs could serve as models 
for developing pro-drugs at inhibiting ACs, where they can be converted into 
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their active-NTP form in the presence of the specific phosphorylating 
systems.  
     All our studies have been carried out with C1 (from AC5) and C2 (from 
AC2) as models for mAC regulation and catalysis (Gille et al., 2004; Mou et 
al., 2005 and 2006). However, it will be important to carry out enzymatic, 
fluorimetric, molecular modeling and crystallographic studies of C1 and C2 
from the same isoforms with TNP-nucleotides. This approach will also help 
understand the isoform-selective inhibition of mACS by TNP-nucleotides. 
Collectively, based on the AC-isoform-selective inhibitory properties of TNP-
nucleotides and their binding to C1/C2 monitored by fluorescence 
spectroscopy, sensitive fluorescence-based assays can be developed to 
identify potent isoform-specific AC inhibitors. Additionally, development of 
cell-based assays will be required for the identification of cell-permeable AC 
inhibitors.  
 
5.1.2 Analysis of the mechanism of homodimerization of C1 and C2 
subunits of mAC and a potential physiological role of AC dimerization in 
cAMP signaling 
    In addition to forming multimeric complexes with GPCRS and G-proteins, 
ACs are also known to dimerize via their transmembrane domains (Neer et 
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al., 1984; Yeager et al., 1985; Smigel, 1986; Gu et al., 2001 and 2002; 
Cooper and Crossthwaithe, 2006). In chapter 3, we have observed that the 
individual subunits of mACs, C1 possess very low catalytic activity and C2 
exhibits almost no catalytic activity. We have observed that C1 and C2 
subunits can form homodimers. Although, it is proposed that the dimer is the 
minimum functional unit of mACs, it is also important to understand if the C1 
and C2 subunits can form only homodimers or higher-order oligomers. It was 
proposed that ACs dimerize in a head-to-tail fashion, thereby bringing the two 
C1 and the two C2 subunits from different ACs molecules together (Gu et al., 
2001 and 2002; Cooper and Crossthwaithe, 2006). Future studies should 
focus on analyzing the properties of C1 and C2 homodimers from various AC 
isoforms. It would also be interesting to see if C1 and C2 subunits from two 
different AC isoforms can homodimerize. More specifically, FRET and BRET 
studies in live cells should be carried out to examine the possibility of 
homodimerization. Chimeric ACs should also be constructed, for example, C1 
from ACX and C1 from ACY, to analyze the homodimerization.   
     Although ACs can dimerize, a physiological role of AC dimerization in the 
production of cAMP is not yet known. Studies should focus on understanding 
the consequences of C1 and C2 homodimerization. It is possible that C1 and 
C2 homodimers serve as a checkpoint to control excess cAMP production. 
Therefore, further insights into the physiological significance of C1 and C2 
305 
 
homodimerization will greatly impact the development of activators and 
inhibitors of dimerized ACs.  
 
5.2 Molecular analysis of EF catalytic activity and  its interaction with 
other proteins.  
5.2.1 Understanding the mechanism of the interactio n of EF with other 
proteins 
     EF and LF bind to PA and PA mediates entry of EF and LF into the cytosol 
((Mock and Fouet, 2001; Mourez et al., 2002). Recent studies suggest that LF 
can bind to both monomeric and heptameric forms of PA (Lacy et al., 2005; 
Chvyrkova et al., 2007). An EF binding site has been mapped on PA (Lacy et 
al., 2002 and 2005) and though evidence suggests that the PA-binding 
domain of EF is not required for the potency of EF inside cells,  it would be of 
considerable interest to inhibit EF alternatively by blocking its interaction with 
PA to prevent its entry into cells. Future studies should specifically focus on 
blocking this important interaction between EF and PA since this is the first 
step for the entry of EF into cells.  
     After PA-mediated entry of EF into the cytosol, CaM binds to, and 
activates EF (Leppla, 1982). We have proposed that CaM initially binds to EF 
in a calcium-independent manner followed by activation of EF catalytic activity 
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dependent on calcium ions. Furthermore, we have observed that methionine 
residues in CaM play an important role in EF-CaM binding. CaM is a 
ubiquitous protein that can bind to several effector proteins. Therefore, it 
would be worth studying the exact mechanism of the EF-CaM interaction to 
aid in the development of inhibitors that specifically block the binding of CaM 
to EF. 
5.2.2 Structural basis for the interaction of MANT- nucleotides with EF 
and rational design of potent EF inhibitors 
     Our enzymatic, fluorescence and molecular modeling studies have shown 
that the 2’ and 3’ isomers of MANT-ATP and MANT-GTP interact differently 
with the catalytic site of EF3. Very recently, using a site-directed mutagenesis 
approach, we have identified important amino acid residues crucial for binding 
and stabilization of MANT-ATP to the EF3 catalytic site (Taha et al., 2008). 
Therefore, future studies should focus on solving the crystal structure of EF3-
CaM in complex with the defined isomers of MANT-nucleotides to understand 
the structural basis for differential inhibition of EF3 by MANT-nucleotides. 
Very similar to mACs, it will be important to develop a pharmacophore model 
of EF3 for differential interaction of MANT-nucleotide inhibitors for rationale 
design of potent EF3 inhibitors.  
     Our fluorescence assays are extremely sensitive in identifying differences 
in the binding of different MANT-nucleotides to EF3. We have observed that 
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the 2’ isomers of MANT-ATP and MANT-GTP are more favorable for FRET 
and direct fluorescence studies. Therefore, based on our experiments, robust 
and non-radiometric fluorescence-based HTS assays can be developed for 
identification of potent EF inhibitors.  
     An important challenge in the development of potent EF inhibitors is the 
specificity of inhibitors for EF alone and not mACs. Though, EF and mACs 
are structurally different and are activated by different mediators, they both 
catalyze the conversion of ATP to cAMP using a two-metal ion catalytic 
mechanism and have a few common residues responsible for ATP-binding 
and catalysis (Tesmer et al., 1997 and 1999; Drum et al., 2002; Shen et al., 
2005). Therefore, it is critical to develop potent inhibitors that specifically bind 
to EF and not to mACs.  
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